---
title: "Obefazimod (ABX464) in Ulcerative colitis: Product information and disease description"
description: "Formulary evidence on Obefazimod (ABX464) in Ulcerative colitis: Product information and disease description. Covers Product description and Place of product in therapy. 280 evidence topics quoted from 111 sources."
canonical: "https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/product-information-and-disease-description"
published: "2026-11-18T10:42:55-05:00"
modified: "2026-11-18T10:42:55-05:00"
---

# Obefazimod (ABX464) in Ulcerative colitis: Product information and disease description

<a id="product-information-and-disease-description"></a>

## 2 Product Information and Disease Description

<a id="heading-2.1"></a>

### 2.1 Product Description

<a id="heading-2.1.1"></a>

#### 2.1.1 Phase of Product Development

<a id="topic-2.1.1-1"></a>

##### Regulatory status: Submission planned; NDA submission planned by the end of 2026

> “End of 2026 Expected Obefazimod US FDA NDA Submission”

Source: [Abivax corporate presentation (2026)](https://ir.abivax.com/static-files/ecf996c4-f156-4dac-8e1e-5c4e7cfb8e7d)

> “End of 2026 – Planned NDA submission for obefazimod in UC”

Source: [Abivax first half 2026 results announcement (2026)](https://ir.abivax.com/news-releases/news-release-details/abivax-presents-business-updates-and-first-half-2026-financial)

> “Constructive FDA feedback resulted in alignment on the Company's planned NDA submission strategy and supported the planned content and format of the NDA submission. Abivax remains on track to submit its first NDA for obefazimod by the end of 2026.”

Source: [Abivax press release, pre-NDA interaction with the FDA (2026)](https://ir.abivax.com/news-releases/news-release-details/abivax-announces-positive-pre-nda-interaction-fda-obefazimod)

> “These additions strengthen Abivax's commercial organization as the Company prepares for the potential U.S. commercialization of obefazimod, including a planned New Drug Application”
> “in the fourth quarter of 2026.”

Source: [Abivax press release, commercial leadership appointments (2026)](https://ir.abivax.com/news-releases/news-release-details/abivax-strengthens-commercial-capabilities-strategic-leadership)

> “The Company remains on track to submit its NDA to the U.S. Food and Drug Administration in the fourth quarter of 2026.”

Source: [Abivax press release, ABTECT maintenance Part 2 results (2026)](https://ir.abivax.com/news-releases/news-release-details/abivax-reports-positive-abtect-maintenance-part-2-results)

> “Abivax intends to submit an NDA to the FDA in late fourth quarter 2026.”

Source: [Abivax press release, ABTECT maintenance results (2026)](https://ir.abivax.com/news-releases/news-release-details/abivax-announces-landmark-phase-3-abtect-maintenance-trial)

<a id="topic-2.1.1-2"></a>

##### Launch

No evidence found.

<a id="topic-2.1.1-3"></a>

##### Approval timing assumed in the company's exclusivity projection: second half of 2027

> “If obefazimod is approved by the FDA in 2H 2027, the FDA will grant an additional 7.5 years of exclusivity for a newly approved chemical entity (5 years of regulatory exclusivity plus 2.5 years of litigation stay against generic(s)), taking obefazimod’s US exclusivity, at a minimum, through 2034.”
> “If obefazimod is granted market authorization by the EMA in 2028, 8 years of data exclusivity + 2 additional years of market exclusivity would be granted”

Source: [Abivax corporate presentation (2026)](https://ir.abivax.com/static-files/ecf996c4-f156-4dac-8e1e-5c4e7cfb8e7d)

<a id="topic-2.1.1-4"></a>

##### Analyst assumption of U.S. market entry in 2027 (LifeSci Capital, June 2026)

> “obefazimod enters the market for moderate to severe ulcerative colitis in 2027”

Source: [Streetwise Reports (2026)](https://www.streetwisereports.com/article/2026/07/01/clinical-stage-biotech-discloses-colitis-retreatment-results-gets-mixed-ratings.html)

<a id="topic-2.1.1-5"></a>

##### Development phase: phase 3 in moderately to severely active ulcerative colitis

> “Abivax’s lead drug candidate, obefazimod (ABX464), is in Phase 3 clinical trials for the treatment of moderately to severely active ulcerative colitis.”

Source: [Abivax first half 2026 results announcement (2026)](https://ir.abivax.com/news-releases/news-release-details/abivax-presents-business-updates-and-first-half-2026-financial)

> “Maintenance trial topline data readout Part 1 & 2 in June 2026”

Source: [Abivax corporate presentation (2026)](https://ir.abivax.com/static-files/ecf996c4-f156-4dac-8e1e-5c4e7cfb8e7d)

<a id="topic-2.1.1-6"></a>

##### Authorization status: not approved in any jurisdiction

> “It has not yet been approved for commercial use in any jurisdiction.”

Source: [Abivax obefazimod web page](https://www.abivax.com/our-science/obefazimod/)

> “The product is not authorised anywhere in the European Community.”

Source: [EMA paediatric investigation plan decision, March 2025 (2025)](https://www.ema.europa.eu/en/documents/pip-decision/ema-pe-0000189672-ema-decision-20-march-2025-acceptance-modification-agreed-paediatric-investigation-plan-obefazimod_en.pdf)

<a id="topic-2.1.1-7"></a>

##### NDA submission timing: company guidance from January 2026 to May 2026

> “NDA submission for obefazimod in UC - Q4 2026 (subject to positive data)”

Source: [Abivax first quarter 2026 results announcement (2026)](https://ir.abivax.com/news-releases/news-release-details/abivax-presents-first-quarter-2026-financial-results-and-reports)

> “Subject to positive data, we currently expect to submit our NDA with the FDA in the fourth quarter of 2026.”

Source: [Abivax Form 20-F (2026)](https://www.sec.gov/Archives/edgar/data/1956827/000195682726000012/abvx-20251231.htm)

> “NDA submission for obefazimod in UC - Q4 2026 (subject to positive data)”

Source: [Abivax full year 2025 results announcement (2026)](https://ir.abivax.com/news-releases/news-release-details/abivax-announces-full-year-2025-financial-results-and-provides)

> “Ongoing New Drug Application (NDA) preparation includes planned engagement with the FDA in anticipation of planned filing in late 2026.”

Source: [Abivax press release, 2026 corporate outlook (2026)](https://ir.abivax.com/news-releases/news-release-details/abivax-provides-2026-corporate-outlook)

<a id="topic-2.1.1-8"></a>

##### Marketing authorization application to the EMA: planned for the second half of 2026, July 2025 statement

> “Regulatory Strategy: Contingent on positive 44-week maintenance results, Abivax intends to submit a New Drug Application”
> “to the U.S. Food and Drug Administration (FDA) and a Marketing Authorization Application”
> “to the European Medicines Agency (EMA) in the second half of 2026.”

Source: [Abivax press release, ABTECT induction results (2025)](https://ir.abivax.com/news-releases/news-release-details/abivax-announces-positive-phase-3-results-both-abtect-8-week)

<a id="topic-2.1.1-9"></a>

##### EU paediatric investigation plan for ulcerative colitis: modification accepted in March 2025

| Field | Quoted record |
| --- | --- |
| Decision | “EMA/PE/0000189672” |
| Decision date | “of 20 March 2025” |
| Condition | “Treatment of ulcerative colitis” |
| Indication targeted by the PIP | “Treatment of patients diagnosed with moderately to severely active ulcerative colitis (UC)” |
| Paediatric subset concerned | “From 2 years to less than 18 years of age” |
| Waiver | “the paediatric population from birth to less than 2 years of age;” |
| Paediatric clinical study | “2-part, multi-centre, double-blind induction and maintenance study to evaluate the efficacy, safety, tolerability and PK of obefazimod in paediatric patients with moderately to severely active ulcerative colitis aged from 2 years to less than 18 years.” |
| Date of completion of the PIP | “By June 2029” |
| Deferral | “Yes” |

Source: [EMA paediatric investigation plan decision, March 2025 (2025)](https://www.ema.europa.eu/en/documents/pip-decision/ema-pe-0000189672-ema-decision-20-march-2025-acceptance-modification-agreed-paediatric-investigation-plan-obefazimod_en.pdf)

<a id="topic-2.1.1-10"></a>

##### EU paediatric investigation plan: modification accepted in June 2024

> “European Medicines Agency decision P/0205/2024 of 14 June 2024”
> “Having regard to the European Medicines Agency’s decision P/0519/2022 issued on 30 December 2022,”
> “Amendment of the scope of the Paediatric Investigation Plan to exclude another condition.”

Source: [EMA paediatric investigation plan decision P/0205/2024 (2024)](https://www.ema.europa.eu/en/documents/pip-decision/p-0205-2024-ema-decision-14-june-2024-acceptance-modification-agreed-paediatric-investigation-plan-obefazimod-emea-003196-pip01-22-m01_en.pdf)

<a id="heading-2.1.2"></a>

#### 2.1.2 Product Information

<a id="heading-2.1.2.1"></a>

##### 2.1.2.1 Generic, Brand Name and Therapeutic Class of Product

<a id="topic-2.1.2.1-1"></a>

###### Generic name, chemical name, and identifiers

| Field | Quoted record |
| --- | --- |
| International nonproprietary name (Latin) | “obefazimodum” |
| International nonproprietary name (English) | “obefazimod” |
| Chemical name | “8-chloro-N-[4-(trifluoromethoxy)phenyl]quinolin-2-amine” |
| Functional description | “immunomodulator” |
| Molecular formula | “C16H10ClF3N2O” |
| CAS registry number | “1258453-75-6” |
| INN list | “Proposed INN: List 125” |

Source: [WHO Drug Information (2021)](https://cdn.who.int/media/docs/default-source/international-nonproprietary-names-%28inn%29/pl125.pdf)

<a id="topic-2.1.2.1-2"></a>

###### Development code: ABX464

> “Abivax’s lead drug candidate, obefazimod (ABX464), is in Phase 3 clinical trials for the treatment of moderately to severely active ulcerative colitis.”

Source: [Abivax first half 2026 results announcement (2026)](https://ir.abivax.com/news-releases/news-release-details/abivax-presents-business-updates-and-first-half-2026-financial)

> “ABX464 (obefazimod) is a small molecule that selectively upregulates miR-124 in immune cells.”

Source: [Vermeire et al. (2022)](https://pubmed.ncbi.nlm.nih.gov/36075249/)

<a id="topic-2.1.2.1-3"></a>

###### Brand name

No evidence found.

<a id="topic-2.1.2.1-4"></a>

###### Therapeutic class: oral small molecule miR-124 enhancer

> “Obefazimod is an investigational, orally administered, once-daily therapy, which we believe has the potential to be a differentiated treatment option for inflammatory bowel diseases. It is the first and only molecule that enhances the expression of microRNA-124 (miR-124), a natural regulator of the inflammatory response.”
> “If approved, this therapy has the potential to establish a new therapeutic class currently being referred to as miR-124 enhancers.”

Source: [Abivax obefazimod web page](https://www.abivax.com/our-science/obefazimod/)

> “Obefazimod is an oral small molecule that selectively enhances the expression of a single micro-RNA (miRNA), miR-124.”

Source: [Vermeire et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12124117/)

> “Obefazimod (ABX464) is a first-in-class, oral small molecule that enhances microRNA-124 (miR-124) biogenesis, suppressing STAT3 and CCL2 signaling, reducing Th17 polarization and macrophage activation.”

Source: [Parra-Izquierdo et al. (2026)](https://pubmed.ncbi.nlm.nih.gov/42777529/)

<a id="topic-2.1.2.1-5"></a>

###### Manufacturer: Abivax

> “Abivax is a clinical-stage biotechnology company focused on developing therapeutics that harness the body’s natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases. Based in France and the United States, Abivax’s lead drug candidate, obefazimod (ABX464), is in Phase 3 clinical trials for the treatment of moderately to severely active ulcerative colitis.”

Source: [Abivax first half 2026 results announcement (2026)](https://ir.abivax.com/news-releases/news-release-details/abivax-presents-business-updates-and-first-half-2026-financial)

> “Achieving alignment with the FDA on our NDA submission strategy marks an important milestone as we prepare to submit Abivax's first New Drug Application for obefazimod.”

Source: [Abivax press release, pre-NDA interaction with the FDA (2026)](https://ir.abivax.com/news-releases/news-release-details/abivax-announces-positive-pre-nda-interaction-fda-obefazimod)

<a id="heading-2.1.2.2"></a>

##### 2.1.2.2 Dosage Forms and Strengths

<a id="topic-2.1.2.2-1"></a>

###### Investigational dosage form: 25 mg and 50 mg oral capsules

| Field | Quoted record |
| --- | --- |
| International nonproprietary name | “Obefazimod” |
| Strengths | “25 mg capsule”; “50 mg capsule” |
| Route of administration | “Oral” |
| Packaging | “Each blister card (=kit) contains 35 capsules.” |
| Blister cards | “IMP will be packaged in child-resistant blister cards with blinded labels.” |

Source: [Abivax ABX464-105 protocol (2024)](https://cdn.clinicaltrials.gov/large-docs/03/NCT05507203/Prot_000.pdf)

> “Obefazimod is formulated as an oral solid capsule.”
> “We have successfully scaled-up active pharmaceutical ingredients and drug product processes, and we have a large supply of active pharmaceutical ingredients and capsules available for clinical trials.”

Source: [Abivax Form 20-F (2026)](https://www.sec.gov/Archives/edgar/data/1956827/000195682726000012/abvx-20251231.htm)

<a id="topic-2.1.2.2-2"></a>

###### Pharmaceutical forms in the EU paediatric investigation plan: hard capsule and an age-appropriate oral liquid

| Field | Quoted record |
| --- | --- |
| Pharmaceutical forms | “Capsule, hard”; “Age-appropriate oral liquid dosage form” |
| Route of administration | “Oral use” |
| Quality-related study | “Development of an age-appropriate oral liquid dosage form.” |

Source: [EMA paediatric investigation plan decision, March 2025 (2025)](https://www.ema.europa.eu/en/documents/pip-decision/ema-pe-0000189672-ema-decision-20-march-2025-acceptance-modification-agreed-paediatric-investigation-plan-obefazimod_en.pdf)

<a id="topic-2.1.2.2-3"></a>

###### Pediatric 50 mg minitablet formulation compared with the adult capsule in healthy participants (ABX464-911)

> “Study to Evaluate Pharmacokinetics, Relative Bioavailability, Palatability of Obefazimod Minitablet Formulation”
> “Participants will receive a single oral dose of obefazimod Capsule administered with water”
> “Participants will receive a single oral dose of obefazimod Minitablet with either Apple sauce, Chocolate pudding, Yogurt, Water”
> “Pediatric formulation”

Source: [ClinicalTrials.gov NCT07453784](https://clinicaltrials.gov/study/NCT07453784)

<a id="topic-2.1.2.2-4"></a>

###### Commercial dosage form and strengths

No evidence found.

<a id="heading-2.1.2.3"></a>

##### 2.1.2.3 Average Sales Price and Wholesale Acquisition Cost

<a id="topic-2.1.2.3-1"></a>

###### Wholesale acquisition cost and average sales price

Not applicable.

<a id="topic-2.1.2.3-2"></a>

###### Analyst assumption of a net annual U.S. price at launch of US$78,000 (LifeSci Capital, June 2026)

> “We currently assume a 90% probability of success with a net annual price at launch of US$78,000 in the U.S.”
> “increased from US$66,000 prior based on recent management commentary”

Source: [Streetwise Reports (2026)](https://www.streetwisereports.com/article/2026/07/01/clinical-stage-biotech-discloses-colitis-retreatment-results-gets-mixed-ratings.html)

<a id="heading-2.1.2.4"></a>

##### 2.1.2.4 American Hospital Formulary Service (AHFS), or Other Drug Classification

<a id="topic-2.1.2.4-1"></a>

###### AHFS classification

No evidence found.

<a id="topic-2.1.2.4-2"></a>

###### WHO INN functional description: immunomodulator

> “immunomodulator”

Source: [WHO Drug Information (2021)](https://cdn.who.int/media/docs/default-source/international-nonproprietary-names-%28inn%29/pl125.pdf)

<a id="topic-2.1.2.4-3"></a>

###### NCI Drug Dictionary: small molecule binder of the cap binding complex

> “An orally available, small molecule binder of the cap binding complex (CBC) 80/20, with potential antiviral and anti-inflammatory activities.”

Source: [NCI Drug Dictionary](https://www.cancer.gov/publications/dictionaries/cancer-drug/def/obefazimod)

<a id="heading-2.1.2.5"></a>

##### 2.1.2.5 Indication

<a id="topic-2.1.2.5-1"></a>

###### Proposed indication: adults with moderately to severely active ulcerative colitis

> “today announced the successful completion of its positive pre-New Drug Application (NDA) interaction with the U.S. Food and Drug Administration (FDA) for obefazimod for the treatment of adults with moderately to severely active ulcerative colitis (UC).”
> “Company remains on track to submit its first New Drug Application for obefazimod for the treatment of moderately to severely active ulcerative colitis by the end of 2026”

Source: [Abivax press release, pre-NDA interaction with the FDA (2026)](https://ir.abivax.com/news-releases/news-release-details/abivax-announces-positive-pre-nda-interaction-fda-obefazimod)

<a id="topic-2.1.2.5-2"></a>

###### Population of the pivotal ABTECT trials: inadequate response to conventional or advanced therapy

> “The ABTECT-1 and ABTECT-2 induction trials are global, multicenter, randomized, double-blind, placebo-controlled trials assessing once-daily oral administration of obefazimod at 25 mg or 50 mg doses in adult patients with moderately to severely active UC. Eligible participants had inadequate response, loss of response, or intolerance to conventional and/or advanced therapies.”

Source: [Abivax press release, ABTECT induction results (2025)](https://ir.abivax.com/news-releases/news-release-details/abivax-announces-positive-phase-3-results-both-abtect-8-week)

> “Subjects with documented inadequate response (defined as lack of response or loss of response or intolerance) to at least one of the following treatments: corticosteroids, immunosuppressant, biologic or biosimilar therapies, S1P receptor modulators and/or JAK inhibitors and/or new drugs approved during the study (note: failure to only 5-ASA or sulfasalazine is not accepted).”
> “Men or women at least 16 years old; Adolescent subjects will only be enrolled if approved by the country regulatory/health authority.”

Source: [ClinicalTrials.gov NCT05507203](https://clinicaltrials.gov/study/NCT05507203)

<a id="topic-2.1.2.5-3"></a>

###### Indication targeted by the EU paediatric investigation plan

> “Treatment of patients diagnosed with moderately to severely active ulcerative colitis (UC)”
> “From 2 years to less than 18 years of age”

Source: [EMA paediatric investigation plan decision, March 2025 (2025)](https://www.ema.europa.eu/en/documents/pip-decision/ema-pe-0000189672-ema-decision-20-march-2025-acceptance-modification-agreed-paediatric-investigation-plan-obefazimod_en.pdf)

<a id="topic-2.1.2.5-4"></a>

###### Crohn's disease in development: phase 2b ENHANCE-CD, induction topline results expected mid-2027

> “Mid-2027 – Topline results from the Phase 2b ENHANCE-CD induction trial evaluating obefazimod in CD”

Source: [Abivax first half 2026 results announcement (2026)](https://ir.abivax.com/news-releases/news-release-details/abivax-presents-business-updates-and-first-half-2026-financial)

> “Patient enrollment for ENHANCE-CD in Crohn’s disease was initiated in Q3 2024; 12-week induction data readout is anticipated mid-year 2027.”

Source: [Abivax obefazimod web page](https://www.abivax.com/our-science/obefazimod/)

> “This study has 3 treatment phases, a 12-Week Induction Phase, a 40-Week Maintenance Phase, and a 48-Week Extension Phase.”
> “Obefazimod 12.5mg given once-daily (QD) in subjects with moderately to severely active Crohn's disease (CD)”

Source: [ClinicalTrials.gov NCT06456593](https://clinicaltrials.gov/study/NCT06456593)

<a id="topic-2.1.2.5-5"></a>

###### ENHANCE-CD induction results timing, January to May 2026, superseded in June 2026

> “Topline results of Phase 2b induction trial for CD - Q4 2026”

Source: [Abivax first quarter 2026 results announcement (2026)](https://ir.abivax.com/news-releases/news-release-details/abivax-presents-first-quarter-2026-financial-results-and-reports)

> “Completion of Phase 2b induction trial for CD - Q4 2026”

Source: [Abivax full year 2025 results announcement (2026)](https://ir.abivax.com/news-releases/news-release-details/abivax-announces-full-year-2025-financial-results-and-provides)

> “The 12-week induction trial results are anticipated in late 2026 and will help inform the design of subsequent registrational studies.”

Source: [Abivax press release, 2026 corporate outlook (2026)](https://ir.abivax.com/news-releases/news-release-details/abivax-provides-2026-corporate-outlook)

Additional sources: [Honap et al. (2026)](https://pubmed.ncbi.nlm.nih.gov/42322247/)

<a id="heading-2.1.2.6"></a>

##### 2.1.2.6 Pharmacology

<a id="heading-2.1.2.6.1"></a>

###### 2.1.2.6.1 Mechanism of Action

<a id="topic-2.1.2.6.1-1"></a>

###### Enhancer of microRNA-124 expression

> “It is the first and only molecule that enhances the expression of microRNA-124 (miR-124), a natural regulator of the inflammatory response.”
> “If approved, this therapy has the potential to establish a new therapeutic class currently being referred to as miR-124 enhancers.”

Source: [Abivax obefazimod web page](https://www.abivax.com/our-science/obefazimod/)

> “Obefazimod is an oral, once-daily, small molecule that increases expression of endogenous miR-124”
> “Restores immune balance while maintaining immune surveillance functions”

Source: [Sands et al. (2026a)](https://www.abivax.com/wp-content/uploads/2026/10/OP097-ABTECT-Topline-OP-DRAFT-07OCT2026-Sands-UEGW2026-ABVX-Obe-1.pdf)

> “Obefazimod is an oral small molecule that selectively enhances the expression of a single micro-RNA (miRNA), miR-124.”

Source: [Vermeire et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12124117/)

> “With a novel mechanism of action, obefazimod is an orally available small molecule with anti-inflammatory properties through the specific and selective upregulation of miR-124 expression.”

Source: [Vermeire et al. (2023)](https://pubmed.ncbi.nlm.nih.gov/37129565/)

<a id="topic-2.1.2.6.1-2"></a>

###### Binding to the cap binding complex and splicing of a long noncoding RNA that houses miR-124

> “ABX464 is a small molecule that binds to the cap binding complex (CBC)2, a complex at the 5′-end of the pre-mRNA transcript that promotes the initial interaction with transcription and processing machinery3–5.”
> “Here, using RNA CaptureSeq and deep sequencing, we report that ABX464 enhances the splicing of HIV RNA in infected PBMCs from six healthy individuals and also the expression and splicing of a single long noncoding RNA to generate the anti-inflammatory miR-124 both ex vivo and in HIV patients.”
> “While ABX464 has no effect on pre-mRNA splicing of cellular genes, depletion of CBC complex by RNAi leads to accumulation of intron retention transcripts.”
> “These results imply that ABX464 did not inhibit the function of CBC in splicing but rather strengthens it under pathological condition like inflammation and HIV infection.”

Source: [Vautrin et al. (2019)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6349857/)

<a id="topic-2.1.2.6.1-3"></a>

###### Pharmacologically active N-glucuronide metabolite acting on the same target

> “Obefazimod is an investigational, oral, once-daily, small molecule that selectively enhances the expression of miR-124 and has been shown to initiate anti-inflammatory downstream effects in preclinical animal models and in humans.”
> “ABX464-N-Glu is pharmacologically active and binds, like obefazimod, to the Cap-Binding Complex (CBC) leading to enhanced expression of miR-124.”

Source: [Abivax ABX464-105 protocol (2024)](https://cdn.clinicaltrials.gov/large-docs/03/NCT05507203/Prot_000.pdf)

<a id="topic-2.1.2.6.1-4"></a>

###### Downstream effects on Th17 cells, macrophages, and cytokines

> “It has been demonstrated that obefazimod enhances the expression of a single micro-RNA, miR-124, which plays a critical role in the regulation of the inflammatory response.”
> “In the context of inflammation, miR-124 is a natural regulator of the inflammatory response, controlling progression of inflammation and restoring homeostasis of the immune system, without causing broader immunosuppression.”
> “Once expressed, micro-RNA interact with specific mRNA targets and decrease their translation into proteins to regulate specific pathways.”
> “miR-124 is known to have an effect on two key immune cells, Th17 cells and macrophages, which causes reductions in both cell populations in the gut, as well as decreases in key related cytokines such as IL-17 and IL-6.”

Source: [Abivax Form 20-F (2026)](https://www.sec.gov/Archives/edgar/data/1956827/000195682726000012/abvx-20251231.htm)

> “Enhanced expression of miR-124 reduces the expression of key cytokines (IL6r, STAT3) and chemokines (CCL2/MCP1) involved in inflammatory pathways in IBD resulting in decreased macrophage recruitment and activation and Th17 cell differentiation (13).”

Source: [Abivax ABX464-105 protocol (2024)](https://cdn.clinicaltrials.gov/large-docs/03/NCT05507203/Prot_000.pdf)

<a id="topic-2.1.2.6.1-5"></a>

###### miR-124 as a modulator of inflammation: review by the discovery group

> “MiR-124 is a crucial modulator of inflammation and innate immunity that could provide therapeutic restitution of physiological pathways lost in inflammatory diseases.”
> “A recently discovered small quinoline, ABX464, was shown to upregulate miR-124 in human immune cells.”

Source: [Tazi et al. (2021)](https://pubmed.ncbi.nlm.nih.gov/33387693/)

<a id="heading-2.1.2.6.2"></a>

###### 2.1.2.6.2 Pharmacodynamics

<a id="topic-2.1.2.6.2-1"></a>

###### miR-124 expression in rectal biopsies and blood: phase 2b induction trial

> “The number of miR-124 copies was determined by ddPCR, at baseline and after 8 weeks of treatment, in rectal biopsies and blood samples from patients who received ABX464 (25, 50, or 100 mg) or placebo during a phase 2b trial (10) (Figure 4).”
> “At week 8, the number of miR-124 copies was significantly higher in the treatment groups than in the placebo group (the mean number of copies/cell: placebo, 746; ABX464 [25, 50, and 100 mg], 8,345, 8,347, and 9,171, respectively; Figure 4b).”
> “At week 8, the number of miR-124 copies was significantly higher in each treatment group than in the placebo group (the mean number of copies/cell: placebo, 28.93; ABX464 [25, 50, and 100 mg], 4,598, 8,517, and 13,753, respectively).”
> “A total of 576 rectal biopsies from 139 patients and 1,104 blood samples from 229 patients who received ABX464 (25, 50, or 100 mg) or placebo were analyzed.”

Source: [Apolit et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10132720/)

<a id="topic-2.1.2.6.2-2"></a>

###### Serum cytokines: phase 2b induction trial

> “For the cell and cytokine (IL1b, IL4, IL6, IL10, IL23, IFNγ, CCL2, TNF-α, and IL17a) analysis in serum samples from patients who received either ABX464 during the phase 2b trial (10), significant changes vs placebo were seen only for IL17a, at all doses, with no dose-dependent effect (Figure 5).”
> “Similarly, a reduction in Th17 population and IL17a expression was observed in serum samples, but it was not dose-dependent (see Discussion).”

Source: [Apolit et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10132720/)

<a id="topic-2.1.2.6.2-3"></a>

###### miR-124 expression and serum IL-17A and IL-6: ABTECT induction trials

> “In both Phase 3 ABTECT trials, Obe-25 and 50 mg significantly enhanced expression of miR-124 in blood (p < 0.0001 vs. PBO) and in rectal and sigmoidal tissue at W8 relative to PBO (p < 0.0001 vs. PBO) (Fig. 1).”
> “In both ABTECT trials, Obe-25 and 50 mg significantly reduced IL-17A levels in serum at W8 compared with PBO (p < 0.0001).”
> “IL-6 levels were decreased by Obe-25 (p = 0.0150) and Obe-50 (p = 0.0039) in serum of pts from ABTECT-1 and ABTECT-2 in comparison to PBO, respectively (Fig. 2).”
> “In the ABTECT induction trials conducted in pts with UC, Obe was associated with enhanced expression of miR-124 and nominally statistically significant reductions in the pro-inflammatory cytokines IL-17A and IL-6.”

Source: [Siegmund et al. (2026)](https://academic.oup.com/ecco-jcc/article/20/Supplement_1/jjaf231.1049/8433989)

> “IL-17A and IL-6 reflect effects on the Th17 and inflammatory macrophage populations, which are all drivers of mucosal inflammation in both UC and CD.”

Source: [Abivax Form 20-F (2026)](https://www.sec.gov/Archives/edgar/data/1956827/000195682726000012/abvx-20251231.htm)

<a id="topic-2.1.2.6.2-4"></a>

###### miR-124 expression through 96 weeks: phase 2b open-label maintenance study

> “Treatment with obefazimod 50 mg significantly enhanced the expression of miR-124 in blood and rectal tissue at weeks 48 and 96 (P < .001 vs. baseline) (Figure 6).”
> “Enhanced expression of miR-124 was observed in both rectal tissue and blood of patients receiving obefazimod 50 mg during the OLM study, including those previously receiving placebo during the induction study (Table S2).”

Source: [Vermeire et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12124117/)

<a id="topic-2.1.2.6.2-5"></a>

###### miR-124 induction and Th17 cells in human immune cells: in vitro studies

> “In this analysis, ABX464 treatment resulted in significant upregulation of miR-124 levels; specifically, the increases in miR-124 levels were 9-fold in PBMCs (Figure 1a), 7-fold in purified CD4+ cells (Figure 1b), and 9-fold in macrophages (Figure 1c).”
> “ABX464 treatment did not change Th1+ cells but significantly decreased Th17 cells (−39.1%, P = 0.0002) or Th17+ like Th1+ (Figure 2b), confirmed by significant decreases (−50.8%, P < 0.0001) in IL17a-secreting cells (Figure 2c).”

Source: [Apolit et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10132720/)

<a id="topic-2.1.2.6.2-6"></a>

###### Dextran sodium sulfate colitis in mice

> “Treatment with ABX464 significantly reversed the increases in several proinflammatory cytokines induced by DSS (GM-CSF, IL10, IL34, TPO, LIF, CXCL12, IL6, and CCL2) and maintained their levels close to those of healthy H2O-treated mice (Figure 7a–c).”
> “ABX464 treatment reversed the DSS-induced upregulation of IL17a-secreting cells (−54.2%, P < 0.0001 vs untreated DSS mice) and maintained them at a level equivalent to that in healthy H2O-treated mice (P > 0.9999) (Figure 8a), which further support the effect of ABX464 on adaptive immunity through the reduction of the Th17-positive and CD4-positive subsets.”

Source: [Apolit et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10132720/)

> “ABX464 treatment strongly attenuated DSS-induced colitis in mice and produced a long-term protection against prolonged DSS-exposure after drug cessation.”
> “However, RNA profiling analysis revealed the capacity of ABX464 to induce the expression of IL-22, a cytokine involved in colitis tissue repair, both in DSS-treated mice and in LPS-stimulated bone marrow-derived macrophages.”
> “Importantly, anti-IL-22 antibodies significantly reduced the protective effect of ABX464 on colitis in DSS-treated mice.”

Source: [Chebli et al. (2017)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5501810/)

<a id="topic-2.1.2.6.2-7"></a>

###### Cytokine and chemokine levels under dysregulated inflammatory conditions: preclinical studies

> “Under dysregulated inflammatory conditions in preclinical studies, enhanced expression of miR-124 resulted in stabilized levels of multiple cytokines and chemokines, bringing them back to homeostatic levels.”

Source: [Abivax obefazimod web page](https://www.abivax.com/our-science/obefazimod/)

<a id="topic-2.1.2.6.2-8"></a>

###### Anti-fibrotic activity in human intestinal fibroblasts and chronic TNBS colitis in mice

> “Our results were as follows: in vitro, obefazimod induced a statistically significant 50% reduction in PRO-C3 at day 12, compared with the IBD-FC condition and upadacitinib (live-cell–adjusted, p<0.0001 vs. IBD-FC).”
> “Additionally, cell-number–adjusted analysis showed significant α-SMA reduction by obefazimod indicating a strong inhibition of fibroblast activation (p< 0.0001 vs. IBD-FC, as shown below).”
> “Moreover, results from this initial experiment showed a reduction in the fibrosis score and collagen deposition was reduced by approximately 52% with day 5 dosing and approximately 42% with day 20 dosing in the Sirius Red assay, whereas thalidomide as a positive control achieved approximately 24%.”

Source: [Abivax Form 20-F (2026)](https://www.sec.gov/Archives/edgar/data/1956827/000195682726000012/abvx-20251231.htm)

<a id="topic-2.1.2.6.2-9"></a>

###### Nonclinical toxicology and genotoxicity

> “The toxicity of obefazimod and ABX464-N-Glu was studied in a range of rodent and non-rodent species (rats, rabbits, dogs, cynomolgus and marmoset monkeys, and minipigs) with treatment durations ranging from 2 weeks to 6 or 9 months.”
> “Obefazimod had no significant adverse effects on the nervous and respiratory systems, or on cardiovascular function.”
> “Obefazimod and ABX464-N-Glu were found to be non-genotoxic.”

Source: [Abivax ABX464-105 protocol (2024)](https://cdn.clinicaltrials.gov/large-docs/03/NCT05507203/Prot_000.pdf)

<a id="heading-2.1.2.6.3"></a>

###### 2.1.2.6.3 Pharmacokinetics

<a id="topic-2.1.2.6.3-1"></a>

###### Absorption and conversion to the N-glucuronide metabolite: first-in-human single ascending dose study

> “A single oral dose of ABX464 (50, 100, 150 or 200 mg) was administered on the morning of day 0 after overnight fasting, with follow-up for 45 days.”
> “ABX464's C max was observed approximately 2 h after administration in all groups.”
> “ABX464 was rapidly and substantially metabolized into ABX464-NGlc.”
> “The C max of ABX464-NGlc was observed approximately 4 h post-dose and was about 160-fold higher than that of the parent with a much longer t 1/2 (90-110 h).”
> “The ratio of metabolite to parent drug was consistent across the complete dose range.”

Source: [Scherrer et al. (2017)](https://pubmed.ncbi.nlm.nih.gov/27999038/)

<a id="topic-2.1.2.6.3-2"></a>

###### Half-lives of the parent compound and the metabolite after repeated doses

> “ABX464 was rapidly eliminated with a half-life (t1/2) of about 1 h, while its metabolite, ABX464-NGlc, was very slowly cleared with a t1/2 of about 100 h.”

Source: [Steens et al. (2017)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5487684/)

<a id="topic-2.1.2.6.3-3"></a>

###### Metabolism by glucuronidation and time to steady state

> “In humans, obefazimod is metabolized via glucuronidation to ABX464-N-Glu, which contributes the majority of plasma exposure.”
> “After repeated administration of obefazimod, an initial decrease in obefazimod plasma area under the curve was observed until steady state was reached after 4 weeks of treatment.”

Source: [Abivax ABX464-105 protocol (2024)](https://cdn.clinicaltrials.gov/large-docs/03/NCT05507203/Prot_000.pdf)

<a id="topic-2.1.2.6.3-4"></a>

###### Effect of food on exposure

> “The maximum concentration (Cmax) and the area under the concentration-time curve from time zero to infinity (AUC0–∞) of ABX464 were demonstrated to increase with food after a single dose of ABX464 (219% and 188%, respectively).”
> “The apparent terminal elimination half-lives (t1/2s) under fed and fasted conditions were comparable, at about 0.80 h.”
> “The median time to maximum concentration (Tmax) was delayed from 1.5 to 2.8 h, and the ratio of the AUC0–∞ obtained under fed conditions to the AUC0–∞ obtained under fasted conditions (Frel) was 2.69.”
> “The increases in Cmax and AUC0–∞ of the metabolite ABX464–N-glucuronide (ABX464-NGlc) were, however, much more limited when ABX464 was given with food.”
> “The t1/2s were also comparable under the two conditions (around 100 h).”

Source: [Scherrer et al. (2016)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5192114/)

> “Food intake prior to administration significantly increased obefazimod exposure, by at least 3- to 4-fold.”

Source: [Abivax ABX464-105 protocol (2024)](https://cdn.clinicaltrials.gov/large-docs/03/NCT05507203/Prot_000.pdf)

<a id="topic-2.1.2.6.3-5"></a>

###### Interindividual variability under fed and fasted conditions

> “Interindividual variability tended to decrease when ABX464 was given with food, since the CVs of AUC0–t and AUC0–∞ under fasted conditions were 67% and 57% compared to 42% and 37%, respectively, under fed conditions.”

Source: [Scherrer et al. (2016)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5192114/)

Additional sources: [ClinicalTrials.gov NCT05032560](https://clinicaltrials.gov/study/NCT05032560)

<a id="heading-2.1.2.7"></a>

##### 2.1.2.7 Contraindications/Warnings/Precautions/Adverse Effects

<a id="heading-2.1.2.7.1"></a>

###### 2.1.2.7.1 Warnings and Precautions

Not applicable.

<a id="heading-2.1.2.8"></a>

##### 2.1.2.8 Special Populations

<a id="topic-2.1.2.8-1"></a>

###### Hepatic impairment: phase 1 pharmacokinetic study in mild and moderate impairment

> “A Phase I study to evaluate the pharmacokinetics, safety, and tolerability of multiple oral doses of obefazimod in patients with mild and moderate hepatic impairment, compared to matched control groups.”
> “Summary of the results: deferred: adult category 1 trial (mostly phase I), results to be published from 11 Mar 2027 (EMA/263067/2023).”

Source: [CTIS.eu 2023-505299-31-00](https://ctis.eu/trial/2023-505299-31-00)

> “(ii) a trial in participants with mild and moderate hepatic impairment compared to matched control normal liver function participants, for the purposes of assessing pharmacokinetics, safety and tolerability in this population, for which we enrolled 30 participants.”

Source: [Abivax Form 20-F (2026)](https://www.sec.gov/Archives/edgar/data/1956827/000195682726000012/abvx-20251231.htm)

<a id="topic-2.1.2.8-2"></a>

###### Renal impairment: phase 1 pharmacokinetic study

> “A Phase I study to evaluate the pharmacokinetics, safety and tolerability of multiple oral doses of obefazimod in participants with renal impairment and matched normal kidney function.”

Source: [EU Clinical Trials Information System 2024-514561-20-00](https://euclinicaltrials.eu/ctis-public/view/2024-514561-20-00)

<a id="topic-2.1.2.8-3"></a>

###### Renal and hepatic laboratory exclusions in the ABTECT induction trials

> “Creatinine clearance < 60 mL.min-1 (Cockroft-Gault formula)”
> “Total serum bilirubin > 1.5 x upper limit of normal (ULN) (except if related to pre-existing and documented Gilbert syndrome)”
> “Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) > 2 x ULN”

Source: [Abivax ABX464-105 protocol (2024)](https://cdn.clinicaltrials.gov/large-docs/03/NCT05507203/Prot_000.pdf)

<a id="topic-2.1.2.8-4"></a>

###### Pregnancy, breastfeeding, and contraception in the ABTECT trials

> “WOCBP subject who is pregnant or breast-feeding at screening, or intends to become pregnant during the study, or male subject with WOCBP partner who intends to be pregnant during the study.”
> “WOCBP should not be administered obefazimod until pregnancy is excluded and should use at least one highly effective method of contraception (failure rate < 1% when used consistently and correctly) depending on their country, during therapy with obefazimod and through the 4-week safety follow-up procedures.”
> “Sexually active male subjects participating in this study should use condoms for the duration of the active treatment period and through the 4-week safety follow-up procedures after the last dose of study medication.”

Source: [Abivax ABX464-105 protocol (2024)](https://cdn.clinicaltrials.gov/large-docs/03/NCT05507203/Prot_000.pdf)

<a id="topic-2.1.2.8-5"></a>

###### Pregnancy: reports in ABTECT maintenance Part 1

| Event | Placebo (N = 192) | Obefazimod 25 mg (N = 193) | Obefazimod 50 mg (N = 195) |
| --- | --- | --- | --- |
| Pregnancy | “0” | “0” | “2 (1.1%)” |

Source: [Sands et al. (2026a)](https://www.abivax.com/wp-content/uploads/2026/10/OP097-ABTECT-Topline-OP-DRAFT-07OCT2026-Sands-UEGW2026-ABVX-Obe-1.pdf)

<a id="topic-2.1.2.8-6"></a>

###### Contraception for male participants: phase 1 study in healthy Japanese men

> “Males receiving the study treatment and their partners must agree to use a highly effective contraceptive method during the study and for 6 months after the last dose of study drug.”

Source: [ClinicalTrials.gov NCT05032560](https://clinicaltrials.gov/study/NCT05032560)

<a id="topic-2.1.2.8-7"></a>

###### Older adults: participants aged 65 years or older in the ABTECT induction trials

> “Among the 1272 randomized and treated pts in ABTECT trials, 1183 were <65 yo and 89 were ≥65 yo”
> “Among pts <65 yo, TEAEs occurred in 59.8%, 49.5%, and 50.3% of those receiving Obe-50, Obe-25, and PBO, respectively.”
> “For patients ≥65 yo, rates were 65.9%, 38.9%, and 55.6%.”
> “Headache was the most frequent TEAE when treated with Obe across all age groups.”
> “Rates of serious TEAEs and TEAEs leading to study drug discontinuation were similar between Obe and PBO.”
> “In both ABTECT induction trials, obefazimod demonstrated consistent efficacy and safety in the elderly population, with no new or unexpected safety findings.”

Source: [Yarur et al. (2026)](https://www.abivax.com/wp-content/uploads/2026/04/abivax-poster-elderly-yarur-ddw-2026.pdf)

<a id="topic-2.1.2.8-8"></a>

###### Pediatric development: European paediatric investigation plan

> “the paediatric population from birth to less than 2 years of age;”
> “From 2 years to less than 18 years of age”
> “2-part, multi-centre, double-blind induction and maintenance study to evaluate the efficacy, safety, tolerability and PK of obefazimod in paediatric patients with moderately to severely active ulcerative colitis aged from 2 years to less than 18 years.”
> “By June 2029”

Source: [EMA paediatric investigation plan decision, March 2025 (2025)](https://www.ema.europa.eu/en/documents/pip-decision/ema-pe-0000189672-ema-decision-20-march-2025-acceptance-modification-agreed-paediatric-investigation-plan-obefazimod_en.pdf)

<a id="topic-2.1.2.8-9"></a>

###### Adolescents aged 16 to 17 years in the ABTECT induction trials

> “Pharmacokinetic (PK) modeling and simulations show that the PK profile of obefazimod is expected to be the same in subjects aged 16 to 18 years old compared with older subjects.”
> “However, no adolescents will be recruited in the EU/EEA and Ukraine, or from any other country unless authorized by the respective Regulatory Authorities and IEC-IRB.”

Source: [Abivax ABX464-105 protocol (2024)](https://cdn.clinicaltrials.gov/large-docs/03/NCT05507203/Prot_000.pdf)

<a id="topic-2.1.2.8-10"></a>

###### Pediatric minitablet formulation: relative bioavailability study in adults

> “The sponsor is developing a pediatric minitablet formulation as part of the overall pharmaceutical development strategy.”
> “The study aims to investigate the relative bioavailability of the 50mg minitablet compared to the adult obefazimod 50 mg capsule in adult healthy volunteers.”

Source: [ClinicalTrials.gov NCT07453784](https://clinicaltrials.gov/study/NCT07453784)

Additional sources: [EMA paediatric investigation plan decision P/0205/2024 (2024)](https://www.ema.europa.eu/en/documents/pip-decision/p-0205-2024-ema-decision-14-june-2024-acceptance-modification-agreed-paediatric-investigation-plan-obefazimod-emea-003196-pip01-22-m01_en.pdf)

<a id="heading-2.1.2.9"></a>

##### 2.1.2.9 Drug/Drug, Drug/disease Interactions

<a id="heading-2.1.2.9.1"></a>

###### 2.1.2.9.1 Effects of Other Drugs on Obefazimod

<a id="topic-2.1.2.9.1-1"></a>

###### Fluvoxamine, a CYP1A2 inhibitor: obefazimod exposure in healthy participants (Part B)

| Parameter | Day 1, obefazimod 50 mg alone | Day 11, obefazimod 50 mg with fluvoxamine 100 mg |
| --- | --- | --- |
| Participants analyzed | “25” | “25” |
| Cmax, ng/mL, mean (SD) | “23.2(12.5)” | “33.4(19.0)” |
| AUC, h*ng/mL, mean (SD) | “55.2(25.7)” | “73.0(34.2)” |

Source: [ClinicalTrials.gov NCT05121714 results](https://clinicaltrials.gov/study/NCT05121714?tab=results)

<a id="topic-2.1.2.9.1-2"></a>

###### Fluvoxamine: exclusions from the pharmacokinetic analysis

> “Of the 35 participants enrolled into Part B of the study, 9 participants were excluded from the PK analysis set due to meeting PK exclusion set criteria for a vomiting episode within 2 x median Tmax on either Day 1 or Day 11 and 1 participant was excluded as an early withdrawal from the study”

Source: [ClinicalTrials.gov NCT05121714 results](https://clinicaltrials.gov/study/NCT05121714?tab=results)

<a id="topic-2.1.2.9.1-3"></a>

###### Fluvoxamine: sponsor plain-language summary of results

> “ABX464 may be metabolised in the same pathway as fluvoxamine, as the levels of ABX464 in the blood showed increases in the presence of fluvoxamine.”
> “With respect to the safety objectives of the study, it was determined ABX464 was considered to be safe and well tolerated at a 50 mg dose strength, both in the presence and absence of caffeine and fluvoxamine respectively.”

Source: [Health Research Authority research summary, ABX464 drug-drug interaction study](https://www.hra.nhs.uk/planning-and-improving-research/application-summaries/research-summaries/a-2-part-drug-drug-interaction-study-of-abx464-in-healthy-volunteers)

<a id="heading-2.1.2.9.2"></a>

###### 2.1.2.9.2 Effects of Obefazimod on Other Drugs

<a id="topic-2.1.2.9.2-1"></a>

###### Caffeine, a CYP1A2 substrate: caffeine exposure with single and repeated obefazimod doses (Part A)

| Parameter | Day 1, caffeine 50 mg alone | Day 4, caffeine with obefazimod 50 mg | Day 17, caffeine with obefazimod after 14 days of daily dosing |
| --- | --- | --- | --- |
| Participants analyzed | “22” | “22” | “22” |
| Caffeine Cmax, ng/mL, mean (SD) | “931(285)” | “930(278)” | “564(242)” |
| Caffeine AUC, h*ng/mL, mean (SD) | “7420(4760)” | “5460(2740)” | “1560(719)” |

Source: [ClinicalTrials.gov NCT05121714 results](https://clinicaltrials.gov/study/NCT05121714?tab=results)

<a id="topic-2.1.2.9.2-2"></a>

###### Caffeine: design of the inhibition and induction assessments

> “Caffeine is administered on Day 1 in the absence of ABX464, on Day 4 simultaneously with ABX464 to evaluate potential CYP1A2 inhibition by ABX464, and on Day 17 simultaneously with ABX464 following 14 days of once daily dosing of ABX464 to evaluate potential CYP1A2 induction by ABX464.”
> “Of the 24 participants enrolled into Part A of the study, 2 participants were excluded from the PK analysis set due to meeting PK exclusion set criteria for non-adherence with pre-dose caffeine restrictions.”

Source: [ClinicalTrials.gov NCT05121714 results](https://clinicaltrials.gov/study/NCT05121714?tab=results)

<a id="topic-2.1.2.9.2-3"></a>

###### Caffeine: sponsor plain-language summary of results

> “ABX464 does not demonstrate any drug-drug interactions for drugs which are broken down (metabolised) by the enzyme CYP1A2 as the levels of caffeine and fluvoxamine in the blood remained similar in both the presence and absence of ABX464.”

Source: [Health Research Authority research summary, ABX464 drug-drug interaction study](https://www.hra.nhs.uk/planning-and-improving-research/application-summaries/research-summaries/a-2-part-drug-drug-interaction-study-of-abx464-in-healthy-volunteers)

<a id="topic-2.1.2.9.2-4"></a>

###### Rosuvastatin: phase 1 interaction study in healthy men

> “A Phase 1, 2-part, open-label, single-sequence study to investigate the effect of single and multiple doses of obefazimod on the pharmacokinetics of rosuvastatin in healthy male participants.”
> “Summary of the results: deferred: adult category 1 trial (mostly phase I), results to be published from 20 Aug 2027 (EMA/263067/2023).”

Source: [CTIS.eu 2023-509226-21-00](https://ctis.eu/trial/2023-509226-21-00)

<a id="topic-2.1.2.9.2-5"></a>

###### Combined oral contraceptive (ethinyl estradiol and drospirenone): phase 1 interaction study in healthy women

> “A study to investigate the effects of multiple doses of obefazimod on a combined oral contraceptive (ethinyl estradiol/drospirenone) in healthy female participants of childbearing potential.”
> “Summary of the results: deferred: adult category 1 trial (mostly phase I), results to be published from 28 Feb 2027 (EMA/263067/2023).”

Source: [CTIS.eu 2023-505297-15-00](https://ctis.eu/trial/2023-505297-15-00)

<a id="topic-2.1.2.9.2-6"></a>

###### Completed interaction studies supporting the planned NDA

> “(i) two drug-drug interaction trials, for the purposes of providing further information on any possible interactions of obefazimod with other drugs, for which we enrolled 24 and 36 healthy volunteers respectively;”
> “The results of these Phase 1 clinical trials provide supportive data for our further clinical development and New Drug Application”

Source: [Abivax Form 20-F (2026)](https://www.sec.gov/Archives/edgar/data/1956827/000195682726000012/abvx-20251231.htm)

Additional sources: [Abivax ABX464-902 protocol and statistical analysis plan (2021)](https://cdn.clinicaltrials.gov/large-docs/14/NCT05121714/Prot_SAP_000.pdf)

<a id="heading-2.1.2.10"></a>

##### 2.1.2.10 Dosing and Administration

<a id="heading-2.1.2.10.1"></a>

###### 2.1.2.10.1 Dosage

<a id="topic-2.1.2.10.1-1"></a>

###### Phase 3 doses: 25 mg and 50 mg once daily for induction and maintenance

> “The ABTECT-1 and ABTECT-2 induction trials are global, multicenter, randomized, double-blind, placebo-controlled trials assessing once-daily oral administration of obefazimod at 25 mg or 50 mg doses in adult patients with moderately to severely active UC.”

Source: [Abivax press release, ABTECT induction results (2025)](https://ir.abivax.com/news-releases/news-release-details/abivax-announces-positive-phase-3-results-both-abtect-8-week)

> “The Phase 3 ABTECT maintenance trial is a global 44-week multicenter, randomized, double-blind, placebo-controlled trial that evaluated the long-term efficacy and safety of obefazimod at 25 mg and 50 mg administered orally once-daily in adults with moderately to severely active UC.”

Source: [Abivax press release, ABTECT maintenance results (2026)](https://ir.abivax.com/news-releases/news-release-details/abivax-announces-landmark-phase-3-abtect-maintenance-trial)

<a id="topic-2.1.2.10.1-2"></a>

###### Fixed dose in ABTECT induction: one capsule daily, no dose adjustment

> “All subjects regardless of the treatment group will receive 1 capsule every day:”
> “No dose escalation/dose adjustments are allowed.”

Source: [Abivax ABX464-105 protocol (2024)](https://cdn.clinicaltrials.gov/large-docs/03/NCT05507203/Prot_000.pdf)

<a id="topic-2.1.2.10.1-3"></a>

###### Maintenance dose strategy: company report of regulatory consultant support for both 25 mg and 50 mg

> “Consensus recommendation to pursue both maintenance doses (25 mg & 50 mg)”
> “Multiple former FDA senior leaders consistently concluded that obefazimod has a favorable benefit-risk profile, that a boxed warning is highly unlikely, and that both the 25 mg and 50 mg maintenance doses should advance”

Source: [Abivax corporate presentation (2026)](https://ir.abivax.com/static-files/ecf996c4-f156-4dac-8e1e-5c4e7cfb8e7d)

<a id="topic-2.1.2.10.1-4"></a>

###### Dose escalation from 25 mg to 50 mg after relapse in ABTECT maintenance Part 2

> “Patients who achieved clinical response with obefazimod during induction and relapsed after being re-randomized to placebo in Part 1 of the maintenance trial were treated with open-label 50 mg obefazimod and achieved clinical response and remission rates of 69.7% and 45.0%, respectively, while patients who relapsed on 25 mg and escalated to 50 mg achieved clinical response and remission rates of 66.7% and 45.5%, respectively.”
> “These findings demonstrate the potential for obefazimod to re-establish disease control following relapse and support a flexible maintenance treatment strategy.”

Source: [Abivax press release, ABTECT maintenance Part 2 results (2026)](https://ir.abivax.com/news-releases/news-release-details/abivax-reports-positive-abtect-maintenance-part-2-results)

<a id="topic-2.1.2.10.1-5"></a>

###### Dose de-escalation from 50 mg to 25 mg in the long-term open-label Study 108

> “In this open-label maintenance (“OLM”) trial, patients who had completed the four-year Phase 2a or two-year Phase 2b OLM trials, where they had received 50 mg of once-daily obefazimod, were given the opportunity to continue receiving obefazimod at a reduced dose of 25 mg daily for up to five additional years”

Source: [Abivax first quarter 2026 results announcement (2026)](https://ir.abivax.com/news-releases/news-release-details/abivax-presents-first-quarter-2026-financial-results-and-reports)

<a id="topic-2.1.2.10.1-6"></a>

###### Phase 2b dose range: 25 mg, 50 mg, and 100 mg once daily

> “Enrolled patients were randomly assigned (1:1:1:1) via an interactive voice and web response system to receive once daily oral ABX464 100 mg, ABX464 50 mg, ABX464 25 mg, or matched placebo.”

Source: [Vermeire et al. (2022)](https://pubmed.ncbi.nlm.nih.gov/36075249/)

<a id="heading-2.1.2.10.2"></a>

###### 2.1.2.10.2 Administration

<a id="topic-2.1.2.10.2-1"></a>

###### Oral, once daily in the morning with food

> “Administered once daily in the morning with food”
> “Subjects will be orally dosed daily in a fed condition ideally at the same time in the morning) for 8 weeks”

Source: [ClinicalTrials.gov NCT05507203](https://clinicaltrials.gov/study/NCT05507203)

> “Subjects will be orally dosed daily in a fed condition (ideally at the same time in the morning) with a glass of water.”

Source: [Abivax ABX464-105 protocol (2024)](https://cdn.clinicaltrials.gov/large-docs/03/NCT05507203/Prot_000.pdf)

> “Administered once daily, preferably in the morning, with food”

Source: [ClinicalTrials.gov NCT05535946](https://clinicaltrials.gov/study/NCT05535946)

<a id="topic-2.1.2.10.2-2"></a>

###### Effect of food on exposure: healthy volunteers, 50 mg

> “The maximum concentration (Cmax) and the area under the concentration-time curve from time zero to infinity (AUC0–∞) of ABX464 were demonstrated to increase with food after a single dose of ABX464 (219% and 188%, respectively).”
> “It was concluded that food has a significant impact on the levels of ABX464 in plasma with a delay in absorption and increased relative bioavailability, with a lesser impact on its biotransformation into ABX464-NGlc.”

Source: [Scherrer et al. (2016)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5192114/)

<a id="heading-2.1.2.11"></a>

##### 2.1.2.11 Access and Distribution

<a id="topic-2.1.2.11-1"></a>

###### Commercial organization: market access, pricing, and patient services leadership appointed in July 2026

> “today announced the expansion of its Commercial Leadership Team with four strategic appointments spanning marketing, patient services, sales, commercial operations, and market access.”
> “As Global Head of Patient Services at Abivax, he leads the development of the Company's patient services model for obefazimod.”
> “As Global Head of Market Access & Pricing, he is responsible for developing market access and pricing strategies to support the potential commercialization of obefazimod.”

Source: [Abivax press release, commercial leadership appointments (2026)](https://ir.abivax.com/news-releases/news-release-details/abivax-strengthens-commercial-capabilities-strategic-leadership)

<a id="topic-2.1.2.11-2"></a>

###### Commercial preparation for a U.S. launch

> “The increase was driven by costs related to the Company’s continued preparation for potential future sales and commercialization efforts for obefazimod in the U.S. which are expected to continue to accelerate in preparation for commercial launch.”

Source: [Abivax first half 2026 results announcement (2026)](https://ir.abivax.com/news-releases/news-release-details/abivax-presents-business-updates-and-first-half-2026-financial)

<a id="topic-2.1.2.11-3"></a>

###### Distribution and channel strategy under board review

> “Review and advise on launch readiness and execution plans, including market positioning, market access, pricing and reimbursement, distribution and channel strategy, patient services, commercial infrastructure, and sales and marketing;”

Source: [Abivax Form 20-F (2026)](https://www.sec.gov/Archives/edgar/data/1956827/000195682726000012/abvx-20251231.htm)

<a id="topic-2.1.2.11-4"></a>

###### Commercial supply: outsourced manufacturing and a second source manufacturer

> “We outsource all manufacturing operations and rely on European and North American third-party CMOs to supply clinical trials and finalize the development of obefazimod.”
> “We are in the process of further optimizing and scaling up our supply chain for obefazimod to ensure capacity for our expected commercial supply, if the FDA or foreign regulatory authority approved.”
> “In addition, we are in process of establishing a second source manufacturer for obefazimod to ensure continuity of product supply.”

Source: [Abivax Form 20-F (2026)](https://www.sec.gov/Archives/edgar/data/1956827/000195682726000012/abvx-20251231.htm)

<a id="topic-2.1.2.11-5"></a>

###### Specialty pharmacy network and patient support program

No evidence found.

<a id="heading-2.1.2.12"></a>

##### 2.1.2.12 Co-prescribed/Concomitant Therapies

<a id="topic-2.1.2.12-1"></a>

###### Background oral 5-ASA and oral corticosteroids permitted at a stable dose in ABTECT induction

> “At study entry, subjects randomized to any treatment group may continue certain background therapy for UC (e.g., 5-aminosalicylic acid [5-ASA] compounds and/or oral CS); therefore, even subjects randomized to the placebo treatment during the treatment period will have concomitant therapies that may be partially effective at controlling UC symptoms.”
> “For the treatment of UC (provided stable dose for at least 2 weeks prior to the screening endoscopy and during the whole induction study) the following medications are allowed upon entry into the study:”
> “Oral 5-ASA.”

Source: [Abivax ABX464-105 protocol (2024)](https://cdn.clinicaltrials.gov/large-docs/03/NCT05507203/Prot_000.pdf)

<a id="topic-2.1.2.12-2"></a>

###### Concomitant therapies prohibited in ABTECT induction: immunosuppressants and advanced therapies

> “Cyclosporine, tacrolimus, mycophenolate mofetil, or thalidomide must be stopped at least 4 weeks prior to Screening endoscopy.”
> “Azathioprine or 6-mercaptopurine or methotrexate must be stopped at least 2 weeks prior to Screening endoscopy.”
> “Infliximab, adalimumab, golimumab, anti-TNF biosimilars, ozanimod, mirikizumab must be stopped at least 8 weeks prior to Screening endoscopy.”
> “Vedolizumab and ustekinumab or their biosimilars must be stopped at least 12 weeks prior to Screening endoscopy.”
> “Tofacitinib, filgotinib, upadacitinib, etrasimod must be stopped at least 2 weeks prior to Screening endoscopy.”
> “Antidiarrheals and motility agents (e.g., loperamide, diphenoxylate with atropine) must be stopped at least 2 weeks prior to Screening endoscopy.”

Source: [Abivax ABX464-105 protocol (2024)](https://cdn.clinicaltrials.gov/large-docs/03/NCT05507203/Prot_000.pdf)

<a id="topic-2.1.2.12-3"></a>

###### Concomitant oral corticosteroids in ABTECT maintenance: randomization stratification and baseline use

> “Randomization stratification factors: clinical remission at maintenance baseline (yes/no), induction treatment (25 mg/50 mg), and maintenance baseline oral corticosteroids usage (yes/no)”

Source: [Sands et al. (2026a)](https://www.abivax.com/wp-content/uploads/2026/10/OP097-ABTECT-Topline-OP-DRAFT-07OCT2026-Sands-UEGW2026-ABVX-Obe-1.pdf)

| Characteristic | Placebo | Obefazimod 25 mg | Obefazimod 50 mg |
| --- | --- | --- | --- |
| Corticosteroid use at maintenance baseline | “35.9%” | “41.5%” | “40.5%” |

Source: [Sands et al. (2026a)](https://www.abivax.com/wp-content/uploads/2026/10/OP097-ABTECT-Topline-OP-DRAFT-07OCT2026-Sands-UEGW2026-ABVX-Obe-1.pdf)

<a id="topic-2.1.2.12-4"></a>

###### Corticosteroid-free clinical remission as a maintenance key secondary endpoint

> “Both doses of obefazimod met all key secondary endpoints (endoscopic improvement, endoscopic remission, HEMI1, corticosteroid free clinical remission, and sustained clinical remission), demonstrating robust and clinically meaningful efficacy results across multiple measures of disease control.”

Source: [Abivax press release, ABTECT maintenance results (2026)](https://ir.abivax.com/news-releases/news-release-details/abivax-announces-landmark-phase-3-abtect-maintenance-trial)

<a id="topic-2.1.2.12-5"></a>

###### Combination therapy with obefazimod: preclinical evaluation

> “Throughout 2026, initial preclinical results from ongoing studies evaluating obefazimod in combination with other agents (currently targeted combination MOAs include IL-23, a4b7, PDE-4 and AhR) will be shared, with a lead combination candidate selected to advance into development by year-end.”

Source: [Abivax press release, 2026 corporate outlook (2026)](https://ir.abivax.com/news-releases/news-release-details/abivax-provides-2026-corporate-outlook)

> “We have initiated a formal process evaluating oral and injectable combination therapy candidate with obefazimod in UC.”

Source: [Abivax Form 20-F (2026)](https://www.sec.gov/Archives/edgar/data/1956827/000195682726000012/abvx-20251231.htm)

> “End of 2026 IBD Combo Therapy Candidate Selection”

Source: [Abivax corporate presentation (2026)](https://ir.abivax.com/static-files/ecf996c4-f156-4dac-8e1e-5c4e7cfb8e7d)

<a id="heading-2.1.2.13"></a>

##### 2.1.2.13 Effect of Obefazimod on Quality Measures

<a id="topic-2.1.2.13-1"></a>

###### MIPS Quality ID 275: hepatitis B virus status assessed before anti-TNF therapy in IBD

> “Quality ID #275: Inflammatory Bowel Disease (IBD): Assessment of Hepatitis B Virus (HBV) Status Before Initiating Anti-TNF (Tumor Necrosis Factor) Therapy”
> “Percentage of patients with a diagnosis of inflammatory bowel disease (IBD) who had Hepatitis B Virus (HBV) status assessed and results interpreted prior to initiating anti-TNF (tumor necrosis factor) therapy.”

Source: [CMS MIPS Quality ID 275 specification (2025)](https://qpp.cms.gov/docs/QPP_quality_measure_specifications/CQM-Measures/2026_Measure_275_MIPSCQM.pdf)

<a id="topic-2.1.2.13-2"></a>

###### Product-specific effect on quality measures

No evidence found.

<a id="heading-2.1.2.14"></a>

##### 2.1.2.14 Product comparison

<a id="topic-2.1.2.14-1"></a>

###### Network meta-analysis of phase 3 induction trials including obefazimod

> “Thirty-three induction trials involving 17 therapies were included.”
> “Upadacitinib demonstrated the highest relative efficacy for clinical remission (risk ratio, 6.90; 95% confidence interval, 3.54-12.45; P score, 0.95; high confidence) and endoscopic improvement (risk ratio, 5.29; 95% confidence interval, 3.38-8.28; P score, 0.97; moderate confidence).”
> “In AT-naïve patients, obefazimod and upadacitinib showed the highest efficacy, whereas in AT-experienced patients, upadacitinib, ustekinumab, and tofacitinib ranked highest.”
> “Novel therapies, like obefazimod and subcutaneous guselkumab, may represent highly effective alternatives.”

Source: [Olivera et al. (2026)](https://pubmed.ncbi.nlm.nih.gov/42838315/)

<a id="topic-2.1.2.14-2"></a>

###### Mechanism of action relative to authorized immunological treatments

> “To our knowledge, currently there are no similar immunological treatments with a mechanism of action based on enhanced expression of a single microRNA miR-124 with marketing authorization granted by competent regulatory authorities.”

Source: [Abivax Form 20-F (2026)](https://www.sec.gov/Archives/edgar/data/1956827/000195682726000012/abvx-20251231.htm)

<a id="topic-2.1.2.14-3"></a>

###### Marketed and investigational classes named by the manufacturer as competitors

> “The molecules on the market and in development have various mechanisms of action and are primarily: (i) TNF-alpha inhibitors; (ii) IL-12/23 inhibitors; (iii) anti-integrin antibodies; (iv) IL-23 inhibitors; (v) JAK inhibitors; (vi) S1P receptor agonists; or (vii) TL1A inhibitors.”
> “Current oral therapies that target inflammatory pathways include JAK inhibitors (such as tofacitinib and upadacitinib), as well as agents that reduce the trafficking of inflammatory cells, such as S1P receptor agonists (e.g., ozanimod and etrasimod).”
> “Merck, Roche, and Teva/Sanofi are all potential future competitors based on recent acquisitions of TL1A molecules.”

Source: [Abivax Form 20-F (2026)](https://www.sec.gov/Archives/edgar/data/1956827/000195682726000012/abvx-20251231.htm)

> “In this context, market research following the announcement of the ABTECT Phase 3 induction results in July 2025 indicates that obefazimod may emerge as the future market leader in UC, potentially outperforming both currently approved therapies and anticipated future entrants, including TL1A inhibitors and oral IL-23 agents.”

Source: [Abivax press release, 2026 corporate outlook (2026)](https://ir.abivax.com/news-releases/news-release-details/abivax-provides-2026-corporate-outlook)

<a id="topic-2.1.2.14-4"></a>

###### Company cross-trial comparison of maintenance clinical remission with approved UC products

> “Maintenance Efficacy of FDA/EMA Approved UC Products: Clinical Remission* at 52 Weeks Induction Responders Only”
> “For illustrative purposes only. Not a head-to-head comparison. Differences exist between trial designs and subject characteristics, and caution should be exercised when comparing data across trials.”

Source: [Abivax corporate presentation (2026)](https://ir.abivax.com/static-files/ecf996c4-f156-4dac-8e1e-5c4e7cfb8e7d)

<a id="topic-2.1.2.14-5"></a>

###### Emerging oral small molecules for ulcerative colitis

> “Some molecules, such as miRNA-124 upregulators, JAKi, S1P modulators, and LANCL2 agonists, may enrich our therapeutic armamentarium in UC management.”

Source: [Lanzotti et al. (2026)](https://pubmed.ncbi.nlm.nih.gov/42251531/)

<a id="topic-2.1.2.14-6"></a>

###### Analyst comment on a possible boxed warning relative to JAK inhibitors and TL1A inhibitors

> “We also remain mindful of the possibility of a Black Box warning, which would limit commercial differentiation against JAK inhibitors and negatively position obefazimod against emerging classes in IBD, including TL1A inhibitors.”

Source: [Streetwise Reports (2026)](https://www.streetwisereports.com/article/2026/07/01/clinical-stage-biotech-discloses-colitis-retreatment-results-gets-mixed-ratings.html)

<a id="heading-2.2"></a>

### 2.2 Place of Product in Therapy

<a id="heading-2.2.1"></a>

#### 2.2.1 Disease Description

<a id="heading-2.2.1.1"></a>

##### 2.2.1.1 Definition and Etiology

<a id="topic-2.2.1.1-1"></a>

###### Disease definition: chronic inflammation of the rectum and colon

> “Ulcerative colitis is a lifelong inflammatory disease affecting the rectum and colon to a variable extent.”

Source: [Le Berre et al. (2023)](https://pubmed.ncbi.nlm.nih.gov/37573077/)

> “Ulcerative colitis (UC) is a chronic inflammatory condition of the colon, with a prevalence exceeding 400 per 100 000 in North America.”

Source: [Gros and Kaplan (2023)](https://pubmed.ncbi.nlm.nih.gov/37698559/)

> “UC is characterized by chronic inflammation of the large intestine that is frequently associated with involvement of the rectum but often extends proximally to involve additional areas of the colon.”
> “Absence of rectal involvement has been noted in fewer than 5% of adult patients with UC at diagnosis but may be seen in up to a third of pediatric onset colitis (3).”
> “UC is an idiopathic chronic inflammatory condition of the rectum and colon which presents with variable degrees of clinical activity and severity and is associated with significant morbidity.”

Source: [Rubin et al. (2025)](https://journals.lww.com/ajg/fulltext/10.14309/ajg.0000000000003463)

> “Ulcerative colitis (UC) is a chronic inflammatory bowel disease (IBD) that affects the mucosa, the innermost lining of the intestinal wall in the large bowel (i.e., the colon and rectum).”

Source: [ICER Targeted Immune Modulators for Ulcerative Colitis final evidence report (2020)](https://icer.org/wp-content/uploads/2020/08/ICER_UC_Final_Evidence_Report_101620.pdf)

<a id="topic-2.2.1.1-2"></a>

###### Etiology: genetic predisposition, environmental exposures, barrier defects, microbiota, and immune dysregulation

> “Ulcerative colitis is thought to occur in people with a genetic predisposition following environmental exposures; gut epithelial barrier defects, the microbiota, and a dysregulated immune response are strongly implicated.”

Source: [Le Berre et al. (2023)](https://pubmed.ncbi.nlm.nih.gov/37573077/)

> “Ulcerative colitis (UC) is a chronic inflammatory bowel disease of unknown aetiology affecting the colon and rectum. Multiple factors, such as genetic background, environmental and luminal factors, and mucosal immune dysregulation, have been suggested to contribute to UC pathogenesis.”

Source: [Kobayashi et al. (2020)](https://pubmed.ncbi.nlm.nih.gov/32913180/)

> “Despite advances in understanding environmental associations and risks, the causes of UC remain complex and unknown (2).”

Source: [Rubin et al. (2025)](https://journals.lww.com/ajg/fulltext/10.14309/ajg.0000000000003463)

<a id="topic-2.2.1.1-3"></a>

###### Genetic susceptibility: shared loci with Crohn's disease, HLA associations, and low twin concordance

> “Most genetic factors (67% of susceptibility loci) are shared between UC and Crohn’s disease (CD)”
> “Sixteen human leukocyte antigen (HLA) allelic associations (mostly class II) are described for UC”
> “Thirdly, despite the identification of many susceptibility loci, genetics explain only 19% of disease heritability in UC 18. The concordance rate amongst monozygotic twins for UC is only 6.3% (compared to nearly 60% in CD).”

Source: [Porter et al. (2020)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7194476/)

<a id="topic-2.2.1.1-4"></a>

###### Environmental factors: Westernization, smoking cessation, and appendicitis

> “Westernisation is accompanied by new urban lifestyle, exposure to pollution, change in diet, access to antibiotics, better hygiene, and fewer infections, all considered as general contributory factors”
> “Appendicitis and smoking are protective in UC; smoking cessation can precede UC”

Source: [Porter et al. (2020)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7194476/)

> “Although the reasons for this increase remain incompletely understood, evidence suggests environmental factors associated with Westernization of society”
> “may have substantially contributed by altering mucosal immune responses to the intestinal microbiome in genetically susceptible individuals”

Source: [Hracs et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12158780/)

> “Potential precipitants of UC may include recent smoking cessation (20), non-steroidal anti-inflammatory drug (NSAID) use (21,22), as well as enteric infections (23).”

Source: [Rubin et al. (2025)](https://journals.lww.com/ajg/fulltext/10.14309/ajg.0000000000003463)

<a id="heading-2.2.1.2"></a>

##### 2.2.1.2 Epidemiology

<a id="heading-2.2.1.2.1"></a>

###### 2.2.1.2.1 Incidence of Ulcerative colitis

<a id="topic-2.2.1.2.1-1"></a>

###### United States: 6.3 per 100,000 person-years in pooled commercial, Medicare, and Medicaid claims

> “Overall, the incidence of ulcerative colitis (6.3, 95% CI 6.1–6.6) was higher than that of Crohn’s disease (4.1, 95% CI 3.9–4.3).”
> “The incidence of IBD, ulcerative colitis and Crohn’s disease peaked in the third decade of life, decreased to a stable relatively stable level across the 4th to 8th decades, and declined further beyond age 80.”
> “However, among children, the incidence of Crohn’s disease was higher than ulcerative colitis (Figure 1, Supplemental Table 1).”

Source: [Lewis et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10592313/)

<a id="topic-2.2.1.2.1-2"></a>

###### United States: age at onset

> “The condition may present at any time and at all ages, but there is a predominant age distribution of onset that peaks in the third decade of life.”

Source: [Rubin et al. (2025)](https://journals.lww.com/ajg/fulltext/10.14309/ajg.0000000000003463)

> “Most individuals are diagnosed between the ages of 15 and 35.”

Source: [ICER Targeted Immune Modulators for Ulcerative Colitis final evidence report (2020)](https://icer.org/wp-content/uploads/2020/08/ICER_UC_Final_Evidence_Report_101620.pdf)

<a id="topic-2.2.1.2.1-3"></a>

###### Global: highest incidence in Scandinavia, with a ceiling of about 40 per 100,000

> “The highest incidence of IBD, particularly UC, has been reported in Scandinavia (Fig. 1a,b).”
> “In Denmark, incidence steadily increased from the 1970s (CR-I: 2.05–3.55 for CD; 6.50–9.12 for UC) to 1990s (CR-I: 7.30–10.68 for CD; 13.18–20.99 for UC) and to 2010s (CR-I: 12.62–15.84 for CD; 22.21–30.64 for UC)”
> “The highest ever reported UC incidence was 73.7 in the Faroe Islands in 2011”
> “Thus, 40 per 100,000 serves as a ceiling threshold for the incidence of CD or UC.”

Source: [Hracs et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12158780/)

<a id="topic-2.2.1.2.1-4"></a>

###### Global: rising incidence in newly industrialized regions of Asia

> “By 2000, the incidence had increased tenfold reaching 4.77 and 1.27 for UC and CD, respectively (Supplementary Fig. 9a).”
> “South Korea showed similar patterns, with low incidence in the 1980s (CR-I: 0–0.03 for CD; 0.21–0.33 for UC) increasing steadily into the 2010s (CR-I: 2.20–3.20 for CD; 4.11–6.27 for UC)”
> “Regions with slower economic development experienced a delayed onset of rapidly rising incidence, as seen in China and Malaysia, where incidence substantially increased after 2000 (Supplementary Figs. 11a and 12a).”

Source: [Hracs et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12158780/)

<a id="topic-2.2.1.2.1-5"></a>

###### Global: incidence increasing worldwide

> “In 2023, the prevalence of ulcerative colitis was estimated to be 5 million cases around the world, and the incidence is increasing worldwide.”

Source: [Le Berre et al. (2023)](https://pubmed.ncbi.nlm.nih.gov/37573077/)

> “UC has evolved into a global burden given its high incidence in developed countries and the substantial increase in incidence in developing countries.”

Source: [Kobayashi et al. (2020)](https://pubmed.ncbi.nlm.nih.gov/32913180/)

<a id="topic-2.2.1.2.1-6"></a>

###### Global: ratio of ulcerative colitis to Crohn's disease by epidemiologic stage

> “We observed a significant difference (P < 0.001) in the UC:CD ratio across the three epidemiologic stages: a median ratio of 3.24:1 in stage 1, decreasing to 1.87:1 in stage 2 and further to 1.54:1 in stage 3 (Supplementary Fig. 17).”
> “On the basis of the assumption that Canada, the United States, most of western Europe, Australia and New Zealand are currently in stage 3, we assigned stage classifications to approximately 65% of our dataset (Supplementary Fig. 16).”

Source: [Hracs et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12158780/)

<a id="heading-2.2.1.2.2"></a>

###### 2.2.1.2.2 Prevalence of Ulcerative colitis

<a id="topic-2.2.1.2.2-1"></a>

###### United States: 378 per 100,000 and an estimated 1.253 million people with ulcerative colitis

> “The age-, sex- and insurance-standardized prevalence per 100,000 population was 721 (95% CI 717 – 726) for IBD, 378 per 100,000 (95% CI 375 – 382) for ulcerative colitis and 305 (95% CI 302 – 308) for Crohn’s disease.”
> “Extrapolated to the 2020 census estimate of 331,449,281 US population, there is an estimated 2.390 million Americans with IBD, 1.253 million with ulcerative colitis and 1.011 million with Crohn’s disease.”
> “Of note, the ratio of ulcerative colitis to Crohn’s disease was higher in Asian (1.6:1) and Hispanic (1.8:1) than in White (1.2:1) or Black (1.2:1) Americans.”

Source: [Lewis et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10592313/)

<a id="topic-2.2.1.2.2-2"></a>

###### United States: prevalence per 100,000 under alternative case definitions and enrollment periods

| Prevalence definition | Minimum enrollment | Prevalence per 100,000 (95% CI) |
| --- | --- | --- |
| Primary | 4 years | “378 (375–382)” |
| Secondary | 4 years | “438 (435–441)” |
| Primary | 1 year | “312 (310–314)” |
| Secondary | 1 year | “358 (356–361)” |

Source: [Lewis et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10592313/)

<a id="topic-2.2.1.2.2-3"></a>

###### United States: prevalence exceeding 400 per 100,000 in North America

> “UC affects approximately 400 of every 100 000 people in North America.”

Source: [Gros and Kaplan (2023)](https://pubmed.ncbi.nlm.nih.gov/37698559/)

<a id="topic-2.2.1.2.2-4"></a>

###### United States: Medicare fee-for-service beneficiaries

> “Among 25 million Medicare fee-for-service beneficiaries, there are approximately 100,000 people with CD (0.40%) and 160,000 people with UC (0.64%).”

Source: [ICER special assessment of Entyvio to inform CMS negotiation (2026)](https://icer.org/wp-content/uploads/2026/03/Entyvio_Final-Evidence-Report_For-Publication_030326.pdf)

<a id="topic-2.2.1.2.2-5"></a>

###### United States: moderately to severely active disease, about 22% of patients in a given year (ICER 2020, citing the Crohn's & Colitis Foundation)

> “To estimate the size of the potential candidate populations for treatment, we used an estimate by Turner et al. of the prevalence of individuals with UC in the US of approximately 900,000 patients.”
> “The Crohn’s and Colitis Foundation has reported that approximately 22% of UC patients have moderate-to-severe disease activity in a given year”

Source: [ICER Targeted Immune Modulators for Ulcerative Colitis final evidence report (2020)](https://icer.org/wp-content/uploads/2020/08/ICER_UC_Final_Evidence_Report_101620.pdf)

<a id="topic-2.2.1.2.2-6"></a>

###### Moderately to severely active disease at diagnosis: population-based inception cohorts

> “In a cohort of patients diagnosed in Copenhagen county between 1962–93, disease course was characterized as indolent, moderate or aggressive in 13%, 73% and 14% of patients, respectively, within the first 5-years of diagnosis; in the same region, in a cohort of patients diagnosed between 2003–04, early disease activity was characterized as mild in 76%, and moderate-to-severe in 24% (23,24).”

Source: [Fumery et al. (2018)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6658168/)

<a id="topic-2.2.1.2.2-7"></a>

###### United States: company estimates of moderate-to-severe patients and advanced therapy use

> “From 2020 to 2025, U.S. advanced therapy usage has increased by approximately 96% from approximately 138,000 advanced therapy patients in 2020 to approximately 271,000 advanced therapy patients in 2025.”
> “We currently estimate that approximately 300,000 moderate-to-severe UC patients in the United States, out of an estimated 500,000 patients, are on conventional therapy or steroids only, and a safe, efficacious, oral therapy will have the unique ability to further penetrate this patient segment.”

Source: [Abivax Form 20-F (2026)](https://www.sec.gov/Archives/edgar/data/1956827/000195682726000012/abvx-20251231.htm)

<a id="topic-2.2.1.2.2-8"></a>

###### United States: advanced therapy use after diagnosis in commercially insured adults, 2007 to 2023

> “Among 3,893 patients with newly diagnosed UC (age at diagnosis, 41±14y; 52% male; 80% White, 7.2% Black and 8.2% Hispanic patients) followed over 4.2±3.0y, 5-year risk of IBD-related hospitalization, colectomy and serious infection was 11%, 6%, and 10%, respectively, with lower risk in Hispanic patients (vs. White patients).”
> “Cumulative 1- and 5y use of advanced therapy was 17% (95% CI, 15–18) and 29% (95% CI, 27–31), respectively (Table 1). In a more contemporary cohort of patients diagnosed in 2019–23, the corresponding rate was 27% (95% CI, 24–29) and 38% (95% CI, 34–41), respectively (aHR, 3.43 [95% CI, 2.86–4.13]) (Figure 2C).”
> “Cumulative 1- and 5y use of TNF antagonists and non-TNF-targeting advanced therapy in the more contemporary cohort was 19% (95% CI, 16–21) and 26% (95% CI, 23–29), and 12% (95% CI, 10–14) and 27% (95% CI, 24–31), respectively.”

Source: [Ahuja et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13456955/)

<a id="topic-2.2.1.2.2-9"></a>

###### Global: about 5 million prevalent cases in 2023

> “In 2023, the prevalence of ulcerative colitis was estimated to be 5 million cases around the world, and the incidence is increasing worldwide.”

Source: [Le Berre et al. (2023)](https://pubmed.ncbi.nlm.nih.gov/37573077/)

<a id="topic-2.2.1.2.2-10"></a>

###### Global: prevalence ranges by epidemiologic stage and projected growth

> “The clear distinctions across stages define the CRs for the incidence and prevalence of IBD”
> “stage 1: CR-I = 0.1–1.2, CR-P = 1.2–10.5; stage 2: CR-I = 3.3–10.6, CR-P = 31.2–100.5; stage 3: CR-I = 18.1–34.1, CR-P = 362.9–660.1 (Fig. 2).”
> “Prevalence remains consistently low in regions classified as stage 1. Prevalence noticeably increases in stage 2 and then rises rapidly in stage 3 (Extended Data Fig. 2).”
> “A slowing of prevalence growth rates was also observed in central difference approximations for both CD and UC (Supplementary Fig. 18c,d).”

Source: [Hracs et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12158780/)

<a id="heading-2.2.1.3"></a>

##### 2.2.1.3 Natural History, Survival, and Mortality

<a id="topic-2.2.1.3-1"></a>

###### Disease course: relapsing and remitting, with relapse in 70% to 80% by 10 years

> “The pattern of inflammatory disease activity is most often, relapsing and remitting, with symptoms of active disease alternating with periods of clinical quiescence (remission). Some patients with UC have persistent disease activity despite available medical therapy, and a small number of patients present with a rapid onset progressive and unresponsive type of fulminant colitis (4,5).”

Source: [Rubin et al. (2025)](https://journals.lww.com/ajg/fulltext/10.14309/ajg.0000000000003463)

> “Majority of patients have a mild-moderate course, most active at diagnosis and then in varying periods of remission or mild activity; about 10–15% patients experience an aggressive course, and the cumulative risk of relapse is 70–80% at 10 years. Almost 50% patients require UC-related hospitalization, and 5-year risk of re-hospitalization is ~50%.”
> “In the 10y follow-up study of the IBSEN cohort, four different profiles of disease activity were reported by patients: remission or mild severity after initial period of high activity (55%), chronic intermittent symptoms (37%), chronic continuous symptoms (6%) and increase activity after period of low activity (1%) (18).”

Source: [Fumery et al. (2018)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6658168/)

<a id="topic-2.2.1.3-2"></a>

###### Disease extent at diagnosis and proximal extension

> “At diagnosis, the majority of patients had left-sided colitis (median 40.1%; IQR, 32.6–44.6); 30.5% (29.8–32.6) and 29.4% (25.3–34.7) were diagnosed with extensive colitis and proctitis, respectively (9–17).”
> “Overall rates of progression ranged from 12–30%, with cumulative 5-year risk of progression being approximately 13% (10,13,14).”

Source: [Fumery et al. (2018)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6658168/)

> “Up to 46% of patients with proctitis and 70% with left-sided colitis may develop extensive colitis on follow-up (95).”

Source: [Rubin et al. (2025)](https://journals.lww.com/ajg/fulltext/10.14309/ajg.0000000000003463)

<a id="topic-2.2.1.3-3"></a>

###### Hospitalization and colectomy: contemporary US inception cohort

> “Cumulative 5y risk of all-cause and IBD-related hospitalization was 17% (95% CI, 16–19) and 11% (95% CI, 10–12), respectively (Table 2). Risk of all-cause and IBD-related hospitalization remained stable over era of IBD diagnosis (Figure 2D).”
> “Cumulative 1- and 5y risk of colectomy was 2.2% (95% CI, 1.8–2.7) and 5.7% (95% CI, 4.8–6.7), respectively (Table 2). Cumulative 5y risk of colectomy was lower in the more contemporary cohort (patients diagnosed in 2019–23 vs. 2007–12: 4.2% vs. 6.7%; aHR, 0.58 [95% CI, 0.38–0.89]) (Figure 2E).”

Source: [Ahuja et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13456955/)

> “Within 5 years of diagnosis, approximately 20% of patients with UC are hospitalized and approximately 7% undergo colectomy.”

Source: [Gros and Kaplan (2023)](https://pubmed.ncbi.nlm.nih.gov/37698559/)

<a id="topic-2.2.1.3-4"></a>

###### Colectomy: meta-analysis of population-based cohorts

> “In patients with UC (26 studies), overall 1-, 5-, and 10-year risk of colectomy was 4.0% (95% CI,3.3–5.0), 8.8% (7.7–10.0) and 13.3% (11.3–15.5), respectively, with decline in risk over time (p<0.001). Corresponding contemporary risks were 2.8% (2.0–3.9), 7.0% (5.7–8.6) and 9.6% (6.3–14.2), respectively.”

Source: [Tsai et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8934200/)

<a id="topic-2.2.1.3-5"></a>

###### Life expectancy: about 5 years shorter than people without ulcerative colitis

> “Life expectancy in people with UC is approximately 80.5 years for females and 76.7 years for males, which is approximately 5 years shorter than people without UC.”

Source: [Gros and Kaplan (2023)](https://pubmed.ncbi.nlm.nih.gov/37698559/)

<a id="topic-2.2.1.3-6"></a>

###### Mortality: all-cause and cause-specific standardized mortality ratios

> “The all-cause mortality summary SMR for inception cohort and population cohort UC studies was 1.19 (95% confidence interval, 1.06–1.35).”
> “Mortality from colorectal cancer, pulmonary disease, and nonalcoholic liver disease was increased, whereas mortality from cardiovascular disease was decreased.”

Source: [Bewtra et al. (2013)](https://pmc.ncbi.nlm.nih.gov/articles/PMC3755276/)

> “UC has not been associated with an increased mortality, as compared to the general population, except in one cohort (23, 57–62).”
> “A meta-analysis of both administrative and inception population-based studies recently observed a pooled mortality rate of respectively 0.7% and 5.3% for elective and emergent surgery, respectively without significant decrease over time (39).”

Source: [Fumery et al. (2018)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6658168/)

> “UC causes significant morbidity but fortunately has a low incidence of mortality (6,7).”

Source: [Rubin et al. (2025)](https://journals.lww.com/ajg/fulltext/10.14309/ajg.0000000000003463)

Additional sources: [Jess et al. (2007)](https://pubmed.ncbi.nlm.nih.gov/17156150/)

<a id="heading-2.2.1.4"></a>

##### 2.2.1.4 Pathophysiology

<a id="topic-2.2.1.4-1"></a>

###### Overview: barrier disruption, dysbiosis, and abnormal mucosal immune activation

> “A widely accepted framework suggests a complex contribution of environmental and host factors that increase the susceptibility of developing UC, and disease onset is triggered by events that perturb the mucosal barrier, alter the healthy balance of the gut microbiota, and abnormally stimulate gut immune responses.”

Source: [Porter et al. (2020)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7194476/)

> “Ulcerative colitis is thought to occur in people with a genetic predisposition following environmental exposures; gut epithelial barrier defects, the microbiota, and a dysregulated immune response are strongly implicated.”

Source: [Le Berre et al. (2023)](https://pubmed.ncbi.nlm.nih.gov/37573077/)

<a id="topic-2.2.1.4-2"></a>

###### Mucosal inflammation: continuous from the rectum and limited to the mucosa

> “These clinical features include the almost-universal involvement of the rectum (the lowest part of the colon) as the first site where inflammation starts and the distinctively confluent nature of inflammation that ends with an abrupt demarcation and transition into normal colonic mucosa.”

Source: [Porter et al. (2020)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7194476/)

> “The disease causes long-lasting inflammation and ulcers in the digestive tract and is typically marked by periods of remission and recurrence of symptoms.”

Source: [ICER Targeted Immune Modulators for Ulcerative Colitis final evidence report (2020)](https://icer.org/wp-content/uploads/2020/08/ICER_UC_Final_Evidence_Report_101620.pdf)

<a id="topic-2.2.1.4-3"></a>

###### Epithelial barrier: impaired barrier and UC-specific epithelial susceptibility genes

> “An impaired epithelial barrier is a pathogenic factor for UC”
> “UC-specific genes implicate epithelial dysfunction”
> “With the histologic observation of subepithelial inflammation, many studies implicate an impaired epithelial barrier as a pathogenic factor for UC.”

Source: [Porter et al. (2020)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7194476/)

<a id="topic-2.2.1.4-4"></a>

###### Microbiota: reduced diversity and loss of short-chain fatty acid producers

> “The UC gut microbiome, virome, and mycobiome is less diverse over time”
> “A depletion of protective bacteria such as short-chain fatty acid (SCFA)-producing Ruminococcaceae and Lachnospiraceae that coincides with an expansion of pro-inflammatory microbes such as Enterobacteriaceae, including Escherichia coli, and Fusobacteriaceae has been noted 37, 38.”
> “It is not known if dysbiosis is a consequence of, or plays a causal role in, gut inflammation in UC.”

Source: [Porter et al. (2020)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7194476/)

<a id="topic-2.2.1.4-5"></a>

###### Immune response: innate activation, atypical Th2 response, and IL-23 and Th17 pathways

> “Innate immune responses (neutrophils/macrophages) may promote a pathogenic adaptive (likely T-cell driven) response”
> “Traditionally, UC is associated with a Th2 response with high IL-4, IL-5, and IL-13, whereas CD has a more dominant Th1/Th17 response 84.”
> “These include the identification of IL-23 as a key driver of Th17 responses 86, genetic associations with IL-23 and its related genes 11, 87, and the presence of Th17 88 (and Th9 89) cells in UC.”
> “Blocking IL-23, however, is effective in UC, e.g. mirikizumab (anti-p19 subunit of IL-23) 92 and ustekinumab (anti-p40 subunit of IL-23) 93.”

Source: [Porter et al. (2020)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7194476/)

> “An improved understanding of the mechanisms underlying UC has led to the emergence of new treatments.”

Source: [Kobayashi et al. (2020)](https://pubmed.ncbi.nlm.nih.gov/32913180/)

<a id="heading-2.2.1.5"></a>

##### 2.2.1.5 Diagnosis

<a id="topic-2.2.1.5-1"></a>

###### Diagnostic approach: clinical, biological, endoscopic, and histological findings

> “Patients usually present with bloody diarrhoea, and the diagnosis is based on a combination of clinical, biological, endoscopic, and histological findings.”

Source: [Le Berre et al. (2023)](https://pubmed.ncbi.nlm.nih.gov/37573077/)

> “UC is diagnosed based on the presence of symptoms with confirmation of disease via colonoscopy and biopsy.”

Source: [ICER Targeted Immune Modulators for Ulcerative Colitis final evidence report (2020)](https://icer.org/wp-content/uploads/2020/08/ICER_UC_Final_Evidence_Report_101620.pdf)

<a id="topic-2.2.1.5-2"></a>

###### ACG 2025 key concept statements: suspicion, exclusion of infection, and colonoscopy with biopsy

> “The diagnosis of UC should be suspected in patients with hematochezia, increased stool frequency, or bowel urgency.”
> “Infectious etiologies should be excluded at the time of diagnosis.”
> “Colonoscopy with intubation of the ileum and biopsies of affected and unaffected areas should be obtained to confirm the diagnosis of UC, with mucosal biopsies interpreted by a pathologist, preferably one with expertise in gastrointestinal pathology.”

Source: [Rubin et al. (2025)](https://journals.lww.com/ajg/fulltext/10.14309/ajg.0000000000003463)

<a id="topic-2.2.1.5-3"></a>

###### ACG 2025 recommendations: Clostridioides difficile testing and serologic antibody testing

> “We recommend stool testing to rule out Clostridioides difficile in patients suspected of having UC (Strong recommendation, very low quality of evidence).”
> “We recommend against serologic antibody testing to establish or rule out a diagnosis of UC (Strong recommendation, very low quality of evidence).”
> “We recommend against serologic antibody testing to determine the prognosis of UC (Strong recommendation, very low quality of evidence).”

Source: [Rubin et al. (2025)](https://journals.lww.com/ajg/fulltext/10.14309/ajg.0000000000003463)

<a id="topic-2.2.1.5-4"></a>

###### Endoscopy and histology: extent by the Montreal classification

> “The diagnosis of UC requires a lower gastrointestinal endoscopic examination with histologic confirmation. For most patients, a complete colonoscopy and direct visualization of the terminal ileum should be performed.”
> “Endoscopically, UC most often presents as a continuously inflamed segment involving the distal rectum and extending proximally. Endoscopic features of inflammation include loss of vascular markings, granularity and friability of the mucosa, erosions, and in the setting of severe inflammation, deep ulcerations and spontaneous bleeding.”
> “The extent of the disease should be characterized according to the currently used Montreal classification as proctitis (E1, usually defined as ≤15 cm of inflammation), left-sided colitis (E2, defined as more than proctitis, but the extent stops at or distal to the splenic flexure), or extensive colitis (E3, defined as extension proximal to the splenic flexure, with pancolitis defining the entire rectum and colon including the cecum) (Figure 1) (33,34).”

Source: [Rubin et al. (2025)](https://journals.lww.com/ajg/fulltext/10.14309/ajg.0000000000003463)

<a id="topic-2.2.1.5-5"></a>

###### Biomarkers: fecal calprotectin, C-reactive protein, and serology

> “The pooled sensitivity and specificity of elevated FC for diagnosis of UC are 0.88 and 0.79, respectively, with a modest positive likelihood ratio of 4.2 and a more clinically meaningful negative likelihood ratio of 0.15.”
> “However, up to a quarter of patients with endoscopically active disease may have a normal CRP and the frequency of elevation is lower in individuals with mild endoscopic activity [reference], so benchmarking the CRP at the time of diagnosis is key to its use and interpretation in later management.”
> “Serologic markers such as perinuclear anti-neutrophil cytoplasmic antibodies (pANCA) may be found in up to 70% of patients with UC, and combination of negative anti-Saccharomyces cerevisiae (ASCA) antibodies with elevated pANCA levels have been proposed to facilitate establishing a diagnosis of UC (59,60). However, the pooled sensitivity of antibody testing for diagnosis of UC is low, and such markers are not used for establishing or ruling out a diagnosis of UC.”

Source: [Rubin et al. (2025)](https://journals.lww.com/ajg/fulltext/10.14309/ajg.0000000000003463)

> “People with UC require monitoring of symptoms and biomarkers of inflammation (eg, fecal calprotectin), and require colonoscopy at 8 years from diagnosis for surveillance of dysplasia. Risk stratification by disease location (eg, Montreal Classification) and disease activity (eg, Mayo Score) can guide management of UC.”

Source: [Gros and Kaplan (2023)](https://pubmed.ncbi.nlm.nih.gov/37698559/)

<a id="topic-2.2.1.5-6"></a>

###### Disease activity assessment: Mayo score and the trial definition of moderately to severely active disease

> “Several quantitative disease activity indices are available (64) including the Mayo score (Table 5) (65), Seo Index (66), Rachmilewitz Index (67), Simple Clinical Colitis Activity Index (SCCAI) (Table 6) (68), PRO2 (69), and the pediatric UC activity index (70).”
> “Inclusion criteria for clinical trials of agents for moderately to severely active UC have required components such as (i) inability to taper off prednisone, (ii) prior failure of immunosuppressants, and (iii) moderate-to-severe disease defined by Modified Mayo score (including the specific endoscopy subscore). In clinical trials, the definition of clinical remission has been a MES of 0 or 1, stool frequency of ≤1, and absence of rectal bleeding.”
> “The MES is frequently used in clinical trials and is simple to use in clinical practice, ranging from 0 for normal or inactive disease to 3 for severely active disease (65).”

Source: [Rubin et al. (2025)](https://journals.lww.com/ajg/fulltext/10.14309/ajg.0000000000003463)

<a id="topic-2.2.1.5-7"></a>

###### Intestinal ultrasound for monitoring disease activity

> “New for these updated guidelines is a defined role for intestinal ultrasound (IUS) as a tool to measure UC disease activity and monitor response to therapy or disease relapse.”

Source: [Rubin et al. (2025)](https://journals.lww.com/ajg/fulltext/10.14309/ajg.0000000000003463)

<a id="topic-2.2.1.5-8"></a>

###### Diagnostic delay: mean 2.0 years from symptom onset

> “The mean duration between UC symptom onset and UC diagnosis was 2.0 years (SD, 5.4); 42% of patients waited ≥1 year for diagnosis, and 11% of patients had waited ≥5 years.”

Source: [Dubinsky et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8528151/)

<a id="heading-2.2.1.6"></a>

##### 2.2.1.6 Clinical Presentation - Signs and Symptoms

<a id="topic-2.2.1.6-1"></a>

###### Intestinal symptoms: bloody diarrhea, rectal bleeding, urgency, and tenesmus

> “Patients usually present with bloody diarrhoea, and the diagnosis is based on a combination of clinical, biological, endoscopic, and histological findings.”

Source: [Le Berre et al. (2023)](https://pubmed.ncbi.nlm.nih.gov/37573077/)

> “UC impairs quality of life secondary to inflammation of the colon causing chronic diarrhea and rectal bleeding.”

Source: [Gros and Kaplan (2023)](https://pubmed.ncbi.nlm.nih.gov/37698559/)

> “The initial presentation of new UC is usually characterized by symptoms of an inflamed rectum that include bleeding, urgency, and tenesmus (a sense of pressure).”
> “The primary symptoms assessed include frequency of bowel movements, including number of nocturnal bowel movements, and rectal bleeding as the proportion of bowel movements that are mixed with visible blood. Other important symptoms to assess include bowel urgency, abdominal pain, bowel cramping, and weight loss, which can be a marker of severity of disease.”

Source: [Rubin et al. (2025)](https://journals.lww.com/ajg/fulltext/10.14309/ajg.0000000000003463)

<a id="topic-2.2.1.6-2"></a>

###### Systemic symptoms: abdominal pain, weight loss, and fatigue

> “Symptoms may include frequent diarrhea, sometimes with blood or pus, abdominal and/or rectal pain, weight loss, and fatigue.”

Source: [ICER Targeted Immune Modulators for Ulcerative Colitis final evidence report (2020)](https://icer.org/wp-content/uploads/2020/08/ICER_UC_Final_Evidence_Report_101620.pdf)

> “In the Manitoba cohort, patients with UC reported high rates of fatigue and sleep difficulties, particularly those with active symptoms (67% and 72%, respectively), as compared to those with inactive UC (30% and 57%, respectively), and these rates were not significantly different than in patients with CD (51).”

Source: [Fumery et al. (2018)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6658168/)

<a id="topic-2.2.1.6-3"></a>

###### Severe disease: fulminant colitis, toxic megacolon, and Truelove and Witts criteria

> “Mild colitis is defined as fewer than 4 bowel movements daily, normal temperature, heart rate, hemoglobin (>11 g/dL), and ESR (<20 mm/hr). Severe disease is defined by bowel frequency greater than 6 times a day in conjunction with fever, tachycardia, anemia, or an elevation in ESR.”
> “The absolute indications for surgery in ASUC include toxic megacolon, perforation, uncontrolled severe hematochezia, or multiorgan dysfunction (311).”

Source: [Rubin et al. (2025)](https://journals.lww.com/ajg/fulltext/10.14309/ajg.0000000000003463)

<a id="topic-2.2.1.6-4"></a>

###### Flares and bowel frequency: patient survey in 10 countries

> “A high proportion (87%) of patients reported having experienced a flare in the past year, with an average of 4.3 flares (SD, 7.4) experienced.”
> “Patients reported visiting the bathroom (for any reason, including to pass stool, air, blood, or mucus) a mean of 3.5 times (SD, 2.9) on their best day and 9.8 times (SD, 7.4) on their worst day.”
> “Patients typically experienced initial symptoms at a mean age of 30.0 years (standard deviation [SD], 12.7; median, 29) and were diagnosed with UC at a mean age of 32.0 years (SD, 12.2; median, 30; Table 1).”

Source: [Dubinsky et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8528151/)

<a id="topic-2.2.1.6-5"></a>

###### Extraintestinal manifestations: joint, skin, ocular, oral, and hepatobiliary

> “In addition, a thorough history should assess the presence of extraintestinal manifestations including joint pain or swelling, skin eruptions or inflammatory lesions, ocular inflammation, oral manifestations including mouth sores and angular cheilitis, and symptoms suggesting hepatobiliary involvement such as jaundice or pruritus.”

Source: [Rubin et al. (2025)](https://journals.lww.com/ajg/fulltext/10.14309/ajg.0000000000003463)

> “A number of extraintestinal manifestations (EIMs) have also been associated with UC, including musculoskeletal, ocular, dermatologic, hepatobiliary, and psychological effects.”

Source: [ICER Targeted Immune Modulators for Ulcerative Colitis final evidence report (2020)](https://icer.org/wp-content/uploads/2020/08/ICER_UC_Final_Evidence_Report_101620.pdf)

> “Extraintestinal manifestations, such as primary sclerosing cholangitis, occur in approximately 27% of patients with UC.”

Source: [Gros and Kaplan (2023)](https://pubmed.ncbi.nlm.nih.gov/37698559/)

<a id="topic-2.2.1.6-6"></a>

###### Psychological symptoms: anxiety and depression with active disease

> “Patients with active disease are more likely to have comorbid psychological conditions of anxiety and depression and are more likely to have impaired social interactions or career progression (8).”

Source: [Rubin et al. (2025)](https://journals.lww.com/ajg/fulltext/10.14309/ajg.0000000000003463)

<a id="heading-2.2.1.7"></a>

##### 2.2.1.7 Long-term Morbidity

<a id="topic-2.2.1.7-1"></a>

###### Colectomy: 10% to 20% of patients require proctocolectomy for refractory disease

> “Although the therapeutic options are expanding, 10-20% of patients still require proctocolectomy for medically refractory disease.”

Source: [Le Berre et al. (2023)](https://pubmed.ncbi.nlm.nih.gov/37573077/)

> “The 5- and 10-year cumulative risk of colectomy is 10–15%; achieving mucosal healing is associated with lower risk of colectomy.”
> “Disease extent consistently influences risk of colectomy (OR 2.2; 95% CI, 1.1–4.3), with significantly higher risk in patients with extensive colitis (10y cumulative risk, 19%), followed by left-sided colitis (8%) and ulcerative proctitis (5%) (16,18,20).”

Source: [Fumery et al. (2018)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6658168/)

> “Indications for colectomy in UC include (i) ASUC or (ii) chronic refractory UC not responding to traditional medical therapy or (iii) development of dysplasia and/or carcinoma in chronic UC.”
> “Extensive colitis, deep ulcers by endoscopy, need for systemic steroids, young age at diagnosis (younger than 30 years), and elevated CRP or ESR are associated with higher rates of colectomy (96,98).”

Source: [Rubin et al. (2025)](https://journals.lww.com/ajg/fulltext/10.14309/ajg.0000000000003463)

<a id="topic-2.2.1.7-2"></a>

###### Colorectal cancer: risk by disease duration and extent

> “The risk of colorectal cancer after 20 years of disease duration is 4.5%, and people with UC have a 1.7-fold higher risk for colorectal cancer compared with the general population.”

Source: [Gros and Kaplan (2023)](https://pubmed.ncbi.nlm.nih.gov/37698559/)

> “Cumulative probability of CRC at 10, 20, and 30 years after UC diagnosis was 0.4–0.6%, 1.1–5.4%, and 2.1–7.5%, respectively (43,44). This risk is increased in patients with pancolitis (SIR, 2.4–14.8) and left-sided colitis (SIR, 1.4–2.8), but not in patients with proctitis (41,45–47). Young age at diagnosis, male sex, extensive colitis, disease duration and concomitant primary sclerosing cholangitis have been consistently identified as risk factors of CRC.”

Source: [Fumery et al. (2018)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6658168/)

> “Longstanding UC is also associated with a defined risk of dysplasia and colorectal cancer (CRC) which is believed to be primarily related to more extensive bowel involvement and longstanding mucosal inflammatory activity (9–11).”

Source: [Rubin et al. (2025)](https://journals.lww.com/ajg/fulltext/10.14309/ajg.0000000000003463)

<a id="topic-2.2.1.7-3"></a>

###### Colorectal cancer: Danish and Swedish cohort of 96,447 patients, 1969 to 2017

> “During follow-up, we observed 1336 incident CRCs in the UC cohort (1·29 per 1000 person-years) and 9544 incident CRCs in reference individuals (0·82 per 1000 person-years; HR 1·66, 95% CI 1·57-1·76). In the UC cohort, 639 patients died from CRC (0·55 per 1000 person-years), compared with 4451 reference individuals (0·38 per 1000 person-years; HR 1·59, 95% CI 1·46-1·72) during the same time period.”
> “The excess risks declined over calendar periods: during the last 5 years of follow-up (2013-17, Sweden only), the HR for incident CRC in people with UC was 1·38 (95% CI 1·20-1·60, or one additional case per 1058 patients with UC per 5 years) and the HR for death from CRC was 1·25 (95% CI 1·03-1·51, or one additional case per 3041 patients with UC per 5 years).”

Source: [Olén et al. (2020)](https://pubmed.ncbi.nlm.nih.gov/31929014/)

<a id="topic-2.2.1.7-4"></a>

###### Extraintestinal manifestations: joint, ocular, or skin manifestations in 27% of patients

> “Fifty-two studies were included that reported on 352 454 patients. The prevalence of at least 1 joint, ocular, or skin extraintestinal manifestation in all IBD, UC, and CD was 24%, 27%, and 35% respectively.”

Source: [Kilic et al. (2024)](https://pubmed.ncbi.nlm.nih.gov/37042969/)

> “Overall risk of EIMs in patients with UC ranges from 7–17%, probably lower as compared to patients with CD, and approximately 1% patients may present with EIMs before UC diagnosis (13,16,64). Articular manifestations are the most frequently observed EIMs (8%), including peripheral arthritis (5.5%), and ankylosing spondylitis (1%), followed by cutaneous EIMs (1.3%), PSC (0.6%) and ocular manifestations (0.6%) (64,65).”
> “The cumulative incidence of spondyloarthropathy was 5%, 14%, and 22% at 10, 20 and 30y after UC diagnosis (66)”

Source: [Fumery et al. (2018)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6658168/)

<a id="topic-2.2.1.7-5"></a>

###### Serious infections, venous thromboembolism, and cardiovascular events: contemporary US inception cohort

> “Cumulative 1- and 5y risk of serious infections in patients with UC was 5.3% (95% CI, 4.6–6.0) and 10.2% (95% CI, 9.1–11.4), respectively.”
> “Cumulative 1- and 5y risks of VTE were 0.1% (95% CI, 0.0–0.1) and 0.3% (95% CI, 0.1–0.5), and of MACE, was 0.2% (95% CI, 0.1–0.3) and 0.9% (95% CI, 0.5–1.3), respectively.”

Source: [Ahuja et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13456955/)

<a id="topic-2.2.1.7-6"></a>

###### Disability: work disability 1.8 times that of the general population

> “Patients with UC had 1.8 times higher risk of work disability (95% CI, 1.4–2.3) as compared to general population, and was comparable to that seen in patients with CD (56).”
> “While UC is not associated with an increased risk of mortality, it is associated with high morbidity and work disability.”

Source: [Fumery et al. (2018)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6658168/)

<a id="heading-2.2.1.8"></a>

##### 2.2.1.8 Burden of Ulcerative colitis

<a id="heading-2.2.1.8.1"></a>

###### 2.2.1.8.1 Humanistic Burden and Health-related Quality of Life

<a id="topic-2.2.1.8.1-1"></a>

###### EQ-5D utilities, SIBDQ scores, and disease activity in 289 US and 1037 European adults with moderate-to-severe ulcerative colitis

> “N = 289 and N = 1037 patient charts with linked surveys were included from the US and EU5, respectively. The disease activity distribution was as follows: active disease = 40.1% (US) and 33.6% (EU5); remission = 48.0 and 53.0%; deep remission = 11.9 and 13.3%. Patients with active disease reported significantly lower levels of EQ-5D health state utilities (adjusted mean [AdjM] = 0.87 [US] and 0.78 [EU5]) compared with remission (AdjM = 0.92 and 0.91) and deep remission (AdjM = 0.93 and 0.91) (all P < 0.05 compared with active disease within each region).”
> “Similarly, patients with active disease also reported lower EQ-5D VAS and SIBDQ scores (adjusted means = 70.8 and 4.6, respectively) compared with patients in remission (adjusted means = 82.4 and 5.5) and deep remission (adjusted means = 88.6 and 5.9) (all P < 0.05).”
> “Among patients with moderate-to-severe UC in the US and EU5, active disease was associated with significant impairments in HRQoL, work and leisure activities.”

Source: [Armuzzi et al. (2020)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6975026/)

<a id="topic-2.2.1.8.1-2"></a>

###### Disease control, flares, and emotional impact in the UC Narrative global survey of 2100 patients

> “Surveys of patients with UC (self-reported diagnosis; n = 2100) and physicians (n = 1254) were completed across 10 countries by The Harris Poll between August 2017 and February 2018.”
> “The majority of patients (82%) had moderate to severe UC (based on medication history; those who had only ever taken 5-aminosalicylates were excluded); 67% described their UC as controlled with few to no symptoms. On average, patients experienced 4.3 flares (standard deviation, 7.4) in the past year.”
> “Globally, the majority of patients with moderate to severe disease (84%) reported UC to be mentally exhausting; even patients with milder UC (75%) or patients who self-reported being in remission (82%) agreed. Most patients (65%) felt that UC controlled their life rather than them controlling their UC”
> “Patients reported visiting the bathroom (for any reason, including to pass stool, air, blood, or mucus) a mean of 3.5 times (SD, 2.9) on their best day and 9.8 times (SD, 7.4) on their worst day.”
> “In total, 21% and 15% of patients self-reported receiving a diagnosis of anxiety or depression, respectively, although this finding varied by country.”

Source: [Dubinsky et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8528151/)

<a id="topic-2.2.1.8.1-3"></a>

###### Bowel urgency and fecal urge incontinence in 200 US and 556 European patients with moderate-to-severe ulcerative colitis (CONFIDE)

> “Surveys were completed by 200 US and 556 European patients and 200 US and 503 European HCPs. The most common UC symptoms experienced in the preceding month were diarrhea, bowel urgency, and increased stool frequency. Many patients (45.0% of US patients, 37.0% of European patients) reported wearing diapers/pads/protection at least once a week in the past 3 months due to fear/anticipation of fecal urge incontinence. The top reasons for declining participation in social events, work/school, and sports/exercise were due to bowel urgency and fear of fecal urge incontinence.”
> “Over 30% of US patients and 40% of European patients do not feel comfortable discussing bowel urgency with their HCP (Figure 3C). The most common reason was due to feeling embarrassed to do so”

Source: [Travis et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11144997/)

<a id="topic-2.2.1.8.1-4"></a>

###### Anxiety and depression symptoms in 30 118 adults with inflammatory bowel disease: meta-analysis of 77 studies

> “Of 5544 studies identified, 77 fulfilled the eligibility criteria, including 30 118 patients in total. Overall, pooled prevalence of anxiety symptoms was 32·1% (95% CI 28·3-36·0) in 58 studies (I2=96·9%) and pooled prevalence of depression symptoms was 25·2% (22·0-28·5) in 75 studies (I2=97·6%).”
> “In studies that reported prevalence of anxiety or depression in patients with Crohn's disease and ulcerative colitis within the same study population, patients with Crohn's disease had higher odds of anxiety symptoms (OR 1·2, 95% CI 1·1-1·4) and depression symptoms (1·2, 1·1-1·4) than patients with ulcerative colitis.”
> “The prevalence of symptoms of anxiety (57·6% [95% CI 38·6-75·4]) or depression (38·9% [26·2-52·3]) was higher in patients with active IBD than in patients with inactive disease (38·1% [30·9-45·7] for anxiety symptoms and 24·2% [14·7-35·3] for depression symptoms; ORs 2·5 [95% CI 1·5-4·1] for anxiety and 3·1 [1·9-4·9] for depression).”

Source: [Barberio et al. (2021)](https://pubmed.ncbi.nlm.nih.gov/33721557/)

<a id="topic-2.2.1.8.1-5"></a>

###### Health-related quality of life with approved advanced therapies: network meta-analysis of 28 randomized controlled trials

> “Twenty-eight RCTs were included; 26 reported HRQoL outcomes during induction and 15 during maintenance. During induction, clinically meaningful improvements in IBDQ were observed with upadacitinib, filgotinib, and guselkumab. During maintenance, upadacitinib 30 mg and vedolizumab showed HRQoL benefits, although clinical meaningfulness was not consistently demonstrated.”
> “SF-36 improvements were modest overall, with upadacitinib and vedolizumab showing selective advantages, while WPAI-UC benefits were observed with upadacitinib, vedolizumab, and ustekinumab.”

Source: [Katsoula et al. (2025)](https://pubmed.ncbi.nlm.nih.gov/41284688/)

<a id="heading-2.2.1.8.2"></a>

###### 2.2.1.8.2 Economic Burden and Healthcare Resource Utilization

<a id="topic-2.2.1.8.2-1"></a>

###### National economic burden of ulcerative colitis in the United States

> “It is estimated that approximately 900,000 individuals in the United States (US) have UC.4 The economic burden of UC is significant, ranging between an estimated $15-32 billion per year.”

Source: [ICER Targeted Immune Modulators for Ulcerative Colitis final evidence report (2020)](https://icer.org/wp-content/uploads/2020/08/ICER_UC_Final_Evidence_Report_101620.pdf)

<a id="topic-2.2.1.8.2-2"></a>

###### National economic burden of inflammatory bowel disease in the United States

> “The economic burden of IBD is significant, with recent estimates of $50 billion per year in the United States.”

Source: [ICER special assessment of Entyvio to inform CMS negotiation (2026)](https://icer.org/wp-content/uploads/2026/03/Entyvio_Final-Evidence-Report_For-Publication_030326.pdf)

<a id="topic-2.2.1.8.2-3"></a>

###### Lifetime health care costs of ulcerative colitis by age at diagnosis in 85,755 patients

> “We collected data from 78,620 patients with CD, 85,755 with UC, and propensity score-matched control subjects from the Truven Health MarketScan insurance claims databases (2008‒2015).”
> “Cost variations over a lifetime were estimated in cost-state Markov models by age at diagnosis, adjusted to 2016 U.S. dollars and discounted at 3% per annum.”
> “For UC, the lifetime incremental cost was $369,955 among patients who received their diagnosis at 0‒11 years, and $132,396 for individuals 70 years or older, averaging $230,102 for a diagnosis at any age. Lifetime total cost was $405,496, consisting of outpatient ($163,670), inpatient ($123,190), pharmacy ($105,142), and ER ($13,493) costs.”
> “Therefore, the prevalent populations of patients with CD or UC in the United States in 2016 are expected to incur lifetime total costs of $498 billion and $377 billion, respectively.”

Source: [Lichtenstein et al. (2020)](https://pubmed.ncbi.nlm.nih.gov/31326606/)

<a id="topic-2.2.1.8.2-4"></a>

###### Annual direct costs in 52,782 commercially insured and Medicare Advantage patients with inflammatory bowel disease, 29,062 with ulcerative colitis

> “There were 52,782 IBD patients (29,062 UC; 23,720 CD) included in the analysis (54.1% females). On a per-annual basis, patients with IBD incurred a greater than 3-fold higher direct cost of care compared with non-IBD controls ($22,987 vs $6956 per-member per-year paid claims)”
> “The burden of costs was most notable in the first year after initial IBD diagnosis (mean = $26,555). The study identified several key drivers of cost for IBD patients: treatment with specific therapeutics (biologics, opioids, or steroids); ED use; and health care services associated with relapsing disease, anemia, or mental health comorbidity.”
> “As shown, although mean all-cause costs of IBD were stable from year to year before 2012, costs have been rising for CD and UC, particularly after 2013.”

Source: [Park et al. (2020)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7534391/)

<a id="topic-2.2.1.8.2-5"></a>

###### Costs of treatment failure with first-line advanced therapy in 5302 adults with moderate-to-severe ulcerative colitis

> “Analysis of treatment failure patterns included data from 6745 patients; HCRU and cost analyses included data from 5302 patients (treatment failure cohort, n = 4295; persistent cohort, n = 1007). In the overall population, 75% experienced treatment failure within the first 12 months (median: 5.1 months).”
> “The treatment failure cohort had significantly (P < .001) higher mean costs than the persistent cohort (all-cause, $74 995 vs $56 169; UC-related, $57 096 vs $47 347) mainly attributed to inpatient admissions and outpatient visits. Dose escalation/interval shortening accounted for the highest total costs ($101 668) across treatment failure events.”

Source: [Lee et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11094759/)

<a id="topic-2.2.1.8.2-6"></a>

###### Hospitalization and costs in the 12 months after initiating immunosuppressant or biologic therapy in 3562 patients

> “In total, 3562 patients were included in the analysis. Most patients (83.0%) used steroids in the 12 months before initiating advanced therapy. Overall, 47.8% remained steroid-free after 12 months (excluding tapering).”
> “Overall, 12.2% of patients had a UC-related hospitalization within 12 months of initiation, with a mean (SD) total length of stay of 8.2 (8.9) days and no significant differences between biologic therapies. Mean, unadjusted, UC-related costs in the 12 months postinitiation were $42,579 and were similar between therapies.”

Source: [Long et al. (2020)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7216775/)

<a id="topic-2.2.1.8.2-7"></a>

###### Health care resource use and costs associated with chronic corticosteroid use

> “Targeted treatment initiators included 1,886 chronic and 1,911 nonchronic corticosteroid users; conventional therapy initiators included 4,980 chronic and 5,199 nonchronic users. Chronic vs nonchronic users had 94% more inpatient days and 16% more outpatient visits among targeted treatment initiators, and 135% more inpatient days and 30% more outpatient visits among conventional therapy initiators (all P < 0.01).”
> “Mean all-cause total costs per patient per year were $73,491 for chronic vs $58,884 for nonchronic users ($14,607 higher; P < 0.01) for targeted treatment initiators, and $39,335 for chronic vs $21,271 for nonchronic users ($18,065 higher; P < 0.01) for conventional therapy initiators.”

Source: [Zhdanava et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10839463/)

<a id="topic-2.2.1.8.2-8"></a>

###### Hospitalization and colectomy after diagnosis in 3,893 commercially insured adults with newly diagnosed ulcerative colitis

> “Among 3,893 patients with newly diagnosed UC (age at diagnosis, 41±14y; 52% male; 80% White, 7.2% Black and 8.2% Hispanic patients) followed over 4.2±3.0y, 5-year risk of IBD-related hospitalization, colectomy and serious infection was 11%, 6%, and 10%, respectively, with lower risk in Hispanic patients (vs. White patients).”
> “Cumulative 5y risk of all-cause and IBD-related hospitalization was 17% (95% CI, 16–19) and 11% (95% CI, 10–12), respectively (Table 2). Risk of all-cause and IBD-related hospitalization remained stable over era of IBD diagnosis (Figure 2D).”

Source: [Ahuja et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13456955/)

<a id="topic-2.2.1.8.2-9"></a>

###### Indirect costs of work impairment by disease activity in 282 US patients with ulcerative colitis

> “The analyses included 281 patients with CD and 282 patients with UC.”
> “In UC, absenteeism (0.6%–11.9%), presenteeism (7.1%–37.1%), and overall work impairment (7.5%–41.9%) increased with increasing disease activity (all P < .0001). Annual indirect costs due to total work impairment increased with increasing disease activity (all P < .0001), from $7169/patient/year (remission) to $29 524/patient/year (moderately-to-severely active disease) in CD and $4348/patient/year (remission) to $24 283/patient/year (moderately-to-severely active disease) in UC.”

Source: [Ding et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9802455/)

<a id="topic-2.2.1.8.2-10"></a>

###### Hospitalization costs of nonelective colectomy or rectal resection in 10,280 US adults

> “All adults with UC in the 2016-2020 Nationwide Readmissions Database undergoing nonelective colectomy or rectal resection were identified.”
> “An estimated 10,280 patients met study criteria with median index hospitalization costs of $40,300 (IQR, $26,400-$65,000). Increased time to surgery was significantly associated with a +$2500 increment in costs per day. Compared with low-volume hospitals, medium- and high-volume centers demonstrated a -$5900 and -$8200 reduction in costs, respectively.”

Source: [Ng et al. (2024)](https://pubmed.ncbi.nlm.nih.gov/38583900/)

<a id="topic-2.2.1.8.2-11"></a>

###### Colectomy cost per admission used in the ICER 2020 model

> “A cost of $33,871 per admission for colectomy is assumed, calculated by the weighted average cost of emergent and non-emergent cost per admission from the Healthcare Cost and Utilization Project (HCUP) National Inpatient Sample (NIS) database”

Source: [ICER Targeted Immune Modulators for Ulcerative Colitis final evidence report (2020)](https://icer.org/wp-content/uploads/2020/08/ICER_UC_Final_Evidence_Report_101620.pdf)

<a id="topic-2.2.1.8.2-12"></a>

###### Direct medical costs before and after proctocolectomy in a population-based cohort of 60 patients

> “Operations included ileal-pouch anal anastomosis (n=45, mean cost of surgery/recovery period $50,530) or total proctocolectomy with Brooke ileostomy (n=15, mean cost of surgery/recovery period $39,309). In the pouch subgroup, direct medical costs on average were reduced by $9,296 (P<0.001, bootstrapped 95% CI: $324 to $15,628) in the 2-years after recovery.”
> “Mean costs are reported in 2007 constant dollars.”

Source: [Holubar et al. (2009)](https://pmc.ncbi.nlm.nih.gov/articles/PMC2791910/)

<a id="topic-2.2.1.8.2-13"></a>

###### Costs, resource use, and quality of life with advanced therapies: systematic review of US and European observational studies

> “47 publications of 40 unique cost/HCRU studies and 13 publications of nine unique HRQoL studies were included. Findings demonstrated that biologics have a positive impact on indirect costs (i.e., productivity, presenteeism, and absenteeism) and HRQoL. High costs of biologics were not always fully offset by reductions in cost and HCRU associated with disease management. For many patients, treatment switching and dose escalations were required, thus increasing drug costs, particularly when switching across treatment classes.”

Source: [Cichewicz et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10130125/)

<a id="heading-2.2.1.8.3"></a>

###### 2.2.1.8.3 Economic Impact of Ulcerative colitis on Families

<a id="topic-2.2.1.8.3-1"></a>

###### Caregiver burden, mental health, and work productivity: meta-analysis of 25 studies

> “Out of 383 records, 25 studies met the inclusion criteria, with 12 eligible for meta-analysis. The pooled prevalence of caregiver burden was 470 per 1000 carers (95% CI: 390–560), depression at 370 per 1000, and anxiety at 400 per 1000. Loss of work productivity and activity impairment were reported in 290 and 300 per 1000 caregivers, respectively. Stress, reduced quality of life, and financial burden were also common.”
> “Only two studies assessed financial loss in caregivers for paediatric and adolescent population with IBD [32, 33]. Both studies provided absolute numbers of financial loss in caregivers as an estimate of annual productivity costs, which were calculated by the human capital approach.”

Source: [Dadoo et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13312674/)

<a id="topic-2.2.1.8.3-2"></a>

###### Caregiver burden and lost productivity among 102 caregivers of adults with inflammatory bowel disease at a US center

> “One hundred two IBD patients and their respective caregiver were included. In total, 39% of IBD caregivers experienced burden. Caregivers with burden experienced significantly more absenteeism and presenteeism (65 and 85% respectively).”
> “Predictors of burden included race/ethnicity, history of fistulas, diagnosis of ulcerative colitis, higher caregiver education, and hours spent caregiving.”
> “The caregivers spent an average of 12 h (SD 25) per week on caregiving and had been caregiving for an average of 8.1 years (SD 8.5).”
> “The employment rate in the caregiver population was 72% (n = 73), of whom 38% (n = 28) experienced absenteeism within the last week, with a mean of 9% of work hours missed (SD 17%); 57% experienced presenteeism with a mean decrease of 22% in productivity at work (SD 30%).”

Source: [Zand et al. (2020)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7302133/)

<a id="topic-2.2.1.8.3-3"></a>

###### Out-of-pocket costs and lost wages of patients with inflammatory bowel disease

> “Compared with non-IBD patients, IBD patients absorbed more than twice the out-of-pocket costs per year ($2213 vs $979), as shown in Figure 2B. Of note, this statistic does not include costs that IBD patients paid for insurance premiums (data not available) and thus likely represents an underestimate of the patient-responsible costs for health care (including IBD care). Patients with IBD also absorbed significantly higher wage-related opportunity loss based on yearly patient time costs, as shown in Figure 2C. Using the median wage, IBD patients’ lost wages were higher than the actual out-of-pocket costs on a per-year basis.”
> “Out-of-pocket and indirect costs of care reported in our analysis were likely substantial underestimates due to the data sets utilized in the analysis because the data did not include insurance premiums or other indirect costs such as actual wages lost, time for caregivers, or transportation required for health care services.”

Source: [Park et al. (2020)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7534391/)

<a id="topic-2.2.1.8.3-4"></a>

###### Work impairment and estimated lost wages in employed US patients with moderate-to-severe ulcerative colitis

> “Patients with active disease in the US and EU5 reported the highest levels of presenteeism (adjusted means = 31.0 and 49.1%, respectively), overall work impairment (adjusted means = 34.5 and 54.4%), and activity impairment (adjusted means = 34.7 and 47.6%) (Figs. 4 and 5). Patients with active disease in the US had significantly higher levels of absenteeism than patients in remission (adjusted means = 9.2% vs. 2.0%, P < 0.05)”
> “Although a formal evaluation of indirect cost estimates is beyond the scope of this study, using a human capital approach, the levels of overall work impairment we observed would equate to $15,400 in lost wages per employed patient with UC per year in the US (based on annualized 2017 median weekly earnings from the US Bureau of Labor Statistics [19])”

Source: [Armuzzi et al. (2020)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6975026/)

<a id="topic-2.2.1.8.3-5"></a>

###### Work absence and family decisions in the UC Narrative global survey

> “Overall, the majority (83%) of patients agreed that having UC impacted their work, with 74% of employed patients reporting work absence because of their UC and missing a mean of 8.1 working days (SD, 16.7) in the past 12 months because of their UC symptoms.”
> “However, 39% of patients had not told their employer about their UC diagnosis because of a fear of repercussions.”
> “More than one-third of patients (37%) reported that UC had influenced their decisions regarding family (including deciding not to have children, to have any more children, postponing having children, deciding to adopt, stopping treatment to start a family, or postponing/ending/avoiding romantic relationships).”

Source: [Dubinsky et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8528151/)

<a id="topic-2.2.1.8.3-6"></a>

###### Effect of bowel urgency on work or school among US patients with moderate-to-severe ulcerative colitis

> “Of the patients who had ever experienced bowel urgency, 78.0% of US and 77.2% of European patients reported that it negatively affected work or school (Figure 3B).”

Source: [Travis et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11144997/)

<a id="heading-2.2.1.8.4"></a>

###### 2.2.1.8.4 Economic Impact of Diagnostic Testing

<a id="topic-2.2.1.8.4-1"></a>

###### Colonoscopy and biopsy for diagnosis

> “UC is diagnosed based on the presence of symptoms with confirmation of disease via colonoscopy and biopsy.”

Source: [ICER Targeted Immune Modulators for Ulcerative Colitis final evidence report (2020)](https://icer.org/wp-content/uploads/2020/08/ICER_UC_Final_Evidence_Report_101620.pdf)

<a id="topic-2.2.1.8.4-2"></a>

###### Cost-effectiveness of fecal calprotectin screening before endoscopy for suspected inflammatory bowel disease in the United States

> “We constructed a decision analytic tree to compare the cost-effectiveness of measuring FC before endoscopy examination with that of direct endoscopic evaluation alone.”
> “In adults, FC screening saved $417/patient but delayed diagnosis for 2.2/32 patients with IBD, among 100 screened patients. In children, FC screening saved $300/patient but delayed diagnosis for 4.8/61 patients with IBD, among 100 screened patients. If endoscopic biopsy analysis remained the standard for diagnosis, direct endoscopic evaluation would cost an additional $18,955 in adults and $6250 in children to avoid 1 false negative result from FC screening.”
> “Pre-test probabilities for IBD of ≤75% in adults and ≤65% in children made FC screening cost-effective, but cost ineffective if the probabilities were ≥85% and ≥78% in adults and children, respectively.”
> “Adopting a third-party payer perspective, only direct costs were considered.”

Source: [Yang et al. (2014)](https://pmc.ncbi.nlm.nih.gov/articles/PMC3865226/)

<a id="topic-2.2.1.8.4-3"></a>

###### Fecal calprotectin for ongoing disease monitoring

> “5. We recommend the use of FC in UC to assess response to therapy, to evaluate suspected relapse, and during maintenance (Strong recommendation, moderate quality of evidence).”
> “FC levels are more sensitive and specific than serum inflammatory markers and obviously also less invasive than endoscopy or mucosal biopsies, so this assessment has become routine for many clinicians who are managing patients with UC (53,118).”

Source: [Rubin et al. (2025)](https://journals.lww.com/ajg/fulltext/10.14309/ajg.0000000000003463)

<a id="heading-2.2.2"></a>

#### 2.2.2 Approaches to Treatment

<a id="heading-2.2.2.1"></a>

##### 2.2.2.1 Current Treatment Options and Standard of Care

<a id="heading-2.2.2.1.1"></a>

###### 2.2.2.1.1 Aminosalicylates

<a id="topic-2.2.2.1.1-1"></a>

###### Recommendations against 5-ASA added to advanced therapy: ACG 2025 guideline

> “32. In patients with moderately to severely active UC who have failed 5-ASA therapy and in whom advanced therapies with biologics or JAK inhibitors are used for induction of remission, we suggest against using 5-ASA for added clinical efficacy (Conditional recommendation, very low quality of evidence).”
> “34. In patients with prior moderately to severely active UC who have achieved remission but previously failed 5-ASA therapy and are now on anti-TNF therapy, we suggest against using concomitant 5-ASA for efficacy of maintenance of remission (162) (Conditional recommendation, low quality of evidence).”
> “In addition, analyses of whether there is efficacy benefit or increased risk of relapse with continuing 5-ASA or withdrawing it, respectively, have demonstrated no benefit to continuation and no harm to stopping 5-ASA in these settings, and a subsequent cost-effectiveness evaluation suggested that it is more cost effective to stop 5-ASA after advanced treatment is needed (217–219).”

Source: [Rubin et al. (2025)](https://journals.lww.com/ajg/fulltext/10.14309/ajg.0000000000003463)

<a id="topic-2.2.2.1.1-2"></a>

###### Recommendations for 5-ASA in mildly to moderately active disease: ACG 2025 guideline

> “12. In patients with mildly to moderately active extensive colitis, oral 5-ASA at a dose of at least 2.0 g daily is recommended to induce remission (Strong recommendation, moderate quality of evidence).”
> “14. In patients with mildly to moderately active UC who fail to reach remission with appropriately dosed 5-ASA (at least 2–4.8 g daily oral mesalamine and/or at least 1 g daily rectal mesalamine), we suggest against changing to an alternate 5-ASA formulation to induce remission. Alternative therapeutic classes should be considered (Conditional recommendation, low quality of evidence).”
> “19. In patients with mildly active left-sided or extensive UC, we recommend oral 5-ASA therapy (at least 1.5 g/d) for maintenance of remission (Strong recommendation, moderate quality of evidence).”

Source: [Rubin et al. (2025)](https://journals.lww.com/ajg/fulltext/10.14309/ajg.0000000000003463)

<a id="topic-2.2.2.1.1-3"></a>

###### Recommendation to stop 5-ASA after escalation: AGA 2024 living guideline

> “13. In adult outpatients with moderate-to-severe UC, who have failed 5-ASAs, and have escalated to therapy with immunomodulators or advanced therapies, the AGA suggests stopping 5-ASAs. [Conditional recommendation, low certainty of evidence]”
> “Large observational studies have suggested no difference in the risk of adverse clinical outcomes between patients who continue vs. stop 5-ASA after starting advanced therapies or immunomodulators99–101.”
> “The guideline panel also acknowledged that one proposed benefit of long-term 5-ASA use is potential chemoprevention effect against colorectal cancer, but this remains unproven.”

Source: [Singh et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12162142/)

<a id="topic-2.2.2.1.1-4"></a>

###### Recommendations for 5-ASA induction, maintenance, and discontinuation: ECCO 2026 guideline

> “We recommend oral 5-aminosalicylates to induce remission in patients with mild-to-moderate ulcerative colitis [strong recommendation, low certainty of evidence] [Agreement: 100%]”
> “We recommend an oral dose of ≥2 g/day of 5-aminosalicylates to maintain remission in patients with mild-to-moderate ulcerative colitis [strong recommendation, very low certainty of evidence] [Agreement: 100%]”
> “We suggest discontinuing oral 5-aminosalicylates in patients with active ulcerative colitis initiating advanced therapy [weak recommendation, low certainty of evidence] [Agreement: 82%]”
> “We suggest discontinuing oral 5-aminosalicylates in patients with ulcerative colitis who achieved remission with advanced therapy or immunomodulators [weak recommendation, low certainty of evidence] [Agreement: 100%]”

Source: [Gisbert et al. (2026)](https://academic.oup.com/ecco-jcc/article/20/7/jjag066/8726617)

<a id="topic-2.2.2.1.1-5"></a>

###### Efficacy of oral 5-ASA versus placebo: ECCO 2026 meta-analysis

> “We performed a meta-analysis of 11 eligible RCTs including a total of 2156 patients evaluated over 4–12 weeks; 5-ASA showed significantly higher efficacy in achieving clinical remission [RR: 1.56; 95% CI: 1.24–1.97] compared with placebo.”
> “5-ASA therapy has demonstrated efficacy for induction of moderately active but not for severely active UC.”
> “According to post-hoc analyses of RCT data, the continuation of 5-ASA in patients with UC initiating advanced therapies appears to provide no additional therapeutic benefit”

Source: [Gisbert et al. (2026)](https://academic.oup.com/ecco-jcc/article/20/7/jjag066/8726617)

<a id="topic-2.2.2.1.1-6"></a>

###### Indication of delayed-release mesalamine tablets

> “induction and maintenance of remission in adult patients with mildly to moderately active ulcerative colitis.”
> “For induction of remission: 2.4 g to 4.8 g (two to four 1.2-g tablets) once daily.”

Source: [Lialda prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/022000s030lbl.pdf)

<a id="topic-2.2.2.1.1-7"></a>

###### Remission at Week 8 in two placebo-controlled induction trials of delayed-release mesalamine tablets

| Dose | Study 1 (n=262) n/N (%) | Study 2 (n=255) n/N (%) |
| --- | --- | --- |
| Mesalamine 2.4 g/day | “30/88 (34)” | “34/84 (41)” |
| Mesalamine 4.8 g/day | “26/89 (29)” | “35/85 (41)” |
| Placebo | “11/85 (13)” | “19/86 (22)” |

Source: [Lialda prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/022000s030lbl.pdf)

<a id="topic-2.2.2.1.1-8"></a>

###### Warnings and precautions for mesalamine

> “Renal Impairment: Assess renal function at the beginning of treatment and periodically during treatment.”
> “Discontinue LIALDA if renal function deteriorates while on therapy.”
> “Mesalamine-Induced Acute Intolerance Syndrome: Symptoms may be difficult to distinguish from an ulcerative colitis exacerbation.”
> “Hypersensitivity Reactions, including myocarditis and pericarditis: Evaluate patients immediately and discontinue LIALDA if a hypersensitivity reaction is suspected.”

Source: [Lialda prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/022000s030lbl.pdf)

<a id="heading-2.2.2.1.2"></a>

###### 2.2.2.1.2 Corticosteroids

<a id="topic-2.2.2.1.2-1"></a>

###### Recommendations for corticosteroid induction and against corticosteroid maintenance: ACG 2025 guideline

> “21. In patients with moderately active UC, we recommend oral budesonide MMX for induction of remission (Strong recommendation, moderate quality of evidence).”
> “22. In patients with moderately to severely active UC of any extent, we recommend oral systemic corticosteroids to induce remission (Strong recommendation, low quality of evidence).”
> “35. In patients with prior moderately to severely active UC, we recommend against systemic corticosteroids for maintenance of remission (Strong recommendation, moderate quality of evidence).”
> “34. Budesonide MMX has not been studied for maintenance of remission of prior moderately to severely active UC.”

Source: [Rubin et al. (2025)](https://journals.lww.com/ajg/fulltext/10.14309/ajg.0000000000003463)

<a id="topic-2.2.2.1.2-2"></a>

###### Efficacy of systemic corticosteroids and budesonide MMX: ACG 2025 guideline

> “In a meta-analysis of trials in patients with active UC, the use of systemic glucocorticoids compared with placebo demonstrated a benefit favoring steroids (RR of failure to achieve remission = 0.65; 95% CI 0.45–0.93) (141,164).”
> “A multicenter phase III RCT showed similar results, with significantly more patients treated with budesonide MMX 9 mg (but not 6 mg) achieving combined clinical and endoscopic remission at week 8 compared with placebo (OR = 4.49; 95% CI 1.47–13.72; P = 0.0047) (163).”
> “Although corticosteroids are efficacious in inducing remission in patients with active UC, they should not be used for maintenance of remission and should be tapered instead (158–160). While the optimal tapering regimen has not been determined, the dose is usually reduced over 8–12 weeks (157).”
> “A patient with UC who needs corticosteroids (as opposed to the one who is prescribed them with 5-ASA and without allowing the 5-ASA to be tried as monotherapy) should be treated with therapies approved for moderately to severely active UC and that have demonstrated steroid-sparing effects.”

Source: [Rubin et al. (2025)](https://journals.lww.com/ajg/fulltext/10.14309/ajg.0000000000003463)

<a id="topic-2.2.2.1.2-3"></a>

###### Recommendations for oral prednisolone and colonic-release corticosteroids: ECCO 2026 guideline

> “We recommend short-term oral prednisolone for induction of remission in non-hospitalized patients with moderate-to-severe ulcerative colitis [strong recommendation, very low certainty of evidence] [Agreement: 100%]”
> “We suggest treatment with colonic-release corticosteroids for induction of remission in patients with mild-to-moderate ulcerative colitis [weak recommendation, low certainty of evidence] [Agreement: 100%]”
> “Therefore, we performed a meta-analysis of just these two studies and calculated an RR of 2.83 [95% CI: 1.79–4.46] for the induction of clinical remission”
> “Although the optimal dose and regimen for systemic corticosteroids in UC is uncertain, a 40 mg/day dose is typically used and this recommendation is based on an outpatient study where 40 mg/day was more effective than 20 mg/day.”
> “It is essential to administer corticosteroids only for short-term use. The dose should typically be tapered over 6–8 weeks.”

Source: [Gisbert et al. (2026)](https://academic.oup.com/ecco-jcc/article/20/7/jjag066/8726617)

<a id="topic-2.2.2.1.2-4"></a>

###### Indication and induction efficacy of budesonide extended-release tablets

> “UCERIS (budesonide) is a glucocorticosteroid indicated for the induction of remission in patients with active, mild to moderate ulcerative colitis.”
> “The primary endpoint was induction of remission after 8 weeks of treatment.”

Source: [Uceris prescribing information (2024)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/203634s012lbl.pdf)

<a id="topic-2.2.2.1.2-5"></a>

###### Induction of remission in Studies 1 and 2 of budesonide extended-release tablets

| Treatment group | Study 1 n/N (%) | Study 2 n/N (%) |
| --- | --- | --- |
| Budesonide 9 mg | “22/123 (17.9)” | “19/109 (17.4)” |
| Budesonide 6 mg | “16/121 (13.2)” | “9/109 (8.3)” |
| Placebo | “9/121 (7.4)” | “4/89 (4.5)” |

Source: [Uceris prescribing information (2024)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/203634s012lbl.pdf)

<a id="topic-2.2.2.1.2-6"></a>

###### Warnings and precautions for budesonide extended-release tablets

> “Systemic effects such as hypercorticism and adrenal suppression may occur with use corticosteroids, including UCERIS.”
> “Glucocorticosteroids, including UCERIS, can reduce the response of the hypothalamus-pituitary-adrenal (HPA) axis to stress.”

Source: [Uceris prescribing information (2024)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/203634s012lbl.pdf)

<a id="topic-2.2.2.1.2-7"></a>

###### Complications of chronic corticosteroid use in US adults with ulcerative colitis

> “Patients with long-term or chronic use of CS may present with both short- and long-term complications including infection, hypertension, new-onset diabetes mellitus, osteoporosis, cataracts, and glaucoma.5,6”
> “Although CS therapy is efficacious in inducing remission among most patients with UC, more than 90% of patients will experience an adverse event, and CS dependence is common.4,8,9”
> “The prevalence of several CS-related complications among targeted treatment initiators was significantly higher in chronic CS users compared with nonchronic CS users, with proportions of 55.5% vs 52.4% for patients with infection, leading to an odds ratio (OR) of 1.14 (95% CI = 1.00-1.29; P = 0.0500); 14.5% vs 7.4% for bone loss, leading to an OR of 2.13 (95% CI = 1.72-2.64; P < 0.001); 5.6% vs 3.0% for venous thromboembolism, leading to an OR of 1.93 (95% CI = 1.39-2.68; P < 0.001); and 2.5% vs 0.3% for adrenocortical insufficiency, leading to an OR of 8.24 (95% CI = 3.50-19.37; P < 0.001; Figure 3).”

Source: [Zhdanava et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10839463/)

<a id="heading-2.2.2.1.3"></a>

###### 2.2.2.1.3 Thiopurines and Methotrexate

<a id="topic-2.2.2.1.3-1"></a>

###### Recommendations for thiopurines and methotrexate: ACG 2025 guideline

> “23. In patients with moderately to severely active UC, we recommend against monotherapy with thiopurines or methotrexate for induction of remission (Strong recommendation, low quality of evidence).”
> “33. When infliximab is used as induction therapy for patients with moderately to severely active UC, we recommend combination therapy with a thiopurine (Strong recommendation, moderate quality of evidence for azathioprine).”
> “36. For patients with prior moderately to severely active UC now in remission because of corticosteroid induction, we suggest thiopurines for maintenance of remission as compared with no treatment or corticosteroids (Conditional recommendation, low quality of evidence).”
> “37. In patients with prior moderately to severely active UC now in remission, we suggest against using methotrexate for maintenance of remission (Conditional recommendation, low quality of evidence).”

Source: [Rubin et al. (2025)](https://journals.lww.com/ajg/fulltext/10.14309/ajg.0000000000003463)

<a id="topic-2.2.2.1.3-2"></a>

###### Efficacy of thiopurines and methotrexate: ACG 2025 guideline

> “Thiopurines are slow-acting and do not induce remission in moderately to severely active UC (164–166). Similarly, methotrexate is not an effective induction agent in moderately to severely active UC.”
> “In an additional 3 RCTs, azathioprine prevented relapse in 127 patients (RR = 0.6; 95% CI 0.37–0.95) (165).”
> “When compared with placebo, treatment with thiopurines resulted in an absolute risk reduction of 23% and an NNT of 5 to prevent recurrence (OR = 2.59; 95% CI 1.26–5.3) (169).”
> “In this study, 29/44 (66%) patients receiving methotrexate experienced relapse compared with 25/40 (63%) patients receiving placebo (172).”

Source: [Rubin et al. (2025)](https://journals.lww.com/ajg/fulltext/10.14309/ajg.0000000000003463)

<a id="topic-2.2.2.1.3-3"></a>

###### Recommendations for immunomodulator monotherapy and combination therapy: AGA 2024 living guideline

> “5. In adult outpatients with moderate-to-severe UC, the AGA suggests AGAINST using thiopurine monotherapy for induction of remission. [Conditional recommendation, very low certainty of evidence]”
> “6. In adult outpatients with moderate-to-severe UC in remission, the AGA suggests using thiopurine monotherapy, rather than no treatment, for maintenance of remission, typically induced by corticosteroids. [Conditional recommendation, low certainty of evidence]”
> “7. In adult outpatients with moderate-to-severe UC, the AGA suggests AGAINST using methotrexate monotherapy, for induction or maintenance of remission. [Conditional recommendation, low certainty of evidence]”
> “8. In adult outpatients with moderate-to-severe UC, the AGA suggests the use of infliximab in combination with an immunomodulator over infliximab or an immunomodulator alone. [Conditional recommendation, moderate certainty of evidence]”
> “9. In adult outpatients with moderate-to-severe UC, the AGA suggests the use of adalimumab or golimumab in combination with an immunomodulator over adalimumab, golimumab or immunomodulator monotherapy. [Conditional recommendation, low certainty of evidence]”

Source: [Singh et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12162142/)

<a id="topic-2.2.2.1.3-4"></a>

###### Efficacy and harms of thiopurines and combination therapy: AGA 2024 living guideline

> “On meta-analysis, thiopurines were more effective than placebo or 5-ASA for decreasing risk of disease relapse (RR, 0.61; 95% CI, 0.49–0.77) among patients with inactive UC (in remission) (eFigure 14).”
> “At week 16, the primary endpoint of corticosteroid-free clinical remission was achieved by 39.7% of patients receiving combination therapy compared to 22.1% of infliximab treated patients and 23.7% of azathioprine treated patients.”
> “Short- and long-term side effects of thiopurines and methotrexate are well-recognized including risk of bone marrow suppression, hepatotoxicity (including liver fibrosis with long-term use of methotrexate), non-melanoma skin cancer and lymphoma, especially with thiopurines78.”

Source: [Singh et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12162142/)

<a id="topic-2.2.2.1.3-5"></a>

###### Recommendations for thiopurines: ECCO 2026 guideline

> “We recommend against the use of thiopurines as monotherapy for the induction of remission in patients with active ulcerative colitis [strong recommendation, very low certainty of evidence] [Agreement: 100%]”
> “We suggest monotherapy with thiopurines for the maintenance of remission in patients under 65 years of age with steroid-dependent ulcerative colitis or who are intolerant to 5-aminosalicylates [weak recommendation, low certainty of evidence] [Agreement: 98%]”
> “In 232 patients followed for 1 year, azathioprine was superior to placebo for the maintenance of clinical remission [RR: 1.59; 95% CI: 1.19–2.11].”

Source: [Gisbert et al. (2026)](https://academic.oup.com/ecco-jcc/article/20/7/jjag066/8726617)

<a id="topic-2.2.2.1.3-6"></a>

###### Boxed warning for azathioprine

> “Chronic immunosuppression with IMURAN, a purine antimetabolite increases risk of malignancy in humans. Reports of malignancy include post-transplant lymphoma and hepatosplenic T-cell lymphoma (HSTCL) in patients with inflammatory bowel disease.”

Source: [Imuran prescribing information (2024)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/016324s040lbl.pdf)

<a id="heading-2.2.2.1.4"></a>

###### 2.2.2.1.4 Tumor Necrosis Factor Inhibitors

<a id="topic-2.2.2.1.4-1"></a>

###### Recommendations for anti-TNF therapy: ACG 2025 guideline

> “28. In patients with moderately to severely active UC, we recommend anti-tumor necrosis factor (TNF) therapy using infliximab for induction of remission (Strong recommendation, high quality of evidence).”
> “29. In patients with moderately to severely active UC, we recommend anti-TNF therapy using adalimumab or golimumab for induction of remission (Strong recommendation, moderate quality of evidence).”
> “42. We recommend continuing anti-TNF therapy using adalimumab, golimumab, or infliximab (IV or SC dosing) for maintenance of remission after anti-TNF induction in patients with prior moderately to severely active UC (Strong recommendation, moderate quality of evidence).”
> “45. Infliximab is the preferred anti-TNF therapy for patients with moderately to severely active UC.”

Source: [Rubin et al. (2025)](https://journals.lww.com/ajg/fulltext/10.14309/ajg.0000000000003463)

<a id="topic-2.2.2.1.4-2"></a>

###### Pivotal trial efficacy of infliximab, adalimumab, and golimumab: ACG 2025 guideline

> “In ACT 1, 39% and 32% of patients receiving infliximab at 5 mg/kg and 10 mg/kg, respectively, attained remission at week 8 (primary endpoint), compared with 15% of patients receiving placebo (P < 0.003 for both doses of infliximab). In ACT 2 at week 8, 34% and 28% of patients receiving infliximab at 5 and 10 mg/kg, achieved remission, respectively, compared with 6% of patients receiving placebo (P < 0.001 for both comparisons).”
> “The overall rates of clinical remission at week 8 were 16.5% for those receiving adalimumab and 9.3% among those receiving placebo (P = 0.019); at week 52, those receiving adalimumab were in remission 17.3% of the time compared with those receiving placebo at 8.5% (P = 0.004).”
> “The phase 3 results identified rates of clinical response at week 6 in patients receiving 200/100 mg and 400/200 mg golimumab of 51.0% and 54.9%, respectively, compared with 30.3% among those receiving placebo (both, P ≤ 0.0001) (180).”
> “All 3 anti-TNF agents have demonstrated superiority over placebo in achieving the primary endpoints of response and remission, but there have been no head-to-head trials comparing the agents with one another (182–184).”

Source: [Rubin et al. (2025)](https://journals.lww.com/ajg/fulltext/10.14309/ajg.0000000000003463)

<a id="topic-2.2.2.1.4-3"></a>

###### Efficacy tiers by prior advanced-therapy exposure: AGA 2024 living guideline

> “In patients who are naïve to advanced therapies, the AGA suggests using a higher efficacy medication (infliximab, vedolizumab, ozanimod, etrasimod, upadacitinib, risankizumab, guselkumab) or an intermediate efficacy medication (golimumab, ustekinumab, tofacitinib, filgotinib, mirikizumab), rather than a lower efficacy medication (adalimumab).”
> “In patients who have previously been exposed to one or more advanced therapies, particularly tumor necrosis factor-α (TNF) antagonists, the AGA suggests using a higher efficacy medication (tofacitinib, upadacitinib, ustekinumab) or an intermediate efficacy medication (filgotinib, mirikizumab, risankizumab, guselkumab), rather than a lower efficacy medication (adalimumab, vedolizumab, ozanimod, etrasimod).”
> “Infliximab has a possibly important benefit in achieving remission compared with adalimumab, mirikizumab, tofacitinib, and filgotinib with a low certainty of evidence.”
> “Notably, there was no RCT for infliximab or golimumab in patients with prior exposure to biologics.”

Source: [Singh et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12162142/)

<a id="topic-2.2.2.1.4-4"></a>

###### Lymphoma risk with TNF antagonists: AGA 2024 living guideline

> “In a French population-based study, Lemaitre and colleagues estimated the annual incidence of lymphoma in patients treated with TNF antagonist monotherapy vs. unexposed patients to be 0.41 per 1000 person-years vs. 0.26 per 1000 person-years; after adjusting for potential confounders, the risk of lymphoma was 2.4-times higher in patients treated with TNF antagonist monotherapy25.”
> “Patients exposed to combination therapy had six-fold increased risk of lymphoma, as compared to unexposed patients, and 2.3–2.5 times higher risk as compared to patients exposed to monotherapy with either agent.”

Source: [Singh et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12162142/)

<a id="topic-2.2.2.1.4-5"></a>

###### Recommendations and meta-analysis for anti-TNF agents: ECCO 2026 guideline

> “We recommend treatment with anti-tumor necrosis factor agents [infliximab, adalimumab, and golimumab] for the induction of remission in moderate-to-severe ulcerative colitis [strong recommendation, moderate certainty of evidence] [Agreement: 98%]”
> “We recommend anti-tumor necrosis factor agents [infliximab, adalimumab, and golimumab] for the maintenance of remission in patients with ulcerative colitis who responded to induction therapy with the same drug [strong recommendation, high certainty of evidence] [Agreement: 100%]”
> “Our meta-analysis revealed evidence of efficacy for induction of clinical remission [RR: 2.23; 95% CI: 1.81–2.76] and clinical response [RR: 1.56; 95% CI: 1.38–1.76].”
> “Anti-TNF agents were effective for the maintenance of clinical remission [RR: 1.98; 95% CI: 1.60–2.45], steroid-free clinical remission [RR: 2.86; 95% CI: 1.67–4.90], sustained clinical remission [RR: 2.76; 95% CI: 1.78–4.28], and improvement in QoL [RR: 1.71; 95% CI: 1.27–2.32].”

Source: [Gisbert et al. (2026)](https://academic.oup.com/ecco-jcc/article/20/7/jjag066/8726617)

<a id="topic-2.2.2.1.4-6"></a>

###### Boxed warning for TNF blockers: infliximab label

> “WARNING: SERIOUS INFECTIONS and MALIGNANCY”
> “Increased risk of serious infections leading to hospitalization or death, including tuberculosis (TB), bacterial sepsis, invasive fungal infections (such as histoplasmosis) and infections due to other opportunistic pathogens.”
> “Lymphoma and other malignancies, some fatal, have been reported in children and adolescent patients treated with tumor necrosis factor (TNF) blockers, including REMICADE.”
> “Postmarketing cases of fatal hepatosplenic T-cell lymphoma (HSTCL) have been reported in patients treated with TNF blockers including REMICADE.”
> “The majority of REMICADE cases were reported in patients with Crohn’s disease or ulcerative colitis, most of whom were adolescent or young adult males.”

Source: [Remicade prescribing information (2025)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/103772s5412lbl.pdf)

<a id="topic-2.2.2.1.4-7"></a>

###### Adalimumab limitation of use after TNF blocker failure

> “The effectiveness of HUMIRA has not been established in patients who have lost response to or were intolerant to TNF blockers”
> “Forty percent (40%) of subjects enrolled in Study UC-II had previously used another TNF-blocker.”

Source: [Humira prescribing information (2025)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/125057s425lbl.pdf)

<a id="heading-2.2.2.1.5"></a>

###### 2.2.2.1.5 Anti-integrin Antibodies

<a id="topic-2.2.2.1.5-1"></a>

###### Recommendations for vedolizumab: ACG 2025 guideline

> “27. In patients with moderately to severely active UC, we recommend vedolizumab for induction of remission (Strong recommendation, moderate quality of evidence).”
> “41. We recommend continuing vedolizumab as compared with no treatment for maintenance of remission (intravenous [IV] or subcutaneous [SC] dosing) in patients with prior moderately to severely active UC now in remission after vedolizumab induction (Strong recommendation, moderate quality of evidence).”
> “45. In patients with moderately to severely active UC, we recommend vedolizumab as compared with adalimumab for induction and maintenance of remission (Strong recommendation, moderate quality of evidence).”

Source: [Rubin et al. (2025)](https://journals.lww.com/ajg/fulltext/10.14309/ajg.0000000000003463)

<a id="topic-2.2.2.1.5-2"></a>

###### Pivotal trial efficacy of vedolizumab: ACG 2025 guideline

> “In the comparison cohort, 16.9% and 40.9% of patients receiving vedolizumab achieved clinical remission and mucosal healing at week 6, respectively, compared with 5.4% and 24.8% of patients receiving placebo (P = 0.001 for both comparisons).”
> “A total of 40% of patients receiving vedolizumab maintained remission at week 52 compared with 16% of patients who received placebo (192).”
> “Clinical remission at week 52 was achieved by 46.2%, 42.6%, and 14.3% of patients in the SC vedolizumab, intravenous vedolizumab, and placebo groups, respectively (vedolizumab SC vs placebo, P < 0.001) (197).”

Source: [Rubin et al. (2025)](https://journals.lww.com/ajg/fulltext/10.14309/ajg.0000000000003463)

<a id="topic-2.2.2.1.5-3"></a>

###### VARSITY head-to-head trial and comparative safety: AGA 2024 living guideline

> “The only head-to-head trial was the VARSITY trial where 769 patients with moderate-to-severe UC were randomized to receive either vedolizumab (n=383) or adalimumab (n=386)38. At week 52, a higher rate of clinical remission was observed in the vedolizumab treated patients (31.3%) compared to adalimumab (22.5%). Corticosteroid-free remission rates, however, were higher with adalimumab (21.8%) compared to vedolizumab (12.6%).”
> “This trial noted no difference between the two agents in maintaining clinical remission (20.3% vs 16.0%) in this subpopulation.”
> “In observational studies, vedolizumab was associated with a lower risk of serious infections compared with TNF antagonists in patients with UC69, 70; there was paucity of evidence for comparative safety of other agents.”

Source: [Singh et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12162142/)

<a id="topic-2.2.2.1.5-4"></a>

###### Efficacy of vedolizumab by prior biologic exposure: AGA 2024 network meta-analysis

> “Intriguingly, the difference in relative efficacy of a drug in biologic-exposed vs. biologic-naïve patients was significantly greater for some drugs, most notably for vedolizumab and ozanimod in our analysis.”

Source: [Ananthakrishnan et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12148344/)

<a id="topic-2.2.2.1.5-5"></a>

###### Recommendations and meta-analysis for vedolizumab: ECCO 2026 guideline

> “We recommend treatment with vedolizumab for the induction of remission in moderate-to-severe ulcerative colitis [strong recommendation, low certainty of evidence] [Agreement: 100%]”
> “We recommend vedolizumab for the maintenance of remission in patients with ulcerative colitis who responded to induction therapy with vedolizumab [strong recommendation, moderate certainty of evidence] [Agreement: 100%]”
> “We suggest the use of vedolizumab rather than adalimumab for the induction and maintenance of remission in moderate-to-severe ulcerative colitis [weak recommendation, low certainty of evidence] [Agreement: 100%]”
> “Induction responders who subsequently received vedolizumab were more likely to achieve clinical remission than those receiving placebo after 52–60 weeks of follow-up [RR: 2.37; 95% CI: 1.74–3.23].”
> “Rates of SAEs in patients treated with vedolizumab were not significantly different from those receiving placebo [RR: 0.71; 95% CI: 0.39–1.30].”
> “In the subgroup analysis, the results were statistically significant in biologic-naive patients and only numerically superior in the biologic-exposed population.”

Source: [Gisbert et al. (2026)](https://academic.oup.com/ecco-jcc/article/20/7/jjag066/8726617)

<a id="topic-2.2.2.1.5-6"></a>

###### Comparative clinical effectiveness of vedolizumab: ICER 2026 special assessment

> “We rated Entyvio as comparable or inferior to ustekinumab (C-).”
> “Entyvio was rated comparable or better than the anti-TNF drugs infliximab and adalimumab (C+).”
> “However, there were fewer serious infections with Entyvio in observational data, and both infliximab and adalimumab carry black box warnings for serious infections and malignancies.”

Source: [ICER special assessment of Entyvio to inform CMS negotiation (2026)](https://icer.org/wp-content/uploads/2026/03/Entyvio_Final-Evidence-Report_For-Publication_030326.pdf)

<a id="topic-2.2.2.1.5-7"></a>

###### Indication and warnings for vedolizumab

> “ENTYVIO is an integrin receptor antagonist indicated in adults for the treatment of:”
> “moderately to severely active ulcerative colitis (UC).”
> “Discontinue ENTYVIO in patients who do not show evidence of therapeutic benefit by Week 14.”
> “Progressive Multifocal Leukoencephalopathy (PML): Although unlikely, a risk of PML cannot be ruled out. Monitor patients for any new or worsening neurological signs or symptoms.”

Source: [Entyvio prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/125476s66lbl.pdf)

<a id="heading-2.2.2.1.6"></a>

###### 2.2.2.1.6 Interleukin-12/23 Inhibitors

<a id="topic-2.2.2.1.6-1"></a>

###### Recommendations for ustekinumab: ACG 2025 guideline

> “25. In patients with moderately to severely active UC, we recommend the interleukin (IL)-12/23p40 antibody ustekinumab for induction of remission (Strong recommendation, moderate quality of evidence).”
> “39. We recommend continuing ustekinumab for maintenance of remission as compared to no treatment in patients who responded to the induction dose of this medication (Strong recommendation, moderate quality of evidence).”

Source: [Rubin et al. (2025)](https://journals.lww.com/ajg/fulltext/10.14309/ajg.0000000000003463)

<a id="topic-2.2.2.1.6-2"></a>

###### UNIFI pivotal trial efficacy of ustekinumab: ACG 2025 guideline

> “At week 8, a larger proportion of patients who received ustekinumab 6 mg/kg (15.5%) achieved clinical remission compared with placebo (5.3%, P < 0.001).”
> “Among responders to ustekinumab induction, patients who were maintained on ustekinumab 90 mg subcutaneously every 8 weeks were more likely to be in clinical remission after 44 weeks (43.8%) compared with those assigned to placebo (24.8%, P < 00.08).”
> “There were no differences in serious adverse events between treatment and placebo groups, and notably, placebo-exposed patients had increased rates of disease-related adverse events.”

Source: [Rubin et al. (2025)](https://journals.lww.com/ajg/fulltext/10.14309/ajg.0000000000003463)

<a id="topic-2.2.2.1.6-3"></a>

###### Comparative efficacy of ustekinumab after prior advanced therapy: AGA 2024 living guideline

> “Ustekinumab demonstrated a likely important benefit over adalimumab, vedolizumab, ozanimod, etrasimod, and mirikizumab with a moderate certainty of evidence.”
> “Biosimilars of infliximab, adalimumab, and ustekinumab can be considered equivalent to their originator drug in their efficacy in terms of therapy selection.”

Source: [Singh et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12162142/)

<a id="topic-2.2.2.1.6-4"></a>

###### Recommendations and trial results for ustekinumab: ECCO 2026 guideline

> “We recommend treatment with ustekinumab for the induction of remission in moderate-to-severe ulcerative colitis [strong recommendation, moderate certainty of evidence] [Agreement: 100%]”
> “We recommend ustekinumab for the maintenance of remission in patients with ulcerative colitis who responded to induction therapy with ustekinumab [strong recommendation, moderate certainty of evidence] [Agreement: 100%]”
> “Of these, 51.6% of randomized patients had previously failed treatment with an alternative biologic, including 18% who failed treatment with both an anti-TNF agent and vedolizumab. The study demonstrated the benefit of ustekinumab [6 mg/kg] over placebo in induction of clinical remission [RR: 2.91; 95% CI: 1.72–4.94], clinical response [RR: 1.97; 95% CI: 1.64–2.37], and endoscopic improvement [RR: 1.96; 95% CI: 1.41–2.72].”
> “SAEs did not differ between ustekinumab and placebo [RR: 0.67; 95% CI: 0.39–1.17].”

Source: [Gisbert et al. (2026)](https://academic.oup.com/ecco-jcc/article/20/7/jjag066/8726617)

<a id="topic-2.2.2.1.6-5"></a>

###### Indication and warnings for ustekinumab

> “STELARA is indicated for the treatment of adults and pediatric patients 2 years of age and older with moderately to severely active ulcerative colitis.”
> “Infections: Serious infections have occurred.”
> “Tuberculosis (TB): Evaluate patients for TB prior to initiating treatment with STELARA.”
> “Malignancies: STELARA may increase risk of malignancy.”
> “Posterior Reversible Encephalopathy Syndrome (PRES): If PRES is suspected, treat promptly, and discontinue STELARA.”

Source: [Stelara prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/125261s173lbl.pdf)

<a id="heading-2.2.2.1.7"></a>

###### 2.2.2.1.7 Interleukin-23 p19 Inhibitors

<a id="topic-2.2.2.1.7-1"></a>

###### ACG 2025 guideline: recommendations for induction and maintenance

> “In patients with moderately to severely active UC, we recommend the IL23p19 inhibitor guselkumab, mirikizumab, or risankizumab for induction of remission (Strong recommendation, moderate quality of evidence).”
> “We recommend continuing guselkumab, mirikizumab, or risankizumab as compared with no treatment for maintenance of remission in patients who respond to the induction dosing of the same treatment (Strong recommendation, moderate quality of evidence).”
> “Guselkumab, mirikizumab, and risankizumab are monoclonal antibodies that target the p19 subunit of IL-23 and are approved for the treatment of moderately to severely active UC.”

Source: [Rubin et al. (2025)](https://journals.lww.com/ajg/fulltext/10.14309/ajg.0000000000003463)

<a id="topic-2.2.2.1.7-2"></a>

###### Pivotal trial results for guselkumab and mirikizumab: ACG 2025 evidence summary

> “In the phase 3 study, guselkumab 200 mg IV at weeks 0, 4, and 8 demonstrated that a significantly greater proportion of clinical remission compared with placebo at week 12 (22.6% vs 7.9%, adjusted ∆ = 14.9%, P < 0.001)”
> “Clinical remission at maintenance week 44 was significantly greater with SC guselkumab 200 mg q4w (50.0% [95/190]; 29.5%, 20.9–38.1) and 100 mg q8w (45.2% [85/188]; 25.2%, 26.4–33.9) compared with placebo (18.9% [36/190]) (both P < 0.001).”
> “In the induction trial, 24.2% of patients receiving mirikizumab achieved clinical remission compared with 13.3% of patients receiving placebo (P < 0.001).”
> “At the end of an additional 40 weeks of maintenance, nearly half (49.9%) of patients receiving mirikizumab achieved clinical remission compared with 25.1% receiving placebo (P < 0.001)”

Source: [Rubin et al. (2025)](https://journals.lww.com/ajg/fulltext/10.14309/ajg.0000000000003463)

<a id="topic-2.2.2.1.7-3"></a>

###### Comparison with ustekinumab and switching within the class: ACG 2025

> “There are prospective comparative trials demonstrating superiority of 2 of the p19 therapies (guselkumab and risankizumab) in patients with moderately to severely active CD, but no such data exist for moderately to severely active UC. In addition, there are no data on cycling within the class of IL23p19 drugs.”
> “Some patients with moderately to severely active UC who are at higher risk for infectious complications may benefit from vedolizumab or an anti-IL-23 strategy over more systemically immunosuppressive medical options.”

Source: [Rubin et al. (2025)](https://journals.lww.com/ajg/fulltext/10.14309/ajg.0000000000003463)

<a id="topic-2.2.2.1.7-4"></a>

###### ECCO 2026 guideline: recommendations and risankizumab trial results

> “We recommend treatment with mirikizumab for the induction of remission in moderate-to-severe ulcerative colitis [strong recommendation, moderate certainty of evidence] [Agreement: 100%]”
> “We recommend treatment with risankizumab for the induction of remission in moderate-to-severe ulcerative colitis [strong recommendation, moderate certainty of evidence] [Agreement: 100%]”
> “We recommend treatment with guselkumab for the induction of remission in moderate-to-severe ulcerative colitis [strong recommendation, moderate certainty of evidence] [Agreement: 100%]”
> “At week 12, risankizumab significantly improved clinical remission rates compared with placebo (20.3% vs 6.2%, respectively; adjusted between-group difference [BGD]: 14.0% [95% CI: 10.0–18.0%]; P < .001).”
> “In the maintenance trial, each dose of risankizumab significantly improved clinical remission rates compared with placebo (40.2% for 180 mg risankizumab and 37.6% for 360 mg risankizumab vs 25.1% for placebo, BGD for 180 mg risankizumab vs placebo: 16.3% [95% CI: 6.1–26.6%]; P < .001)”
> “SC guselkumab is also effective for induction of remission in UC; this indication is supported by the efficacy and safety results from the ASTRO program.”
> “Data for IL-23 antagonist dose escalation are minimal and require further evidence before broader implementation.”

Source: [Gisbert et al. (2026)](https://academic.oup.com/ecco-jcc/article/20/7/jjag066/8726617)

<a id="topic-2.2.2.1.7-5"></a>

###### Network meta-analyses: rankings of interleukin-23 p19 inhibitors

> “Ater excluding JAK inhibitors, amongst biologic-naïve patients with moderately to severely active UC, risankizumab (P-score 0.86) and ozanimod (P-score 0.83) were ranked highest for induction of clinical remission (Figure 1b).”

Source: [Ananthakrishnan et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12148344/)

> “Risankizumab ranked first in the induction of histological remission (89.4%), followed by guselkumab (88.3%).”

Source: [Shehab et al. (2025)](https://pubmed.ncbi.nlm.nih.gov/39182898/)

> “Anti-p19 inhibitors, including risankizumab, subcutaneous guselkumab, and mirikizumab, were associated with the most favorable safety profiles for serious adverse events and adverse events leading to discontinuation, although confidence in safety estimates was lower.”

Source: [Olivera et al. (2026)](https://pubmed.ncbi.nlm.nih.gov/42838315/)

<a id="topic-2.2.2.1.7-6"></a>

###### Mirikizumab: mechanism and dosing in ulcerative colitis

> “Mirikizumab-mrkz is a humanized IgG4 monoclonal antibody that selectively binds to the p19 subunit of human IL-23 cytokine and inhibits its interaction with the IL-23 receptor.”
> “Week 0, Week 4, and Week 8: Infuse 300 mg intravenously over at least 30 minutes”
> “Week 12 and every 4 weeks thereafter: Inject 200 mg subcutaneously (given as one injection of 200 mg or as two consecutive injections of 100 mg each)”

Source: [Omvoh prescribing information (2025)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/761279s005lbl.pdf)

<a id="topic-2.2.2.1.7-7"></a>

###### Risankizumab: mechanism and dosing in ulcerative colitis

> “Risankizumab-rzaa is a humanized IgG1 monoclonal antibody that selectively binds to the p19 subunit of human IL-23 cytokine and inhibits its interaction with the IL-23 receptor.”
> “The recommended induction dosage of SKYRIZI is 1,200 mg administered by intravenous infusion over a period of at least two hours at Week 0, Week 4, and Week 8”
> “The recommended maintenance dosage of SKYRIZI is 180 mg or 360 mg administered by subcutaneous injection at Week 12, and every 8 weeks thereafter.”

Source: [Skyrizi prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/761105s053lbl.pdf)

<a id="topic-2.2.2.1.7-8"></a>

###### Guselkumab: mechanism and dosing in ulcerative colitis

> “Guselkumab is a human monoclonal IgG1λ antibody that selectively binds to the p19 subunit of interleukin 23 (IL-23) and inhibits its interaction with the IL-23 receptor.”
> “200 mg administered by intravenous infusion over at least one hour at Week 0, Week 4, and Week 8”
> “400 mg administered by subcutaneous injection (given as two consecutive injections of 200 mg each) at Week 0, Week 4, and Week 8.”
> “100 mg administered by subcutaneous injection at Week 16, and every 8 weeks thereafter, or”

Source: [Tremfya prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/761061s034lbl.pdf)

<a id="heading-2.2.2.1.8"></a>

###### 2.2.2.1.8 Janus Kinase Inhibitors

<a id="topic-2.2.2.1.8-1"></a>

###### ACG 2025 guideline: recommendations for induction and maintenance

> “In patients with moderately to severely active UC, we recommend the Janus kinase (JAK) inhibitor tofacitinib for induction of remission (Strong recommendation, moderate quality of evidence).”
> “In patients with moderately to severely active UC, we recommend the JAK inhibitor upadacitinib for induction of remission (Strong recommendation, high quality of evidence).”
> “We recommend continuing tofacitinib or upadacitinib as compared with no treatment for maintenance of remission in patients with prior moderately to severely active UC now in remission after induction with tofacitinib or upadacitinib (Strong recommendation, moderate quality of evidence).”

Source: [Rubin et al. (2025)](https://journals.lww.com/ajg/fulltext/10.14309/ajg.0000000000003463)

<a id="topic-2.2.2.1.8-2"></a>

###### Pivotal trial results for tofacitinib and upadacitinib: ACG 2025 evidence summary

> “In both trials, clinical remission at week 8 occurred in a significantly higher proportion of patients treated with tofacitinib 10 mg twice a day (BID) (18.5% and 16.6%, respectively) compared with those receiving placebo (8.2% and 3.6%, respectively).”
> “At 52 weeks, in the maintenance trial, 40.6% of patients treated with tofacitinib 10 mg BID and 34.3% of patients treated with 5 mg BID achieved remission compared with 11.1% of those treated with placebo.”
> “In the U-ACHIEVE induction study, 26% of patients treated with upadacitinib achieved clinical remission compared with 5% of patients receiving placebo (P < 0.0001). In the U-ACCOMPLISH trial, 34% of patients receiving upadacitinib achieved clinical remission at 8 weeks compared with 4% of patients on placebo (P < 0.0001).”
> “At the end of follow-up, clinical remission was achieved by a larger proportion of patients treated with upadacitinib 15 mg/d (42%) or 30 mg/d (52%) compared with placebo (12%; P < 0.0001 for both).”
> “Filgotinib is an additional JAK-1 selective inhibitor which has demonstrated efficacy in moderately to severely active UC and is approved for use for this indication in Europe (204). However, this therapy is not available in the United States.”

Source: [Rubin et al. (2025)](https://journals.lww.com/ajg/fulltext/10.14309/ajg.0000000000003463)

<a id="topic-2.2.2.1.8-3"></a>

###### U.S. positioning after TNF antagonist failure: ACG 2025

> “This led to a label change for tofacitinib in the United States (only in the United States) to be positioned after failure of anti-TNF.”
> “Nonetheless, tofacitinib is labeled to be used after anti-TNF failure and with caution in patients with risk factors for cardiovascular disease or VTE complications.”
> “There were no significant MACE or VTE events with upadacitinib in these trials, but the US FDA extended the label used with tofacitinib to upadacitinib to use after inadequate response or intolerance to one or more TNF inhibitors, with caution in patients with cardiovascular risk factors, and to use the lowest effective dose in maintenance.”

Source: [Rubin et al. (2025)](https://journals.lww.com/ajg/fulltext/10.14309/ajg.0000000000003463)

<a id="topic-2.2.2.1.8-4"></a>

###### Restricted first-line use: AGA 2024 guideline

> “JAK inhibitors have restricted use in advanced therapy-naïve patients. The FDA label recommends the use of JAK inhibitors in patients with prior failure or intolerance to TNF antagonists.”

Source: [Singh et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12162142/)

<a id="topic-2.2.2.1.8-5"></a>

###### ECCO 2026 guideline: recommendations, safety, and European risk minimization

> “We recommend treatment with tofacitinib for the induction of remission in moderate-to-severe ulcerative colitis [strong recommendation, moderate certainty of evidence] [Agreement: 100%]”
> “We recommend treatment with upadacitinib for the induction of remission in moderate-to-severe ulcerative colitis [strong recommendation, moderate certainty of evidence] [Agreement: 100%]”
> “We recommend treatment with filgotinib for the induction of remission in moderate-to-severe ulcerative colitis [strong recommendation, moderate certainty of evidence] [Agreement: 98%]”
> “The measures specified that JAKi should be used only if no suitable treatment alternatives are available in those aged ≥65 years and those with cardiovascular risk factors. They also recommended using JAKi with caution in patients with risk factors for venous thromboembolism.”
> “A systematic review has demonstrated that risks of herpes zoster are dose-related for both tofacitinib and upadacitinib, underscoring the importance of dose de-escalation where possible.”

Source: [Gisbert et al. (2026)](https://academic.oup.com/ecco-jcc/article/20/7/jjag066/8726617)

<a id="topic-2.2.2.1.8-6"></a>

###### Tofacitinib: U.S. indication in ulcerative colitis

> “XELJANZ tablets and XELJANZ XR (extended-release tablets) are indicated for the treatment of adult patients with moderately to severely active ulcerative colitis (UC), who have an inadequate response or intolerance to one or more TNF blockers.”
> “Use of XELJANZ tablets or XELJANZ XR in combination with biological therapies for UC or with potent immunosuppressants such as azathioprine and cyclosporine is not recommended.”

Source: [Xeljanz prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/203214s042lbl.pdf)

<a id="topic-2.2.2.1.8-7"></a>

###### Upadacitinib: U.S. indication and dosing in ulcerative colitis

> “RINVOQ is indicated for the treatment of adult patients with moderately to severely active ulcerative colitis (UC) who have had an inadequate response or intolerance to one or more TNF blockers. If TNF blockers are clinically inadvisable, patients should have received at least one approved systemic therapy prior to use of RINVOQ.”
> “The recommended induction dosage of RINVOQ is 45 mg once daily for 8 weeks.”
> “The recommended dosage of RINVOQ for maintenance treatment is 15 mg once daily. A dosage of 30 mg once daily may be considered for patients with refractory, severe or extensive disease.”

Source: [Rinvoq prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/218347Orig1s008,211675Orig1s034lbl.pdf)

<a id="topic-2.2.2.1.8-8"></a>

###### Network meta-analyses: rankings of Janus kinase inhibitors

> “With the inclusion of JAK inhibitors as first-line therapy, upadacitinib was more efficacious compared with all other medications except ozanimod and risankizumab with low to moderate certainty evidence. In patients with prior biologic exposure, upadacitinib, tofacitinib and ustekinumab were ranked highest for achieving remission.”

Source: [Ananthakrishnan et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12148344/)

> “Upadacitinib ranked highest in inducing clinical remission (99.6%), and endoscopic improvement (99.2%), followed by risankizumab (91.4%) and (82.3%), respectively.”

Source: [Shehab et al. (2025)](https://pubmed.ncbi.nlm.nih.gov/39182898/)

> “Upadacitinib demonstrated the highest relative efficacy for clinical remission (risk ratio, 6.90; 95% confidence interval, 3.54-12.45; P score, 0.95; high confidence) and endoscopic improvement (risk ratio, 5.29; 95% confidence interval, 3.38-8.28; P score, 0.97; moderate confidence).”

Source: [Olivera et al. (2026)](https://pubmed.ncbi.nlm.nih.gov/42838315/)

> “In re‐randomised studies, upadacitinib 30 mg o.d. ranked first for clinical remission (RR of failure to achieve clinical remission = 0.52; 95% CI 0.44–0.61, p‐score 0.99) and endoscopic improvement (RR = 0.43; 95% CI 0.35–0.52, p‐score 0.99).”

Source: [Barberio et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12151545/)

> “The guideline does not provide a hierarchy of treatments, due predominantly to the lack of head-to-head data, but network meta-analysis (NMA) of trials for induction and maintenance of moderate to severe UC demonstrate a large magnitude of effect for upadacitinib and tofacitinib, with moderate magnitude of effect for risankizumab, filgotinib and ozanimod, and a small magnitude of effect for infliximab, etrasimod, golimumab, mirikizumab, ustekinumab and vedolizumab.”

Source: [Butler and Segal (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7619135/)

<a id="topic-2.2.2.1.8-9"></a>

###### Medicare drug price negotiation: tofacitinib selected for the third cycle

> “Any negotiated prices will be effective beginning in 2028.”
> “Xeljanz; Xeljanz XR”

Source: [CMS fact sheet, third cycle of negotiation (2026)](https://www.cms.gov/files/document/fact-sheet-medicare-drug-price-negotiation-third-cycle.pdf)

<a id="heading-2.2.2.1.9"></a>

###### 2.2.2.1.9 Sphingosine-1-phosphate Receptor Modulators

<a id="topic-2.2.2.1.9-1"></a>

###### ACG 2025 guideline: recommendations for induction and maintenance

> “In patients with moderately to severely active UC, we recommend sphingosine-1-phosphate (S1P) receptor modulators, ozanimod and etrasimod, for induction of remission (Strong recommendation, moderate quality of evidence).”
> “We recommend continuing S1P receptor modulators ozanimod or etrasimod for maintenance of remission as compared wih no treatment after induction of remission with these agents (Strong recommendation, moderate quality of evidence).”

Source: [Rubin et al. (2025)](https://journals.lww.com/ajg/fulltext/10.14309/ajg.0000000000003463)

<a id="topic-2.2.2.1.9-2"></a>

###### Mechanism and pivotal trial results: ACG 2025 evidence summary

> “The small molecule S1P receptor modulators ozanimod and etrasimod have a mechanism of action that sequesters activated lymphocytes in lymph nodes in patients with UC and results in decreased cellular inflammation in the bowel and a corresponding decreased circulating lymphocyte count.”
> “At the end of 10 weeks, a larger proportion of patients receiving ozanimod achieved clinical remission (18.4%) compared with placebo (6.0%, P < 0.001)).”
> “At the end of the maintenance period, 37% of patients continuing ozanimod achieved clinical remission compared with 18.5% of patients receiving placebo (P < 0.001).”
> “In the ELEVATE UC 52 study, at the completion of 12 and 52 weeks of treatment, 27% and 32% of patients receiving etrasimod achieved clinical remission compared with 7% and 7% of patients treated with placebo (P < 0.0001 for both comparisons).”
> “Unlike all other modern pivotal trials for moderately to severely active UC which excluded patients with isolated proctitis, the pivotal trials for etrasimod included patients with isolated proctitis and demonstrated a clinical remission rate in these patients of 43.2% at week 12, compared with 13.6% with placebo (P < 0.001).”
> “Significant cardiovascular disease, severe untreated sleep apnea, cardiac conduction defects, and concomitant use of monoamine oxidase inhibitors contraindicate the use of ozanimod.”

Source: [Rubin et al. (2025)](https://journals.lww.com/ajg/fulltext/10.14309/ajg.0000000000003463)

<a id="topic-2.2.2.1.9-3"></a>

###### ECCO 2026 guideline: recommendations and etrasimod safety

> “We recommend treatment with ozanimod for the induction of remission in moderate-to-severe ulcerative colitis [strong recommendation, moderate certainty of evidence] [Agreement: 100%]”
> “We recommend treatment with etrasimod for the induction of remission in moderate-to-severe ulcerative colitis [strong recommendation, low certainty of evidence] [Agreement: 98%]”
> “There were isolated cases of bradyarrhythmias [mostly asymptomatic], occurring mainly during the initial days of treatment and resolving without specific intervention.”
> “In the etrasimod group, the incidence of macular edema was low and comparable with placebo. No increased infection risk or malignancies were reported in etrasimod trials.”

Source: [Gisbert et al. (2026)](https://academic.oup.com/ecco-jcc/article/20/7/jjag066/8726617)

<a id="topic-2.2.2.1.9-4"></a>

###### Ozanimod: indication, mechanism, dosing, and monitoring

> “ZEPOSIA is a sphingosine 1-phosphate receptor modulator indicated for the treatment of:”
> “Moderately to severely active ulcerative colitis (UC) in adults.”
> “The recommended maintenance dosage is 0.92 mg orally once daily.”
> “Ozanimod blocks the capacity of lymphocytes to egress from lymph nodes, reducing the number of lymphocytes in peripheral blood.”
> “Macular Edema: Increases the risk of macular edema. Obtain a baseline evaluation of the fundus, including the macula, near the start of treatment with ZEPOSIA.”

Source: [Zeposia prescribing information (2024)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/209899s011s012lbl.pdf)

<a id="topic-2.2.2.1.9-5"></a>

###### Etrasimod: indication, mechanism, and dosing

> “VELSIPITY is indicated for the treatment of moderately to severely active ulcerative colitis (UC) in adults.”
> “The recommended dosage is 2 mg orally once daily.”
> “Etrasimod partially and reversibly blocks the capacity of lymphocytes to egress from lymphoid organs, reducing the number of lymphocytes in peripheral blood.”

Source: [Velsipity prescribing information (2025)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/216956s002lbl.pdf)

<a id="topic-2.2.2.1.9-6"></a>

###### Network meta-analyses: rankings of sphingosine-1-phosphate receptor modulators

> “After excluding JAK inhibitors as potential first-line treatment (in accordance with FDA), low-certainty evidence supports clinically important benefit with infliximab, ozanimod, risankizumab and guselkumab over adalimumab and mirikizumab for achieving remission with induction therapy in biologic-naïve patients with moderate-severe UC, with risankizumab and ozanimod being ranked the highest for induction of clinical remission.”

Source: [Ananthakrishnan et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12148344/)

> “In treat‐through studies, etrasimod 2 mg o.d. ranked first for clinical remission (RR = 0.73; 95% CI 0.64–0.83, p‐score 0.88)”

Source: [Barberio et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12151545/)

<a id="heading-2.2.2.1.10"></a>

###### 2.2.2.1.10 Calcineurin Inhibitors

<a id="topic-2.2.2.1.10-1"></a>

###### Rescue therapy in acute severe ulcerative colitis: ACG 2025

> “In patients with ASUC failing to adequately respond to intravenous corticosteroids (IVCS) by 3 days, we recommend medical rescue therapy with infliximab or cyclosporine (Strong recommendation, moderate quality of evidence).”
> “In patients with ASUC who achieve remission with cyclosporine treatment, we suggest maintenance of remission with thiopurines (Conditional recommendation, low quality of evidence).”
> “In patients with ASUC, the choice between infliximab and cyclosporine should be based on provider experience with the agent, history of prior failure of immunomodulator or anti-TNF therapy, and serum albumin.”
> “By contrast, because cyclosporine is used less frequently and only at select centers, its use in steroid-refractory colitis should be restricted to providers who are familiar with dosing, monitoring trough concentrations, and managing adverse effects.”

Source: [Rubin et al. (2025)](https://journals.lww.com/ajg/fulltext/10.14309/ajg.0000000000003463)

<a id="topic-2.2.2.1.10-2"></a>

###### Tacrolimus in steroid-refractory disease: ACG 2025

> “Tacrolimus is a calcineurin inhibitor that has been examined in the treatment of steroid-refractory UC in both children and adults. In a double-blind placebo-controlled trial of 62 patients, the clinical response rate at week 2 was 50% with tacrolimus compared with 13% with placebo (P = 0.003) (178).”

Source: [Rubin et al. (2025)](https://journals.lww.com/ajg/fulltext/10.14309/ajg.0000000000003463)

<a id="topic-2.2.2.1.10-3"></a>

###### Cyclosporine compared with infliximab: ECCO 2026

> “We recommend either cyclosporine or infliximab as rescue therapy in patients with steroid-refractory acute severe ulcerative colitis [strong recommendation, high certainty of evidence] [Agreement: 100%]”
> “Colectomy rates at day 98 were 17% in the infliximab group versus 21% in the cyclosporine group; the differences were not statistically significant.”
> “Colectomy rates were 30.9% and 34.9% in the infliximab group versus 29.1% and 38.5% in the cyclosporine group at 1 and 5 years, respectively [P = .97].”
> “In summary, the available evidence supports the use of either infliximab or cyclosporine as rescue therapy in ASUC refractory to IV corticosteroids, with comparable colectomy rates, safety profiles, and QoL outcomes across trials. However, infliximab was associated with significantly greater short-term endoscopic remission.”

Source: [Gisbert et al. (2026)](https://academic.oup.com/ecco-jcc/article/20/7/jjag066/8726617)

<a id="topic-2.2.2.1.10-4"></a>

###### Third-line sequential rescue therapy: ECCO 2026

> “We suggest that the use of a third-line sequential rescue therapy with infliximab, a calcineurin inhibitor, or a Janus kinase inhibitor may be considered in highly selected patients with acute severe ulcerative colitis who are refractory to intravenous corticosteroids and a second-line treatment [infliximab or calcineurin inhibitor] in experienced multidisciplinary centers and after discussion of surgical options and potential risks and benefits [weak recommendation, low certainty of evidence] [Agreement: 100%]”
> “In a recent systematic review that included 23 studies, third-line rescue therapy resulted in avoidance of colectomy in 53% of patients with ASUC [95% CI: 47%–58%].”

Source: [Gisbert et al. (2026)](https://academic.oup.com/ecco-jcc/article/20/7/jjag066/8726617)

<a id="topic-2.2.2.1.10-5"></a>

###### Calcineurin inhibitors prohibited during obefazimod open-label maintenance

> “The use of biologics (eg, TNF-α inhibitors, vedolizumab, ustekinumab), JAK inhibitors, cyclosporin, and tacrolimus was prohibited during the study.”

Source: [Vermeire et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12124117/)

<a id="heading-2.2.2.1.11"></a>

###### 2.2.2.1.11 Colectomy

<a id="topic-2.2.2.1.11-1"></a>

###### Indications for surgical consultation and colectomy: ACG 2025

> “Obtain consultation with a surgeon and consider colectomy in patients with moderately to severely active UC who are refractory or intolerant to medical therapy.”
> “Patients with moderately to severely active UC who do not maintain remission despite optimized medical therapy should be considered for elective proctocolectomy.”
> “Toxic megacolon, colonic perforation, severe refractory hemorrhage, and refractoriness to medical therapy are indications for surgery in patients with ASUC.”

Source: [Rubin et al. (2025)](https://journals.lww.com/ajg/fulltext/10.14309/ajg.0000000000003463)

<a id="topic-2.2.2.1.11-2"></a>

###### ECCO 2026 surgical guideline: timing, reconstruction, and center volume

> “We recommend surgical treatment when moderately-to-severely active UC is refractory to optimised medical therapy [EL3] [Agreement 97.5%]”
> “Despite major advances in medical therapy, colectomy rates in UC have remained largely unchanged,”
> “Conversely, delaying surgery increases the risk of emergency colectomy, which is associated with higher rates of postoperative complications, prolonged hospitalization, and increased mortality.”
> “While IPAA remains the standard of care [EL3], IRA is an option for selected patients.”
> “We recommend that reconstructive surgery after colectomy for UC with IPAA should be performed in specialized centers by experienced surgeons [EL4] [Agreement 97.5%]”
> “Although definitions vary, a minimum institutional volume of eight IPAA procedures per year has been proposed as a threshold for improved outcomes,”

Source: [Adamina et al. (2026)](https://academic.oup.com/ecco-jcc/article/20/6/jjag072/8722674)

<a id="topic-2.2.2.1.11-3"></a>

###### Cumulative risk of colectomy: meta-analysis of population-based cohorts

> “On meta-analysis, the cumulative risk of colectomy 1-, 5-, and 10-years after diagnosis was 4.0% (95% CI, 3.3–5.0), 8.8% (95% CI, 7.7–10.0) and 13.3% (95% CI, 11.3–15.5), respectively, with considerable heterogeneity (I2=95–98%) (Figures 1A–C).”

Source: [Tsai et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8934200/)

<a id="topic-2.2.2.1.11-4"></a>

###### Cumulative risk of colectomy in newly diagnosed U.S. adults, 2007 to 2023

> “Cumulative 5y risk of colectomy was lower in the more contemporary cohort (patients diagnosed in 2019–23 vs. 2007–12: 4.2% vs. 6.7%; aHR, 0.58 [95% CI, 0.38–0.89]) (Figure 2E).”

Source: [Ahuja et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13456955/)

<a id="topic-2.2.2.1.11-5"></a>

###### Hospitalization cost of nonelective colectomy in the United States

> “An estimated 10,280 patients met study criteria with median index hospitalization costs of $40,300 (IQR, $26,400-$65,000). Increased time to surgery was significantly associated with a +$2500 increment in costs per day.”

Source: [Ng et al. (2024)](https://pubmed.ncbi.nlm.nih.gov/38583900/)

<a id="topic-2.2.2.1.11-6"></a>

###### Colectomy cost input in the ICER 2020 model

> “A cost of $33,871 per admission for colectomy is assumed”

Source: [ICER Targeted Immune Modulators for Ulcerative Colitis final evidence report (2020)](https://icer.org/wp-content/uploads/2020/08/ICER_UC_Final_Evidence_Report_101620.pdf)

<a id="heading-2.2.2.1.12"></a>

###### 2.2.2.1.12 Limitations of Current Therapies

<a id="topic-2.2.2.1.12-1"></a>

###### Summary: limitations of current therapies

A review states that the highest response to medical therapies “ranges from 30% to 60% in clinical trials”, and another review states that “10-20% of patients still require proctocolectomy for medically refractory disease.” The ACG 2025 guideline states that up to one-fifth of patients receiving anti-TNF agents may not respond initially and that “an additional 10%–15% may lose response every year”; the ECCO 2026 guideline reports that 40% of patients on vedolizumab maintenance lose response. Among 3,562 patients initiating advanced therapy, 47.8% remained steroid-free after 12 months, and mean UC-related costs in the 12 months after initiation were $42,579. The two oral classes carry restrictions: the tofacitinib label carries a boxed warning for serious infections, mortality, malignancy, major adverse cardiovascular events, and thrombosis, and both U.S. JAK inhibitor labels indicate them in ulcerative colitis after an inadequate response or intolerance to one or more TNF blockers (for upadacitinib, after at least one approved systemic therapy when TNF blockers are clinically inadvisable); the S1P receptor modulators require pre-treatment assessments, and the ACG 2025 guideline states that significant cardiovascular disease and cardiac conduction defects, among other conditions, contraindicate ozanimod. Biologics require injections or intravenous infusions, which Abivax describes as resulting in “patient inconvenience and burden”.

Source: [Gros and Kaplan (2023)](https://pubmed.ncbi.nlm.nih.gov/37698559/); [Le Berre et al. (2023)](https://pubmed.ncbi.nlm.nih.gov/37573077/); [Rubin et al. (2025)](https://journals.lww.com/ajg/fulltext/10.14309/ajg.0000000000003463); [Gisbert et al. (2026)](https://academic.oup.com/ecco-jcc/article/20/7/jjag066/8726617); [Long et al. (2020)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7216775/); [Xeljanz prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/203214s042lbl.pdf); [Rinvoq prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/218347Orig1s008,211675Orig1s034lbl.pdf); [Zeposia prescribing information (2024)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/209899s011s012lbl.pdf); [Velsipity prescribing information (2025)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/216956s002lbl.pdf); [Abivax Form 20-F (2026)](https://www.sec.gov/Archives/edgar/data/1956827/000195682726000012/abvx-20251231.htm)

<a id="topic-2.2.2.1.12-2"></a>

###### Ceiling of response to current therapies

> “Despite advances in medical therapies, the highest response to these treatments ranges from 30% to 60% in clinical trials.”

Source: [Gros and Kaplan (2023)](https://pubmed.ncbi.nlm.nih.gov/37698559/)

> “Although the therapeutic options are expanding, 10-20% of patients still require proctocolectomy for medically refractory disease.”

Source: [Le Berre et al. (2023)](https://pubmed.ncbi.nlm.nih.gov/37573077/)

<a id="topic-2.2.2.1.12-3"></a>

###### Primary nonresponse and loss of response

> “Up to one-fifth of patients receiving anti-TNF agents may not respond initially, and an additional 10%–15% may lose response every year despite an initial benefit (227,228).”

Source: [Rubin et al. (2025)](https://journals.lww.com/ajg/fulltext/10.14309/ajg.0000000000003463)

> “For anti-TNFs, 10%–13% of patients lose response annually, and dose escalation benefits 50%–75% of these patients.”
> “In patients with UC on vedolizumab maintenance therapy, 40% lose response, and approximately half will recapture response with dose escalation.”

Source: [Gisbert et al. (2026)](https://academic.oup.com/ecco-jcc/article/20/7/jjag066/8726617)

<a id="topic-2.2.2.1.12-4"></a>

###### Continued corticosteroid use after starting advanced therapy

> “In total, 3562 patients were included in the analysis. Most patients (83.0%) used steroids in the 12 months before initiating advanced therapy. Overall, 47.8% remained steroid-free after 12 months (excluding tapering).”
> “Mean, unadjusted, UC-related costs in the 12 months postinitiation were $42,579 and were similar between therapies.”

Source: [Long et al. (2020)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7216775/)

<a id="topic-2.2.2.1.12-5"></a>

###### Boxed warning on Janus kinase inhibitors

> “WARNING: SERIOUS INFECTIONS, MORTALITY, MALIGNANCY, MAJOR ADVERSE CARDIOVASCULAR EVENTS, and THROMBOSIS”
> “Higher rate of all-cause mortality, including sudden cardiovascular (CV) death with XELJANZ vs. TNF blockers in rheumatoid arthritis (RA) patients.”

Source: [Xeljanz prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/203214s042lbl.pdf)

<a id="topic-2.2.2.1.12-6"></a>

###### Cardiac contraindications to sphingosine-1-phosphate receptor modulators

> “In the last 6 months, experienced myocardial infarction, unstable angina pectoris, stroke, transient ischemic attack, decompensated heart failure requiring hospitalization, or Class III or IV heart failure.”
> “Assessments are required prior to initiating VELSIPITY.”

Source: [Velsipity prescribing information (2025)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/216956s002lbl.pdf)

<a id="topic-2.2.2.1.12-7"></a>

###### Administration burden and waning efficacy: manufacturer statement

> “Furthermore, biological agents require injections or intravenous infusions, resulting in patient inconvenience and burden, which often negatively impacts patient compliance.”

Source: [Abivax Form 20-F (2026)](https://www.sec.gov/Archives/edgar/data/1956827/000195682726000012/abvx-20251231.htm)

<a id="heading-2.2.2.2"></a>

##### 2.2.2.2 Place in Treatment, Anticipated Use, and Care Setting

<a id="topic-2.2.2.2-1"></a>

###### Summary: anticipated place in therapy

Obefazimod is investigational, and no labeled indication exists. Abivax describes its pre-NDA interaction with the FDA as concerning obefazimod “for the treatment of adults with moderately to severely active ulcerative colitis”. ABTECT-1 and ABTECT-2 enrolled participants with a modified Mayo score of 5 or more who had an inadequate response, loss of response, or intolerance to at least one prior therapy, including corticosteroids, immunosuppressants, biologics, S1P receptor modulators, or JAK inhibitors, with no upper limit; 602 of 1,272 participants (47.3%) had a prior inadequate response to an advanced therapy. Obefazimod is taken orally once daily, whereas the IL-23 p19 inhibitors require intravenous induction (or subcutaneous induction for guselkumab) and subcutaneous maintenance.

Abivax states that it hopes “to position obefazimod as a potential first-line advanced therapy” and that there is no guarantee it would be approved for that use. Abivax estimates that approximately 300,000 moderate-to-severe U.S. patients, out of an estimated 500,000, are on conventional therapy or steroids only, and its research reported that physicians would likely initiate obefazimod in this population “where reluctance to advanced therapies hinder their use.” A Wedbush analyst noted that a boxed warning would limit commercial differentiation against JAK inhibitors.

The AGA 2024 guideline suggests early use of advanced therapies rather than gradual step-up after 5-aminosalicylate failure, and ranks therapies by efficacy separately for advanced therapy-naive and -exposed patients. The ECCO 2026 guideline recommends no treatment or class over another as first-line or subsequent therapy, apart from vedolizumab over adalimumab. The ACG 2025 guideline did not use indirect or post hoc data for its positioning recommendations and states that third-party payers and step therapy requirements “should not come between the patient and their healthcare team”. The BSG 2025 guideline provides no hierarchy. In a cohort of patients newly diagnosed with ulcerative colitis in 2019 to 2023, cumulative 1-year and 5-year use of advanced therapy was 27% and 38%.

Source: [Abivax press release, pre-NDA interaction with the FDA (2026)](https://ir.abivax.com/news-releases/news-release-details/abivax-announces-positive-pre-nda-interaction-fda-obefazimod); [UEG Week (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12605988/); [Tremfya prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/761061s034lbl.pdf); [Abivax Form 20-F (2026)](https://www.sec.gov/Archives/edgar/data/1956827/000195682726000012/abvx-20251231.htm); [Abivax press release, 2026 corporate outlook (2026)](https://ir.abivax.com/news-releases/news-release-details/abivax-provides-2026-corporate-outlook); [Streetwise Reports (2026)](https://www.streetwisereports.com/article/2026/07/01/clinical-stage-biotech-discloses-colitis-retreatment-results-gets-mixed-ratings.html); [Singh et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12162142/); [Gisbert et al. (2026)](https://academic.oup.com/ecco-jcc/article/20/7/jjag066/8726617); [Rubin et al. (2025)](https://journals.lww.com/ajg/fulltext/10.14309/ajg.0000000000003463); [Butler and Segal (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7619135/); [Ahuja et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13456955/); [Omvoh prescribing information (2025)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/761279s005lbl.pdf); [Skyrizi prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/761105s053lbl.pdf)

<a id="topic-2.2.2.2-2"></a>

###### Proposed indication named in the pre-NDA announcement

> “today announced the successful completion of its positive pre-New Drug Application (NDA) interaction with the U.S. Food and Drug Administration (FDA) for obefazimod for the treatment of adults with moderately to severely active ulcerative colitis”

Source: [Abivax press release, pre-NDA interaction with the FDA (2026)](https://ir.abivax.com/news-releases/news-release-details/abivax-announces-positive-pre-nda-interaction-fda-obefazimod)

<a id="topic-2.2.2.2-3"></a>

###### Population studied in the phase 3 induction trials

> “The multicenter, randomized, double‐blind, placebo‐controlled ABTECT trials enrolled pts with moderate‐to‐severe UC (defined as modified Mayo score (MMS) ≥ 5, with rectal bleeding sub‐score (RBS) ≥ 1 and centrally read endoscopic score ≥ 2) who had inadequate response, loss of response, or intolerance to at least one prior therapy (with no upper limit), including corticosteroids, immunosuppressants, biologics, S1P receptor modulators and/or JAK inhibitors.”
> “Obefazimod (Obe), an oral, once‐daily (QD), small molecule which enhances expression of microRNA‐124 was studied in patients (pts) with moderately to severely active ulcerative colitis (UC) in Phase 2 studies [1–3].”

Source: [UEG Week (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12605988/)

<a id="topic-2.2.2.2-4"></a>

###### Manufacturer positioning as an oral advanced therapy

> “Advance obefazimod through pivotal clinical trials and establish obefazimod as a potential preferred advanced therapy for IBD.”
> “While we hope to position obefazimod as a potential first-line advanced therapy, there is no guarantee that even if approved, it would be approved for first-line advanced therapy. This could limit our potential market opportunity. In addition, we may have to conduct additional clinical trials prior to gaining approval for first-line advanced therapy.”
> “Obefazimod is being developed as a once-daily, oral medication which, combined with its observed tolerability to date, would represent a meaningfully differentiated clinical profile from existing therapies. We believe this may position obefazimod as a potential first-line advanced therapy choice for both prescribers and patients, if approved.”

Source: [Abivax Form 20-F (2026)](https://www.sec.gov/Archives/edgar/data/1956827/000195682726000012/abvx-20251231.htm)

<a id="topic-2.2.2.2-5"></a>

###### Manufacturer estimate of patients on conventional therapy

> “We currently estimate that approximately 300,000 moderate-to-severe UC patients in the United States, out of an estimated 500,000 patients, are on conventional therapy or steroids only, and a safe, efficacious, oral therapy will have the unique ability to further penetrate this patient segment.”
> “We believe the potential for oral agents to gain significant market share is supported by physician and patient preference for the convenience of oral administration over injectable agents”

Source: [Abivax Form 20-F (2026)](https://www.sec.gov/Archives/edgar/data/1956827/000195682726000012/abvx-20251231.htm)

> “The research estimated that roughly 500K patients within the United States are currently on conventional therapies (5ASA’s/corticosteroids), with approximately 60% of these patients being moderate/severe (~300K patients). Physicians indicated they would likely initiate treatment with obefazimod for this population where reluctance to advanced therapies hinder their use.”

Source: [Abivax press release, 2026 corporate outlook (2026)](https://ir.abivax.com/news-releases/news-release-details/abivax-provides-2026-corporate-outlook)

<a id="topic-2.2.2.2-6"></a>

###### Analyst view on positioning against Janus kinase inhibitors

> “We also remain mindful of the possibility of a Black Box warning, which would limit commercial differentiation against JAK inhibitors and negatively position obefazimod against emerging classes in IBD, including TL1A inhibitors.”

Source: [Streetwise Reports (2026)](https://www.streetwisereports.com/article/2026/07/01/clinical-stage-biotech-discloses-colitis-retreatment-results-gets-mixed-ratings.html)

<a id="topic-2.2.2.2-7"></a>

###### Guideline sequencing: early advanced therapy and absence of a hierarchy

> “In adult outpatients with moderate-severe UC, the AGA suggests early use of advanced therapies with or without immunomodulator therapy, rather than gradual step up after failure of 5-aminosalicylates.”

Source: [Singh et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12162142/)

> “Apart from suggesting the use of vedolizumab rather than adalimumab, no individual treatment or class of treatment can be recommended over another as first-line or subsequent therapy in the treatment of patients with moderate-to-severe ulcerative colitis.”
> “Sequencing therapies in individual patients with moderate-to-severe UC is based on many factors, which among others include patient preference, disease severity, previous treatments, age, efficacy and safety profile of the chosen drug, existing comorbidities, extra-intestinal manifestations, wish to become pregnant, adherence, local availability, and prevailing federal regulations.”

Source: [Gisbert et al. (2026)](https://academic.oup.com/ecco-jcc/article/20/7/jjag066/8726617)

> “Therefore, we determined not to use indirect or post hoc data to guide our positioning recommendations.”
> “Patients with UC should have available all medical options as recommended by their doctor and healthcare team. Third-party payers and requirements for step therapy should not come between the patient and their healthcare team in making decisions about treatment for UC.”

Source: [Rubin et al. (2025)](https://journals.lww.com/ajg/fulltext/10.14309/ajg.0000000000003463)

> “A summary of recommendations from the 2025 BSG IBD guidelines regarding the use of advanced therapies for induction and maintenance of remission in patients with moderate to severe IBD. Medications are not listed hierarchically.”

Source: [Butler and Segal (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7619135/)

<a id="topic-2.2.2.2-8"></a>

###### Current use of advanced therapy in newly diagnosed U.S. adults

> “In a more contemporary cohort of patients diagnosed in 2019–23, the corresponding rate was 27% (95% CI, 24–29) and 38% (95% CI, 34–41), respectively (aHR, 3.43 [95% CI, 2.86–4.13]) (Figure 2C).”

Source: [Ahuja et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13456955/)

<a id="topic-2.2.2.2-9"></a>

###### Analyst commentary on cancer risk and a possible boxed warning, June 2026

> “Wedbush analyst David Nierengarten, Ph.D., was less optimistic, citing concerns”
> “on how the FDA will view cancer risk associated with obefazimod.”
> “We also remain mindful of the possibility of a Black Box warning, which would limit commercial differentiation against JAK inhibitors and negatively position obefazimod against emerging classes in IBD, including TL1A inhibitors.”

Source: [Streetwise Reports (2026)](https://www.streetwisereports.com/article/2026/07/01/clinical-stage-biotech-discloses-colitis-retreatment-results-gets-mixed-ratings.html)

Additional sources: [Digestive Disease Week poster, ABTECT integrated safety (2026)](https://www.abivax.com/wp-content/uploads/2026/04/abivax-poster-iss-sands-ddw-2026.pdf)

<a id="heading-2.2.2.3"></a>

##### 2.2.2.3 Heterogeneity of Treatment Effect

<a id="topic-2.2.2.3-1"></a>

###### Summary: response by prior advanced therapy exposure

In the pooled ABTECT induction trials, 47.3% of participants had a prior inadequate response to an advanced therapy (AT-IR). The placebo-adjusted difference in clinical remission at week 8 with obefazimod 50 mg was 10.1% in participants with AT-IR and 22.4% in those without; with 25 mg, the difference was lower than with 50 mg in participants with AT-IR, and the two doses performed similarly in participants without AT-IR. In participants with prior JAK inhibitor failure, the pooled placebo-adjusted difference in clinical response with 50 mg was 34%. In the maintenance trial, clinical remission at Week 52 occurred in 72 of 117 (25 mg) and 62 of 105 (50 mg) participants against 15 of 120 with placebo among AT-IR-naive participants, and in 26 of 76 and 38 of 90 against 5 of 72 among participants with prior AT-IR. In the phase 2b open-label maintenance study, clinical remission at week 96 was 63.8% in participants naive to biologics or JAK inhibitors, and 38.8% of those with prior inadequate response were in clinical remission at both weeks 48 and 96. The same direction of effect is reported for comparators: the ACG 2025 guideline states that patients have higher response and remission rates with their first therapies than after failure of other advanced therapies, and the AGA 2024 guideline places different agents in its higher-efficacy tier for advanced therapy-naive and -exposed patients. In a 2026 network meta-analysis of induction trials, obefazimod and upadacitinib showed the highest efficacy in AT-naive patients, and upadacitinib, ustekinumab, and tofacitinib ranked highest in AT-experienced patients. All obefazimod subgroup p-values are nominal.

Source: [UEG Week (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12605988/); [Abivax press release, UEG late-breaking AT-IR subgroup data (2025)](https://ir.abivax.com/news-releases/news-release-details/abivax-announces-late-breaking-presentation-8-week-abtect); [Danese et al. (2026)](https://www.abivax.com/wp-content/uploads/2026/10/OP260-ABTECT-ATIR-19OCT2026-Danese-UEGW2026.pdf); [Vermeire et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12124117/); [Rubin et al. (2025)](https://journals.lww.com/ajg/fulltext/10.14309/ajg.0000000000003463); [Singh et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12162142/); [Olivera et al. (2026)](https://pubmed.ncbi.nlm.nih.gov/42838315/)

<a id="topic-2.2.2.3-2"></a>

###### Obefazimod induction: efficacy with and without prior inadequate response to advanced therapy

> “Among pts who participated in ABTECT‐1, ABTECT‐2, and the pooled analysis, 45.3% (288/636), 49.4% (314/636), and 47.3% (602/1272) were AT‐IR‐Yes, respectively; 54.7% (348/636), 50.6% (322/636), 52.7% (670/1272) were AT‐IR‐No.”
> “In ABTECT‐1, ABTECT‐2, and pooled, a higher proportion of the AT‐IR‐Yes subgroup receiving Obe‐50 achieved all efficacy measures relative to PBO including clinical remission (Obe‐50‐PBO difference: ABTECT‐1 12.7%, p = 0.0039; ABTECT‐2 7.6%, p = 0.0652, pooled 10.1%, p = 0.0009).”
> “In the AT‐IR‐Yes subgroup, the difference from PBO across all efficacy measures was lower for pts receiving Obe‐25 relative to Obe‐50 (Table 1).”
> “In the AT‐IR‐No subgroup, larger proportions achieved all efficacy measures relative to PBO including clinical remission (Obe‐50‐PBO difference: ABTECT‐1 25.0%, p < 0.0001; ABTECT‐2 19.4%, p = 0.0004; pooled 22.4%, p < 0.0001).”
> “In the subset of pts who failed JAKi, higher proportion of pts receiving Obe‐50 or Obe‐25 achieved clinical response versus PBO. The difference from PBO in clinical response for Obe‐25 and Obe‐50 was similar across lines of treatment, from AT‐IR‐No through 4+ AT‐IRs (Table).”

Source: [UEG Week (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12605988/)

<a id="topic-2.2.2.3-3"></a>

###### Obefazimod induction: prior Janus kinase inhibitor failure and number of prior advanced therapies

> “In participants without prior AT-IR, obefazimod 50mg delivered a placebo-adjusted difference in clinical response of 28% (p<0.0001), and in participants with up to four or more prior AT-IR, a placebo-adjusted difference of 29% (p=0.0242). Treatment with obefazimod 50mg also demonstrated robust clinical response in participants who had previously failed JAK inhibitor therapy, with a placebo-adjusted difference of 34% (p=0.0017).”
> “Of the total pooled population, approximately 47% were classified as having a prior inadequate response to advanced therapy (‘AT-IR Yes’) with approximately 21% having failed to respond to a JAK inhibitor.”

Source: [Abivax press release, UEG late-breaking AT-IR subgroup data (2025)](https://ir.abivax.com/news-releases/news-release-details/abivax-announces-late-breaking-presentation-8-week-abtect)

<a id="topic-2.2.2.3-4"></a>

###### Obefazimod maintenance: efficacy with and without prior inadequate response to advanced therapy

| Clinical remission at Week 52 | Placebo | Obefazimod 25 mg | Obefazimod 50 mg |
| --- | --- | --- | --- |
| AT-IR naive, n/N | “15/120” | “72/117” | “62/105” |
| Prior AT-IR, n/N | “5/72” | “26/76” | “38/90” |

Source: [Danese et al. (2026)](https://www.abivax.com/wp-content/uploads/2026/10/OP260-ABTECT-ATIR-19OCT2026-Danese-UEGW2026.pdf)

> “50 mg cohort had a higher percentage of patients with prior advanced therapy failure relative to patients on 25 mg and placebo”
> “Placebo-adjusted treatment differences were generally numerically larger in AT-IR naïve vs. with patients with prior ATIR”
> “Clinical remission rates numerically favored both obefazimod doses across 0 to ≥4 prior AT-IR therapies and in JAK-IR patients”
> “P-values are nominal and have not been adjusted for multiplicity; therefore, they should be interpreted as descriptive rather than confirmatory.”

Source: [Danese et al. (2026)](https://www.abivax.com/wp-content/uploads/2026/10/OP260-ABTECT-ATIR-19OCT2026-Danese-UEGW2026.pdf)

<a id="topic-2.2.2.3-5"></a>

###### Obefazimod phase 2b open-label maintenance: participants naive to or refractory to biologics or JAK inhibitors

> “Among the 98 patients with inadequate response to biologics (anti-TNFα, vedolizumab, ustekinumab) or JAK inhibitors, 74/98 (75.5%) achieved clinical response at week 48 and 66/98 (67.3%) at week 96; 38/98 patients (38.8%) were in clinical remission at both weeks 48 and 96 (Figure 4).”
> “In this subset, clinical remission was achieved by 81/119 patients (68.1%) at week 48 and by 76/119 patients (63.8%) at week 96; 89/119 (74.8%) and 82/119 patients (68.9%) had endoscopic improvement, and 54/119 (45.4%) and 58/119 patients (48.7%) achieved endoscopic remission at weeks 48 and 96, respectively.”
> “Rates of clinical remission, endoscopic improvement, and endoscopic remission at weeks 48 and 96 were numerically higher, from 25% to 33%, in the subgroup of naïve relative to refractory patients.”

Source: [Vermeire et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12124117/)

<a id="topic-2.2.2.3-6"></a>

###### Obefazimod long-term extension after dose reduction to 25 mg, by prior advanced therapy

> “Clinical and symptomatic remission were stable regardless of prior AT-IR”
> “Endoscopic improvement was stable over time regardless of prior AT-IR”

Source: [Sands et al. (2026b)](https://www.abivax.com/wp-content/uploads/2026/10/OP107_Obe-3yr-LTE-ATIR-OP-DRAFT-07OCT2026-Sands-UEGW2026-ABVX-BES.pdf)

<a id="topic-2.2.2.3-7"></a>

###### Network meta-analysis including obefazimod, stratified by prior advanced therapy

> “Analyses were stratified by prior exposure to ATs.”
> “In AT-naïve patients, obefazimod and upadacitinib showed the highest efficacy, whereas in AT-experienced patients, upadacitinib, ustekinumab, and tofacitinib ranked highest.”

Source: [Olivera et al. (2026)](https://pubmed.ncbi.nlm.nih.gov/42838315/)

<a id="topic-2.2.2.3-8"></a>

###### Comparator rankings in biologic-exposed patients: network meta-analyses

> “Overall, upadacitinib (P-score 0.93), tofacitinib (P-score 0.88), and ustekinumab (P-score 0.87) ranked highest in inducing remission in biologic-exposed patients with moderate-to-severely active UC.”

Source: [Ananthakrishnan et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12148344/)

> “In the biologic/Janus kinase inhibitor (JAKi)-naïve population, induction studies showed similar clinical response and remission rates across most interventions, with upadacitinib demonstrating significant improvements versus most other interventions.”

Source: [Dignass et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11550281/)

<a id="topic-2.2.2.3-9"></a>

###### Guideline efficacy tiers by prior advanced therapy exposure: AGA 2024

> “In adult outpatients with moderate-to-severe UC who are naïve to advanced therapies, the AGA suggests using a HIGHER efficacy medication (infliximab, vedolizumab, ozanimod, etrasimod, upadacitinib*, risankizumab, guselkumab) OR an INTERMEDIATE efficacy medication (golimumab, ustekinumab, tofacitinib*, filgotinib*, mirikizumab), rather than a LOWER efficacy medication (adalimumab).”
> “In adult outpatients with moderate-to-severe UC who have previously been exposed to one or more advanced therapies, particularly TNF antagonists, the AGA suggests using a HIGHER efficacy medication (tofacitinib, upadacitinib, ustekinumab) OR an INTERMEDIATE efficacy medication (filgotinib, mirikizumab, risankizumab, guselkumab), rather than a LOWER efficacy medication (adalimumab, vedolizumab, ozanimod, etrasimod).”
> “In the Phase 3 randomized trial of ozanimod against placebo, ozanimod was significantly more effective than placebo in achieving clinical remission with rates of 23% (vs 7%) and 17% (vs. 8%) in biologic-naïve and single biologic-exposed patients. In contrast, in patients who had been on ≥2 biologics previously, ozanimod was no more effective than placebo (4% vs. 3%) in inducing clinical remission.”

Source: [Singh et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12162142/)

<a id="topic-2.2.2.3-10"></a>

###### Lower response after prior advanced therapy: ACG 2025

> “Patients with moderately to severely active UC have higher rates of response and remission with their first therapies than after failure of one or more other advanced therapies.”
> “Post hoc subgroup analyses and network meta-analyses provide hypothesis-generating data but are not sufficient to stratify therapies for individual patients.”
> “Similar to other therapies in IBD, patients who are advanced therapy-naive had substantially better results than those who were advanced therapy-experienced, supporting the recommendation to treat earlier.”
> “A post hoc analysis demonstrated that patients who were anti–TNF-naive were more likely to respond to vedolizumab compared with those who had received anti-TNF therapy previously (193).”

Source: [Rubin et al. (2025)](https://journals.lww.com/ajg/fulltext/10.14309/ajg.0000000000003463)

<a id="topic-2.2.2.3-11"></a>

###### Comparator subgroups by prior exposure: ECCO 2026

> “Tofacitinib had broadly similar differences in induction of clinical and endoscopic outcomes compared with placebo in patients with previous anti-TNF agent exposure, although the absolute remission rates achieved were lower.”
> “Although clinical and steroid-free clinical remission rates were numerically lower among patients previously treated with biologics or JAKi, differences versus placebo remained statistically significant.”

Source: [Gisbert et al. (2026)](https://academic.oup.com/ecco-jcc/article/20/7/jjag066/8726617)

<a id="heading-2.2.2.4"></a>

##### 2.2.2.4 Care Management Intervention Strategies

<a id="topic-2.2.2.4-1"></a>

###### Treat-to-target with endoscopic improvement and fecal calprotectin: ACG 2025

> “We recommend treating patients with UC to achieve endoscopic improvement (defined as resolution of inflammatory changes [MES 0 or 1]) to increase the likelihood of sustained steroid-free remission and to prevent hospitalizations and surgery (Strong recommendation, moderate quality of evidence).”
> “We recommend the use of FC in UC to assess response to therapy, to evaluate suspected relapse, and during maintenance (Strong recommendation, moderate quality of evidence).”
> “As mentioned in the prior section on Goals of Management, any treatment that is selected and administered to a patient with UC should be assessed at a defined time point (6–12 weeks) to confirm its efficacy and safety, and given risk of losing response to therapy over time, a disease monitoring strategy should be incorporated, with the intention of identifying secondary nonresponse (loss of response) early and to allow subsequent adjustment in treatment to prevent complications and additional morbidity.”

Source: [Rubin et al. (2025)](https://journals.lww.com/ajg/fulltext/10.14309/ajg.0000000000003463)

<a id="topic-2.2.2.4-2"></a>

###### Monitoring schedule after starting advanced therapy: AGA 2024

> “Initiation of advanced therapy should be followed by monitoring for symptomatic response within 3 months of initiation, symptomatic and biochemical remission within 3–6 months, and endoscopic improvement/ remission within 6–12 months.”
> “On-treatment monitoring for potential toxicity from immunosuppressive therapies, such as periodic monitoring of hemogram, chemistries and transaminases, should be performed, according to drug label.”

Source: [Singh et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12162142/)

<a id="topic-2.2.2.4-3"></a>

###### Treat-to-target, escalation, and multidisciplinary care: ECCO 2026

> “describes an approach in which a treatment goal is set and agreed upon following discussions between individual patients and treating clinicians, and which is to be achieved within a defined period.”
> “Until then, treat-to-target beyond steroid-free clinical remission remains a promising but not yet conclusively validated framework.”
> “In patients on either conventional or advanced therapies, the presence of both active symptoms [such as increased liquid stool frequency, rectal bleeding, and often bowel urgency] and either biomarker or endoscopic evidence of inflammation should prompt action.”
> “A multidisciplinary team approach is an important element of inflammatory bowel disease care, helping to coordinate and personalize the management of complex cases. Regular multidisciplinary team meetings assist shared decision-making, reduce variation in practice, and contribute to improved outcomes and service governance [Agreement: 98%]”

Source: [Gisbert et al. (2026)](https://academic.oup.com/ecco-jcc/article/20/7/jjag066/8726617)

<a id="topic-2.2.2.4-4"></a>

###### Therapeutic drug monitoring

> “In patients with moderately to severely active UC who are responders to anti-TNF therapy and now losing response, we suggest measuring serum drug levels and antidrug antibodies (if there is not sufficient drug present) to assess reason for loss of response (Conditional recommendation, very low quality of evidence).”
> “There is insufficient evidence to recommend assessment of serum concentrations of vedolizumab, ustekinumab, guselkumab, mirikizumab, or risankizumab.”

Source: [Rubin et al. (2025)](https://journals.lww.com/ajg/fulltext/10.14309/ajg.0000000000003463)

> “There are insufficient data to support proactive therapeutic drug monitoring with anti-tumor necrosis factor agents, vedolizumab, or ustekinumab in the management of ulcerative colitis. We suggest reactive therapeutic drug monitoring in patients with loss of response to an anti-tumor necrosis factor agent to guide the treatment strategy [Agreement: 92%]”

Source: [Gisbert et al. (2026)](https://academic.oup.com/ecco-jcc/article/20/7/jjag066/8726617)

<a id="topic-2.2.2.4-5"></a>

###### Payer utilization management: ACG 2025 position

> “These strategies include step therapy requirements, denials of recommended treatments in favor of alternative advanced therapy options, increased copayment requirements, and frequent reauthorization practices. Insurance companies have also denied coverage for needed monitoring and drug-related assessments such as FC and serum concentrations of anti-TNF therapies.”

Source: [Rubin et al. (2025)](https://journals.lww.com/ajg/fulltext/10.14309/ajg.0000000000003463)

<a id="topic-2.2.2.4-6"></a>

###### Pre-treatment screening required by labels of oral advanced therapies

> “Test for latent TB before and during therapy; treat latent TB prior to use.”

Source: [Xeljanz prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/203214s042lbl.pdf)

> “Obtain an electrocardiogram (ECG) to assess for preexisting cardiac conduction abnormalities before starting treatment.”

Source: [Velsipity prescribing information (2025)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/216956s002lbl.pdf)

<a id="topic-2.2.2.4-7"></a>

###### Obefazimod-specific care management program

No evidence found.

<a id="heading-2.2.2.5"></a>

##### 2.2.2.5 Other Product Development or Post-marketing Obligations Required by the FDA

Not applicable.

<a id="heading-2.2.2.6"></a>

##### 2.2.2.6 Ongoing Post-approval Monitoring

Not applicable.

<a id="heading-2.2.2.7"></a>

##### 2.2.2.7 Expected Outcomes of Therapy

<a id="topic-2.2.2.7-1"></a>

###### Summary: expected outcomes

STRIDE-II sets clinical remission and endoscopic healing as long-term treatment targets, adds absence of disability and restoration of quality of life, and sets symptomatic relief and normalization of serum and fecal markers as short-term targets; histological healing in ulcerative colitis is not a formal target. The ACG 2025 guideline recommends treating to endoscopic improvement (Mayo endoscopic subscore 0 or 1) to increase the likelihood of sustained steroid-free remission and to prevent hospitalization and surgery, and the ECCO 2026 guideline describes treat-to-target beyond steroid-free clinical remission as not yet conclusively validated. In the pooled ABTECT induction trials, the placebo-adjusted clinical remission rate at Week 8 with obefazimod 50 mg was 16.4%. In the ABTECT maintenance trial, clinical remission at Week 44 was 50.8% with 25 mg and 51.3% with 50 mg against 10.4% with placebo among 580 induction responders. At week 8 of induction, 37% of participants on 50 mg reported no bowel urgency against 18.1% on placebo. In Study 108, 68% (88/130) of participants were in clinical remission at week 144 after dose reduction to 25 mg. These obefazimod results come from press releases and congress presentations; no peer-reviewed full report of ABTECT has been published.

Source: [Turner et al. (2021)](https://pubmed.ncbi.nlm.nih.gov/33359090/); [Rubin et al. (2025)](https://journals.lww.com/ajg/fulltext/10.14309/ajg.0000000000003463); [Gisbert et al. (2026)](https://academic.oup.com/ecco-jcc/article/20/7/jjag066/8726617); [Abivax press release, ABTECT induction results (2025)](https://ir.abivax.com/news-releases/news-release-details/abivax-announces-positive-phase-3-results-both-abtect-8-week); [Abivax press release, ABTECT maintenance results (2026)](https://ir.abivax.com/news-releases/news-release-details/abivax-announces-landmark-phase-3-abtect-maintenance-trial); [Abivax press release, patient-reported outcomes from ABTECT induction (2025)](https://ir.abivax.com/news-releases/news-release-details/abivax-announces-patient-reported-outcomes-data-phase-3-abtect); [Abivax first quarter 2026 results announcement (2026)](https://ir.abivax.com/news-releases/news-release-details/abivax-presents-first-quarter-2026-financial-results-and-reports)

<a id="topic-2.2.2.7-2"></a>

###### Treatment targets: STRIDE-II

> “STRIDE-II confirmed STRIDE-I long-term targets of clinical remission and endoscopic healing and added absence of disability, restoration of quality of life, and normal growth in children. Symptomatic relief and normalization of serum and fecal markers have been determined as short-term targets. Transmural healing in Crohn's disease and histological healing in ulcerative colitis are not formal targets but should be assessed as measures of the remission depth.”

Source: [Turner et al. (2021)](https://pubmed.ncbi.nlm.nih.gov/33359090/)

<a id="topic-2.2.2.7-3"></a>

###### Goals of management: ACG 2025

> “Symptomatic remission relates to improvement in PROs while endoscopic healing is defined as restoration of intact mucosa without friability. Deep remission is a combination of symptomatic remission and endoscopic healing and is a preferred goal of management.”
> “Initial treatment of UC should focus on restoration of normal bowel frequency and control of the primary symptoms of bleeding and bowel urgency. An endoscopically healed mucosa is associated with sustained remission and reduced risk of colectomy.”
> “Histologic remission is associated with some improved clinical outcomes but has not yet been validated prospectively as a preferred target for treatment.”

Source: [Rubin et al. (2025)](https://journals.lww.com/ajg/fulltext/10.14309/ajg.0000000000003463)

<a id="topic-2.2.2.7-4"></a>

###### Mucosal and histologic healing and long-term outcomes: ECCO 2026

> “Retrospective studies have convincingly shown that mucosal healing is associated with improved long-term outcomes in patients with UC (eg, achievement of long-term [steroid-free] clinical remission and mucosal healing as well as avoidance of colectomy).”
> “Moreover, long-term analyses have demonstrated that the risk of clinical relapse and the need for surgery and hospitalization are significantly lower in patients with histologic remission.”

Source: [Gisbert et al. (2026)](https://academic.oup.com/ecco-jcc/article/20/7/jjag066/8726617)

<a id="topic-2.2.2.7-5"></a>

###### Obefazimod: clinical remission after 8 weeks of induction

> “50 mg once-daily dose of obefazimod led to a compelling pooled 16.4% (p<0.0001) placebo-adjusted clinical remission rate at Week 8 in the ABTECT-1 (Study 105) and ABTECT-2 (Study 106) trials.”

Source: [Abivax press release, ABTECT induction results (2025)](https://ir.abivax.com/news-releases/news-release-details/abivax-announces-positive-phase-3-results-both-abtect-8-week)

<a id="topic-2.2.2.7-6"></a>

###### Obefazimod: clinical remission and secondary endpoints after 44 weeks of maintenance

> “At Week 44, both the 25 mg and 50 mg once-daily obefazimod doses met the primary endpoint, demonstrating placebo-adjusted clinical remission rates of ∆39.3% and ∆40.3%, respectively (25 mg: 50.8%, 50 mg: 51.3% vs placebo 10.4%; p<0.0001)”
> “Both doses of obefazimod met all key secondary endpoints (endoscopic improvement, endoscopic remission, HEMI1, corticosteroid free clinical remission, and sustained clinical remission), demonstrating robust and clinically meaningful efficacy results across multiple measures of disease control.”

Source: [Abivax press release, ABTECT maintenance results (2026)](https://ir.abivax.com/news-releases/news-release-details/abivax-announces-landmark-phase-3-abtect-maintenance-trial)

<a id="topic-2.2.2.7-7"></a>

###### Obefazimod: patient-reported outcomes after 8 weeks of induction

> “Improvements across all patient reported outcomes (PROs) were observed from baseline to Week 8 in all PRO instruments utilized in the ABTECT induction trials evaluating bowel urgency, sleep interruption, fatigue, quality of life, and work productivity for both 50mg and 25mg once-daily obefazimod.”
> “At week 8 in the ABTECT 1 & 2 trials, 37% of patients taking once daily 50mg obefazimod reported no bowel urgency (BU) compared to 18.1% of patients in the placebo group”

Source: [Abivax press release, patient-reported outcomes from ABTECT induction (2025)](https://ir.abivax.com/news-releases/news-release-details/abivax-announces-patient-reported-outcomes-data-phase-3-abtect)

<a id="topic-2.2.2.7-8"></a>

###### Obefazimod: durability of clinical remission over three years

> “At study baseline, 89% (116/130) of patients were in clinical remission. At weeks 48, 96 and 144 of treatment, 73% (95/130), 69% (90/130), and 68% (88/130) of patients evaluated were in clinical remission, respectively.”

Source: [Abivax first quarter 2026 results announcement (2026)](https://ir.abivax.com/news-releases/news-release-details/abivax-presents-first-quarter-2026-financial-results-and-reports)

<a id="topic-2.2.2.7-9"></a>

###### Health-related quality of life expected with comparator advanced therapies

> “During induction, clinically meaningful improvements in IBDQ were observed with upadacitinib, filgotinib, and guselkumab. During maintenance, upadacitinib 30 mg and vedolizumab showed HRQoL benefits, although clinical meaningfulness was not consistently demonstrated.”

Source: [Katsoula et al. (2025)](https://pubmed.ncbi.nlm.nih.gov/41284688/)

## Related pages
- [Obefazimod (ABX464): Ulcerative colitis](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis) · [Markdown](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis.md)
- [Obefazimod (ABX464) in Ulcerative colitis: Terms and abbreviations](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/terms-and-abbreviations.md)
- [Obefazimod (ABX464): Ulcerative colitis](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/executive-summary) · [Markdown](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/executive-summary.md)
- [Obefazimod (ABX464) in Ulcerative colitis: Clinical evidence](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/clinical-evidence.md)
- [Obefazimod (ABX464) in Ulcerative colitis: Economic information and modeling report](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/economics) · [Markdown](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/economics.md)
- [Obefazimod (ABX464) in Ulcerative colitis: References](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/references) · [Markdown](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/references.md)
